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ABSTRACT 
MICRONUTRIENTS, INFLAMMATION AND DEPRESSION AMONG WOMEN OF 
REPRODUCTIVE AGE FROM THE NATIONAL HEALTH AND NUTRITION 
EXAMINATION SURVEY 2005-2008 
 
 
MAY 2017 
 
JOYCELYN M. FARAJ, B.S., UNIVERSITY OF MASSACHUSETTS AMHERST 
 
M.S., UNIVERSITY OF MASSACHUSETTS AMHERST 
 
Ph.D., UNIVERSITY OF MASSACHUSETTS AMHERST 
 
Directed by: Associate Professor Alayne Ronnenberg 
 
 
Depression is the leading cause of disease burden among women of childbearing 
age, rendering female mental health a major public health problem in the U.S. 
Recent evidence indicates that inflammation is associated with depression, and 
many of the factors that contribute to inflammation can be addressed through 
nutritional and lifestyle interventions. There are two micronutrients that have been 
linked previously with depression and have established roles in inflammation: 
vitamins B6 and D. There is scarce research on the potential association between 
these micronutrients, inflammation, and depression. The purpose of this research 
was to investigate how high sensitivity C-reactive protein (hs-CRP), a biomarker of 
inflammation, may be contributing to different dimensions of depression and to 
determine to what degree inflammation or lifestyle factors may be affecting the 
association between vitamins B6 and D and depression symptoms among women of 
reproductive age. We carried out a secondary data analysis of non-pregnant women 
vii 
ages 18-44 from the National Health and Nutrition Examination Survey (NHANES) 
2005-2008. All analyses were weighted using NHANES sample weights to account 
for the complex survey design, survey non-response, and post-stratification. 
Depression scores were calculated based on the Patient Health Questionnaire-9 
(PHQ-9) and categorized into total depression, somatic depression and non-somatic 
depression. High depression score (PHQ-9≥10) use was also used as an outcome, as 
well as individual symptoms of depression. Overall, 7.5% of our population 
experienced high depression symptoms. 
In the first study, hs-CRP was positively associated with sum depression scores after 
adjustments for demographics and behavioral characteristics, but prior to 
adjustment by body mass index (BMI), which significantly attenuated this 
association. In stratified analysis, hs-CRP was associated with higher depression 
scores after adjustments among underweight women (p<0.05). With regards to 
individual depression symptoms, hs-CRP was associated with sleep disturbance 
(OR: 1.31, 95% CI 1.01-1.71) and changes in appetite.  
In the second study, vitamin B6, as serum pyridoxal-5'phosphate (PLP), was 
categorized as deficient (<20 nmol/L), insufficient (20-29.9 nmol/L) or normal (≥30 
nmol/L). We found the prevalence of depression to vary by CRP level and by vitamin 
B6 concentration. Among those with moderate inflammation, the prevalence of 
depression was highest among women with vitamin B6 deficiency (20%), followed 
by those with vitamin B6 insufficiency (10%), and those with normal vitamin 
B6 status (5%) (p= 0.02). In multivariable models including individual depression 
symptoms, vitamin B6 levels below 30 nmol/L were associated with higher odds of 
viii 
experiencing suicidal ideation (OR: 7.33, p=0.01 and OR: 3.5, p=0.06 for B6 
deficiency and insufficiency, respectively) and depressed mood (OR: 3.12, p=0.004 
for B6 insufficiency). Among those with moderate CRP levels, vitamin B6 deficiency 
was associated with a higher score for psychomotor abnormalities (β: 0.14, p=0.02). 
In our third study, suboptimal vitamin D levels were significantly associated with 
higher odds for depression among women who had elevated CRP (OR: 6.55, p=0.02 
and OR: 9.54, p=0.001 for 25-OHD<75nmol/L and 25-OHD<50nmol/L, respectively).  
Among women who reported sleeping 7 or more hours per night, vitamin D was 
inversely associated with depression, whereas the opposite was true among women 
who slept less than 7 hours per night (p-interaction: 0.01). Together, the results of 
these studies suggest that inflammation may be interacting with BMI, sleep, or 
micronutrient deficiencies, and altogether contributing to different symptoms or 
severities of depression. Lifestyle factors, such as BMI or sleep could be used 
together with nutritional interventions, to aid in efforts to prevent or help treat 
depression among women of reproductive age. 
ix 
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CHAPTER 1 
 
INTRODUCTION 
Depression is the leading cause of disability world-wide, affecting 350 million 
individuals. 1  Within developed countries, major depression is second only to heart disease 
as the leading source of disease burden, and for women, it is already the primary cause of 
disease burden. 1  Women in their childbearing years make up the largest group of 
Americans with depression and women are 2 to 3 times more likely than men to 
experience depression. 2,3 This high prevalence of depression among women renders 
female mental health a major public health problem in the U.S., especially since not all 
depressed individuals respond to drug treatment and additional therapies are urgently 
needed. 4 
The complexity of depression is unmistakable, yet a key to its prevention and 
treatment may be a factor so fundamental that it has been broadly overlooked: overall 
nutritional status. 5  Recent evidence indicates that inflammation is associated with 
depression 6 and many of the factors that contribute to inflammation can be addressed 
through nutritional interventions. 7  Two micronutrients – Vitamins D and B6 – have 
potential roles in both inflammation 8,9 and depression, 10,11 but to date, no studies have 
examined the potential association between these nutrients, inflammation, and depression, 
which is the main objective of my dissertation.  
 
Depression is a multifaceted construct with a large range of symptoms.  Research 
into the etiology of depression needs to account for the heterogenous nature of the 
condition and requires developing methods to characterize and objectively assess the 
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severity of depression and to classify depression into its different subtypes. 12  In order to 
address the issue of symptom diversity, subtypes of depressive symptoms have been 
proposed based on specific combinations of symptoms. 13  Somatic depression, 
characterized by sleep disturbance, fatigue, or changes in appetite,  has been found to be 
more prevalent in females compared to males. 14 Evidence suggests that gender differences 
may account for heterogeneity in depression symptoms and the involvement of 
inflammation in the etiology of depression may be affected by lifestyle factors. 15 To the 
best of our knowledge, prior literature has not assessed how inflammation or nutritional 
deficiencies may be contributing to different sub-types of depression or individual 
depression symptoms among women of childbearing age. This lack of knowledge is 
problematic because an understanding of the modifiable nutritional and lifestyle factors 
that may be contributing to depressive symptoms, especially in the context of 
inflammation, is important for the prevention and early treatment of depression. This 
dissertation examined cross-sectional data from 1,489 non-pregnant women ages 18-44 
years from the National Health and Nutrition Examination Survey (NHANES) to evaluate 
the extent to which inflammation, suboptimal vitamin B6 and D concentrations, and 
lifestyle factors are associated with different dimensions of depression in women 
representative of the U.S. population.  
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CHAPTER 2 
 
DEPRESSION 
2.1 Epidemiology of Depression 
Depression is a commonly occurring, seriously impairing, and often recurring 
psychiatric disorder.4,5  The World Health Organization identified depression as the leading 
cause of disability world-wide, affecting 350 million individuals.1  In the US, recent samples 
estimate a lifetime depression prevalence of 16.2% (approximately 33 million adults) and a 
12-month prevalence of 6.6% or 13.5 million adults.6  It is also the leading cause of 
disability for people ages 15-44 years old, resulting in almost 400 million disability days 
per year. 19 With a quarter of women all ages reporting depression symptoms according to 
recent national estimates,7 they are 2 to 3 times more likely than men to experience 
depression.2,3  Not only is depression the most common mental illness experienced by 
women, but rates of depression are on the rise.8  The chance of suffering from depression is 
ten times greater for women today than it was for their grandmothers.9   
2.2 Definition of Depression 
Major depressive disorder goes beyond the normal bounds of sadness and is marked by 
hopelessness, loss of mood reactivity, inability to experience pleasure, suicidal thoughts, 
and psychotic symptoms such as delusions or hallucinations.10  The actual diagnosis of 
major depressive disorder is based on criteria established in the Diagnostic and Statistical 
Manual of Mental Disorders, fifth edition (DSM-V) by the American Psychiatric Association 
(APA).11  Major depressive disorder is characterized by discrete episodes of at least 2 week 
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duration involving clear-cut changes in affect, cognition, and neuro-vegetative functions 
and inter-episode remissions.11  Common symptoms of major depressive disorder or 
unipolar depression include a persistent sad mood, loss of interest or pleasure in activities 
that were once enjoyed, changes in appetite or weight, difficulty sleeping or oversleeping, 
physical slowing or agitation, energy loss, feeling worthlessness or inappropriate guilt, 
difficulty thinking or concentrating, and recurrent thoughts of death or suicide.11  A 
diagnosis of major depressive disorder is made if a person has five or more of these 
symptoms and experiences impairment in usual functioning nearly every day during the 
same 2-week period and at least one of the symptoms must be either depressed mood or 
anhedonia (loss of interest of pleasure).11   
Other manifestations of depressive disorders include: dysthymic disorder (or 
dysthymia), which is characterized by long-term (2 years or longer) symptoms that may 
not be severe enough to disable a person but can prevent normal functioning or feeling 
well; and minor depression, which is characterized by having symptoms for 2 weeks or 
longer that do not meet full criteria for major depression.12   Those with minor depression 
are at increased risk for developing major depressive disorder.12  Other forms of 
depression vary slightly or may develop under different circumstances, such as postpartum 
depression or seasonal affective disorder.12  
 
 
 
 
 5 
 
2.2.1 Subtypes of Depression 
Major depressive disorder patients vary considerably in clinical presentation, cause, 
treatment response, genetics, and neurobiology.13,14  One explanation for this diversity is 
the polyethic definition of major depressive disorder, meaning that a patient needs to only 
satisfy some but not all symptoms to be classified as depressed.14  This approach suggests 
there are 227 possible combinations of symptoms leading to a diagnosis of depression.14   
In order to tackle the issue of symptom diversity, subtypes of depressive disorders have 
been proposed based on specific combination of symptoms (i.e. melancholic depression, 
psychotic depression), onset (seasonal affective disorder postpartum, early versus late in 
life), course (single, recurrent, chronic), or severity.15   Several subtypes of depression such 
as atypical, psychotic, cognitive, somatic and melancholic depression have been found in 
theoretical frameworks.14  Of these, somatic symptomology has been found to be more 
prevalent in females compared to males.16  Research into the etiology of depression needs 
to account for the heterogenous nature of the condition and requires developing methods 
to characterize and objectively assess the severity of depression and to classify depression 
into its different subtypes.5 Investigating risk factors for specific symptoms offers 
opportunities to discover potential biological factors that may be related to specific 
syndromes but may be masked by aggregate scoring; individuals with similar total 
depression scores often have drastically different clinical conditions.16  In conclusion, 
depression is a heterogeneous disorder with a highly variable course, 30 an inconsistent 
response to treatment, 4 and no established mechanism.13 Therefore, further attempts to 
characterize depression and find new potential treatments are warranted. 
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2.3 Public Health Challenge 
Currently, depression is one of the three leading causes of global disease burden, but it 
is predicted to become the leading cause by 2030.17  This poses an important public health 
challenge because depression is often undiagnosed and untreated by physicians in primary 
care settings.18   Despite heightened awareness and treatment of depression in primary 
care settings, the prevalence of depressive symptoms remains high, treatment levels 
remain low, and control of depressive symptoms are suboptima.7   A recent study of a 
nationally representative sample of adults from NHANES found that even among 
individuals with severe depressive symptoms, a large proportion (36.9%) did not receive 
treatment for depression.7   Furthermore, not all depressed individuals respond to drug 
treatment and additional therapies are urgently needed.4   Among U.S. adults taking 
antidepressants, 26% reported feeling mild depressive symptoms and 19% reported 
feeling moderate, moderately severe, or severe depressive symptoms.7  This suggests that 
antidepressants alone may not be the optimal treatment for depression, and further 
avenues, such as nutritional therapy, could be beneficial in treating depression.  
Among women, maternal depression is a major public health problem in the United 
States20 encompassing a range of emotional and physical changes that mothers can 
experience especially during pregnancy (prenatal) or in the year after giving birth 
(postnatal).21   Ante-, peri- and postpartum depression occur in 10-20% of women, with 
rates of depression increasing in the last 2 trimesters of pregnancy up to 51% in the 
general population of pregnant women.21  These estimates are likely conservative due to 
under-reporting and under-diagnosing maternal depression.  Indeed, as many as half of all 
cases of perinatal depression go undetected, in part because many of the symptoms can be 
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wrongly attributed to the hormonal and physiological changes characteristic of 
pregnancy.22  Furthermore, studies have shown that depression in the postpartum period 
can last for months or even years after giving birth.23,24 
2.4 Public Health Impact of Depression 
Depression has a major impact on functioning and quality of life, on public health and 
on the economy.  In 2000, the estimated costs of depression totaled $83.1 billion, including 
$26.1 billion for direct medical costs, $5.4 billion for suicide-related mortality costs, and 
$51.5 billion for workplace costs, including absenteeism and disability.25 Based on a 
nationally representative sample of U.S. workers, Kessler and colleagues (2006) estimated 
that major depression resulted in 27.2 lost workdays per ill worker each year.26   
Additionally, they found that the major workplace impact of depression is more likely to be 
due to presenteeism (being physically present at work, but unable to function) than 
absenteeism, which can be several times the cost of work loss time alone.26  
From an interpersonal and domestic perspective, depression can have devastating 
effects on a child’s development and family health.  Parents represent the earliest, most 
constant, and most proximal influence on child development. Their psychological health, in 
addition to parenting behavior, serves as an important environmental risk or protective 
factor in the developmental outcomes for children, especially with regard to emergence 
and course of behavior problems.27  Depression among mothers is increasingly recognized 
as a common and devastating public health problem affecting not only women but also the 
children in their care.  Maternal depression can have devastating effects on a child’s health, 
starting in pregnancy. Depressed mothers are more likely to have poor nutrition and to 
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smoke, drink, and/or use illicit drugs compared to non-depressed women; they are also 
more likely to engage in risky behavior, including suicidal thoughts, as well as 
underutilization of prenatal care services.28  Maternal depression is one of the most 
common complications during pregnancy and it can lead to increased obstetrical 
complications, such as pre-eclampsia, excessive bleeding, placental rupture, and preterm 
birth and low birth weight babies.29  The effects of maternal postpartum depression on 
infants can be long-lasting, affecting a child’s development and well-being. Infancy is a vital 
developmental period, covering the time-frame when children develop social interaction 
skills, experience parental attachment and bonding, and learn how to communicate. If a 
mother’s ability to interact with her child is impaired due to her own depression, her infant 
may fail to develop these important skills. Infants of depressed mothers often suffer from 
developmental delays in their emotional, social, cognitive, and linguistic abilities.30,31   
Furthermore, even mild or unrecognized maternal depressive symptoms in the first 4 
months postpartum may have a significant impact on bonding with the infant.32  In addition 
to emotional and development issues, maternal depression during the first years 
postpartum is a also a strong predictor of child overweight and obesity.39 Long-term effects 
of maternal depression include increased risk of depression and anxiety in childhood and 
adolescence.40  This is especially important because the earlier onset of depression in life is 
associated with greater severity of illness and higher risk of suicide than later onset 
depression.40 
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2.5 Risk factors for Depression in Women 
Depression is a multifactorial condition involving genetic and environmental risk 
factors.41  Even though depression may have a large genetics component including 
polymorphisms of the serotonin transporter promoter gene (5-HTTLPT),213 studies on 
mood disorders have not provided consistent evidence regarding the roles of specific 
susceptibility genes or their pattern of inheritance. 50,51 A genetic predisposition, in 
combination with several potential environmental influences, is likely involved in the 
development of depression.22 54,55   Environmental factors associated with depression in 
women include stress (e.g. physical, mental, and emotional trauma); viral infections; 
hormonal disorders; chronic diseases; and some medications (e.g. sedatives). 22,42  
However, environmental factors do not appear to act alone, but can increase the risk for 
depression in those with a genetic susceptibility for the condition.22  
In addition to genetic predisposition and environmental risk factors, several social and 
biological factors are associated with an increased risk for developing depression for 
women. Social risk factors include a history of depression/anxiety, lack of marital partner 
or marital difficulties,44  low socioeconomic status,45  lack of social support or social 
isolation,46  major life events as well as family violence,47  increased life stress, and 
substance abuse.21  Psychological factors include history of depression 48 and history of 
psychiatric illness, such as premenstrual dysphoric disorder,46 and depressive symptoms 
during pregnancy.49   
Biological risk factors associated with depression in women are more challenging to 
determine. Some biological factors that may contribute to the pathophysiology of 
depression include hormonal fluctuations,50 neurotransmitter function, 62–64 metabolic 
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syndrome,54 increased inflammation,55 and nutrient deficiencies from malnutrition or poor 
diet quality.56  
 In summary, depression is a multifaceted construct whose etiology remains a 
mystery, and this may partly be due to the many potential risk factors that may be playing a 
role in its development and severity. 
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CHAPTER 3 
INFLAMMATION 
3.1 What is the Immune System and How Does it Function? 
The immune system includes two major components: specialized cells that carry out 
the wide array of immune processes, and the chemical messengers that enable 
communication among immune cells, and between immune cells and other cells and tissues 
within the body.57  The specialized cells and the messengers are coordinated to carry out 
two forms of protection, innate and acquired immunity, which also work together in a very 
complex manner to protect the body from foreign pathogens. Innate immunity is a general, 
non-specific first line of defense comprised of anatomic, physiologic, endocytic and 
phagocytic, and inflammatory barriers.58  Innate immunity is moderated and enhanced by 
the acquired immune system, a specific form of defense that targets and labels pathogens 
for elimination.59  Innate and acquired immunity operate in cooperative and 
interdependent ways. The activation of innate immune responses produces signals that 
stimulate and direct subsequent acquired immune responses, which involves cell-mediated 
responses.58  The innate immune system continuously surveys the body for presence of 
invaders, and when activated, it sets in motion a localized inflammatory response to fight 
most pathogenic threats.60  
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3.2 What is Inflammation? 
Inflammation is an essential immune response that enables survival during 
infection or injury and maintains tissue homeostasis under a variety of conditions.61  The 
inflammatory response was first characterized in the 1st century AD by Cornelius Celsus, 
who coined the four cardinal symptoms of inflammation: rubor et tumor cum calore et 
dolore (redness and swelling with heat and pain).62  The physiology behind these 
symptoms was discovered in the 1800s, when Augustus Waller (1846) and Julius 
Cohnheim (1867) discovered leukocyte emigration from blood vessels and other vascular 
changes characteristic of an acute inflammatory response. Upon microscopic observation 
of living tissue, Cohnheim noticed vasodilation, leakage of plasma, and migration of 
leukocytes out of blood vessels and into the surrounding tissue.62 The 5th cardinal symptom 
of inflammation, function laesa (disturbance of function), was added in 1858 by Rudolph 
Virchow in this book Cellularpathologie.62    
Currently, it is known that inflammation may be of different forms and modalities, 
which are directed by different mechanisms of induction, regulation, and resolution.61  In 
the past few decades, the spectrum of inflammatory conditions has shifted from acute 
inflammatory reactions in response to wounds and infections to chronic inflammatory 
states that accompany chronic diseases such as type 2 diabetes, atherosclerosis, asthma, 
cancer, and neurodegenerative diseases.61  
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3.2.1 Acute Inflammatory Response 
A typical acute inflammatory response consists of four components: inflammatory 
inducers, the sensors that detect them, the inflammatory mediators induced by the sensors, 
and the target tissues that are affected by the inflammatory mediators.61  
 
Each component comes in various forms, and their combinations function in distinct 
inflammatory pathways. The type of pathway induced under given circumstances depends 
on the source of the inflammatory stimulus. Thus, bacterial pathogens are detected by 
receptors of the innate immune system expressed on tissue-resident macrophages and 
induce the production of inflammatory cytokines and chemokines, as well as 
prostaglandins.61  These inflammatory mediators then act on target tissues, including local 
blood vessels, to induce vasodilation, extravasation of neutrophils, and leakage of plasma 
into the infected tissue. Depending on the type of infection (bacterial, viral, or parasitic), 
the sensors, mediators, and target tissues vary such that the most adequate type of 
inflammatory response is induced.61  The acute inflammatory response is normally 
terminated once the trigger insult is eliminated, the infection is cleared, and damaged 
tissue is repaired. This is known as the resolution of inflammation.  
3.2.2 Chronic Inflammation 
Many chronic inflammatory conditions have been described where the initiating 
trigger is not well defined but does not seem to involve infection or tissue damage. These 
inflammatory conditions accompany many chronic diseases, including obesity and type 2 
diabetes, atherosclerosis, neurodegenerative diseases, and cancer.61  Several inflammatory 
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mediators, such as acute-phase proteins, cytokines or chemokines, can be used to assess 
inflammation.  
3.2.3 Inflammatory Mediators: Cytokines and Acute-Phase Reactants 
As part of the inflammatory response, damaged or infected cells secrete chemical 
messengers or mediators called cytokines, which act as chemoattractants. The term 
“cytokines” encompasses a large family of proteins, including interleukins (IL), interferons 
(IFN) and colony-stimulating factors, as well as various growth factors and eicosanoids, 
including prostaglandins.63  To differentiate among cytokines’ biological activity, they are 
often described as either pro-inflammatory or anti-inflammatory. Following damage to or 
infection of cells and tissues, pro-inflammatory cytokines are produced and secreted to 
stimulate the activation of the immune system.64  Anti-inflammatory cytokines, such as IL-
10, are also secreted during inflammation in order to terminate pro-inflammatory cytokine 
activity.63 
Cytokine expression normally occurs in a step-wise manner, with the expression of 
certain cytokines dependent upon the prior expression of others; for example, IL-1 is 
necessary to induce production of IL-2, IL-6 and tumor necrosis factor (TNF).63  Cytokines 
are mainly produced by immune cells, but are also produced by a variety of other cell types, 
such as brain cells and adipose cells.63  Peripheral cytokine production depends to a great 
degree on the state of immune activation. In pathological conditions of acute or chronic 
inflammation and tissue damage, the immune system is activated and macrophage activity 
increases, accounting for increased production of cytokines, such as IL-1, IL-6, and TNF-α. 
In the case of a viral infection, IFNs, released by activated T-cells, play a major role.59  These 
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mediators, when secreted in sufficient amounts, can have systemic effects and can induce 
liver cells to produce acute phase proteins such as C-reactive protein (CRP) and 
coagulation factors, including pro-inflammatory prostaglandins.61  
3.3 C-Reactive Protein: The Main Acute-Phase Reactant 
C-reactive protein (CRP) is the prototypical acute phase protein in humans.65  CRP is a 
serum protein that is massively induced as part of the innate immune response to infection 
and tissue injury.66 CRP is composed of five 23-kDa subunits, and was named for its 
capacity to precipitate the somatic C-polysaccharide of Streptococcus penumoniae.65  Even 
though it was the first acute-phase protein to be described and traditionally was viewed 
only as an acute phase reactant, CRP is currently considered the “best” systemic marker of 
non-specific inflammation and tissue damage.67   
3.3.1 Biosynthesis of CRP 
CRP was traditionally thought to be produced only by hepatocytes, but recent 
studies showed that CRP can be produced by non-hepatic tissues such as the renal 
epithelium and respiratory tract.68,69  CRP synthesis is stimulated by inflammatory 
cytokines, such as IL-6 70 and this synthesis is enhanced synergistically by IL-1β.71   De novo 
hepatic synthesis initiates rapidly after a single stimulus, leading to serum concentrations 
above 5mg/L for approximately 6 hours and peaking at 48 hours.72  The plasma half-life of 
CRP is roughly 19 hours and is constant under all conditions of health and disease, so that 
the sole determinant of circulating CPR levels is the synthesis rate, which is a direct 
reflection of the intensity of the pathological process stimulating CRP production.67  When 
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the stimulus for increased production ceases, the circulating CRP level falls rapidly, at 
almost the rate of plasma CRP clearance.67   
3.3.2 Circulating CRP Concentration 
Healthy individuals in the general population tends to have stable CRP 
concentration, apart from occasional spikes thought to be related to minor or subclinical 
infections, inflammation, or trauma. There is no significant seasonal variation in baseline 
CRP concentration, and, remarkably, the self-correlation coefficient of measurements 
repeated years apart is approximately 0.5, which is comparable to that of cholesterol.67  
Acute-phase CRP values also show no diurnal variation and are unaffected by the fed state. 
Liver failure impairs CRP production, but no other pathologies and very few drugs reduce 
CRP values unless they also affect the underlying pathology providing the acute-phase 
stimulus.67  The CRP concentration is a useful nonspecific biochemical marker of 
inflammation, measurement of which contributes importantly to screening for organic 
disease, monitoring of the response to treatment of inflammation and infection, and 
detection of intercurrent infection in immunocompromised individuals.67   
In healthy young adults, the median concentration of CRP is 0.8 mg/L, the 90th 
percentile is 3.0 mg/L and the 99th percentile is 10 mg/L.73   However, CRP is part of the 
acute phase response, and following injury, CRP levels increase dramatically, up to 10,000-
fold from less than 50 ug/L to more than 500 mg/L.67  This increase is rapid, but not 
immediate: circulating concentrations reach 5 mg/L by approximately 6 hours and peak at 
48 hours.72   CRP is clearance occurs at a constant rate, rendering CRP levels a reliable 
index of ongoing inflammation.72  Dramatic elevations in CRP levels indicate ongoing 
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infection, and in the absence of infection, CRP reflects the degree of background 
inflammation characteristic of an individual.67   
3.3.3 Role of CRP in the Inflammation Process 
There are several mechanisms through which CRP enhances inflammation and 
activates the immune response. Human CRP binds with high affinity to phosphocholine 
residues, but it also binds to a variety of other autologous and extrinsic ligands, and it 
aggregates or precipitates the cellular, particular, or molecular structures bearing these 
ligands.67   Autologous ligands include native and modified plasma proteins,74 damaged cell 
membranes,75 several different phospholipids and related compounds as well as small 
nuclear ribonucleoprotein particles,76  and apoptotic cells.77  Extrinsic ligands include many 
glycan, phospholipid, and other constituents of microorganisms, such as components of 
bacteria, fungi and parasites, as well as plant products. When aggregated or bound to 
macromolecular ligands, human CRP is resembles some of the key properties of antibodies, 
suggesting that under various circumstances CRP may contribute to host defense against 
infection, function as a pro-inflammatory mediator, and participate in physiological and 
pathophysiological handling of autologous constituents.65   
 
3.4 Lifestyle Factors that can Impact Inflammation 
3.4.1 Obesity and Inflammation 
Increasing evidence indicates that obesity causes chronic low-grade inflammation, 
which contributes to the development of obesity-associated disorders, mainly 
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characterized by metabolic dysfunction.78,79  Excess adipose mass is associated with 
increased levels of the pro-inflammatory marker CRP in the blood in children and adults.80 
Furthermore, weight loss interventions in those who were previously obese lead to 
reductions in the levels of pro-inflammatory proteins, including CRP.81–83  
Adipose tissue is traditionally considered a long-term energy storage organ, but it 
also functions as a key endocrine organ by releasing multiple bioactive substances, known 
as adipose-derived secreted factors or adipokines, that have pro-inflammatory or anti-
inflammatory activities.78,84  The expression of adipokines varies depending on whether the 
fat is stored in visceral or subcutaneous adipose tissues, as each of these sites produces a 
unique profile of adipokines 85.  The production of most adipokines is upregulated in the 
obese state, and these pro-inflammatory proteins include: leptin, TNF, IL-6, resistin, 
retinol-binding protein 4, lipocalin 2, IL-18, angiopoietin-like protein 2, CC-chemokine 
ligand 2, CXC-chemokine ligand 5, and nicotinamide phosphor-ribosyltransferase.78  Among 
these, leptin upregulates production of TNF and IL-6 by monocytes and increases the 
production of the TH1-type cytokines IL-2 and IFN-, therefore acting as a pro-
inflammatory adipokine.86   Tumor-necrosis factor is another pro-inflammatory cytokine, 
mainly produced by monocytes and macrophages in visceral depots whose levels are 
increased in adipose tissue and plasma of obese individuals, and reduced following weight 
loss.87,88  Interleukin-6 increases transcription of CRP, and is positively associated with 
adiposity in human populations.89   Similarly to CRP and TNF, increased levels of IL-6 are 
seen in obese subjects, with weight loss leading to reduced IL-6 levels.83  Furthermore, 
approximately one third of total circulating IL-6 is produced by adipose tissue.89  
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Interleukin-18 is another pro-inflammatory adipokine produced by adipose tissue, whose 
levels fall after obese subjects undergo weight loss.90  
3.4.2 Estrogens and Inflammation 
Studies conducted among users of exogenous hormones suggest that oral 
contraceptive (OC) use 91,92  and orally administered hormone replacement therapy (HRT) 
consistently elevate CRP, whether the preparation includes progesterone and estrogen or 
estrogen alone.91,93 A study by Dreon (2003) comparing CRP levels in 18 OC users vs 12 
non-OC users found that plasma CRP levels were twice as high among OC users compared 
to non-OC users (2±0.2 vs 0.9 ±0.3 mg/L; p<0.001) independent of phase of menstrual 
cycle. Furthermore, they found that in this group, OC use predicted 32% of the variance in 
CRP levels (p<0.001).92  Even though exogenous estrogen has been demonstrated to 
increase CRP, dose and delivery method appear to mediate this increase. Prestwood et al 
(2004) found significantly higher CRP among women taking a higher estrogen HRT 
preparation and significantly lower levels among women taking a lower estrogen 
preparation; transdermally administered HRT has no observable effect on CRP.94,95   
Studies examining the effects of endogenous hormones on CRP are inconsistent with 
the trends shown for exogenous hormones. Jilma et al (1997) examined CRP changes in 18 
women during the follicular phase, at mid-cycle, and in the luteal phase of one menstrual 
cycle, and found that median CRP levels increased by 44% (p<0001) at mid-cycle and by 
31% (p=0.002) in the luteal phase  compared to the follicular phase.96  Additionally, they 
found a significant association between an individual’s relative increase in CRP and 
progesterone concentration from the follicular phase to mid-cycle (r=0.60, p=0.01) and 
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from the follicular phase to the luteal phase (r=0.71, p=0.001).96  In a second study of 
endogenous hormones, Blum et al (2005) examined 15 measures from 15 women across 
one menstrual cycle, and found an inverse association between estrogen and CRP (β=-0.23, 
p<0.001) such that a 10-fold increase in estrogen was associated with a 41% decrease in 
CRP.97   A third study of the effects of endogenous hormones on CPR found a 10-fold 
increase in progesterone to be associated with a 23% increase in CRP (p=0.01), a ten-fold 
increase in estrogen was associated with a 29% decrease in CRP (p=0.05).98  
Thus the effects of exogenous and endogenous hormones on CRP appear to differ: 
exogenous estrogen at most doses is associated with elevations in CRP,91–93 whereas 
endogenous estrogen seems to be correlated with lower CRP,97,98  conversely, exogenous 
progesterone may be associated with decreases in CRP,99–101  whereas endogenous 
progesterone seems to be associated with increases in CRP.96,98 
 
3.4.3 Smoking and Inflammation 
  Environmental factors, such as smoking, have been reported to modify 
inflammation progression, severity and outcome.102 Chronic inhalation of cigarette smoke 
alters a wide range of immunological functions, including innate and adaptive immune 
responses.103  Inflammatory mediators have been detected at higher levels in smokers in 
several studies.104,105  A large scale analysis with 2,920 healthy men ages 60-79 found that 
current cigarette smokers showed significantly higher levels of CRP (2.53 vs 1.35 mg/L) 
compared with never-smokers.104  In women, Bermudez et al (2002) found higher levels of 
plasma CRP in smokers enrolled in the Women’s Health Study compared to never smokers 
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(3.80 vs 3.0 mg/L, p=0.032). 105  Therefore, the systemic inflammatory process appears 
heightened in those who smoke compared to nonsmoking subjects. 
3.4.4 Physical Activity and Inflammation 
Cross-sectional studies show an inverse association between regular physical 
activity and the serum concentration of inflammatory markers, suggesting that physical 
activity may have anti-inflammatory properties. Pitsavos et al found that CRP levels 
decreased with increasing physical activity in the ATTICA study, as sedentary subjects had 
the highest CRP concentration (1.47±1.4 mg/dL), followed by those who reported light-
moderate physical activity (1.01±1.5 mg/dL); finally those with highest level of physical 
activity had the lowest serum CRP (0.91±1.3 mg/dL; p=0.020).106    A study in older adults 
measuring weekly caloric expenditure and inflammation found a dose-response 
relationship between physical activity and CRP in the Cardiovascular Health Study.107 The 
results from several cross-sectional studies suggest that physical activity and fitness are 
associated with lower CRP levels.108 Furthermore, recent longitudinal studies suggest that 
physical activity reduces CRP levels. A 2-year dietary and lifestyle intervention study in 
postmenopausal women showed that serum CRP was reduced by 34% in obese 
postmenopausal women; however, it is unclear as to whether the reduction in CRP was due 
to weight loss, the physical activity or a combination of both.83 In a second longitudinal 
study, Obisesan et al found a 15% reduction in CRP following a six-month exercise and diet 
intervention, which did not result in weight loss.109  
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3.4.4.1 Effect of type, duration, and intensity of physical activity on CRP levels 
 Despite limited evidence on the relationship between physical activity and CRP, 
several studies have tried to ascertain the effect of type, duration, and intensity of physical 
activity on inflammatory markers in healthy adults. For the mode of physical activity that 
may most impact CRP, King et al (2003) found that activities such as jogging, swimming, 
cycling, aerobic dance and weight lifting performed over 12 times per month were 
associated with a lower likelihood of elevated CRP in adults ages 17-65 years old when 
compared to non-exercisers using data from NHANES III.110  In particular, frequent jogging 
and aerobic dance were associated with the lowest proportion of exercising individuals 
with high CRP.110 This analysis was limited, however, by the inability to assess differences 
in duration or intensity of each activity.  Albert and colleagues assessed the baseline 
frequency of physical activity in adults participating in the Pravastatin Inflammation/CRP 
Evaluation (PRINCE) study, a multicenter community-based study.111 They created 4 
groups of physical activity based solely on frequency: less than once per week, once per 
week, 2-3 times per week, and 4 or more times per week; they found that CRP levels 
decreased progressively with increasing levels of physical activity frequency (p-trend 
<0.001). 111  In order to assess the relationship between intensity of physical activity and 
CRP levels, Pitsavos et al (2003) studied leisure-time activities such as walking, cycling, 
running, swimming, etc, in healthy adults ages 18 and older from the ATTICA study.106 They 
found that among individuals who claimed to exercise at least once a week, a high exercise 
intensity (7 kcal/minute or more) was associated with a 38% decrease in CRP levels 
compared with light exercise intensity (<4 kcal/min. 106 With regards to overall duration of 
physical activity, the minimum length of time observed associated with lower CRP levels in 
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longitudinal studies has been 2 months.108,112  Geffken et al (2001) observed that 3-4 days 
of physical activity per week, for 40-80 minutes per day at an intensity of 70-80% of 
V02max can lower CRP levels in as little as 2 months in a healthy elderly population.107 
Despite all the limitations encountered, there is sufficient evidence to suggest that physical 
activity lowers inflammatory biomarkers such as CRP in a variety of settings and 
populations.  
3.4.5 Sleep and Inflammation 
Inadequate sleep and sleep deprivation cause several neurobehavioral and 
physiological changes, including increases in a range of inflammatory markers. 216  Chronic 
sleep disruption is regarded as a physiological stressor that can impair brain function217 
and raises pro-inflammatory cytokines by inducing a functional alteration of the 
proinflammatory cytokine response in monocytes, which is greater among females 
compared to males. 218 
3.4.6 Other correlates of CRP 
Among individuals not experiencing infection, CRP concentrations may vary with 
many additional factors.98  In adults, CRP has been found to be positively associated with 
age113  and negatively associated with birth weight.114  Adult females have higher CRP than 
males113,115  Furthermore, some component of variation in circulating levels of CRP may be 
heritable: estimates of heritability between 30% and 50% have been suggested.116,117 
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3.5 Physiology of Inflammation and Depression 
Depression is a complex condition, and it is likely that alterations in multiple 
interacting systems underlie its pathogenesis.118 Therefore, numerous hypotheses have 
been proposed to elucidate its origins. One of these is the inflammatory hypothesis, initially 
called the macrophage theory of depression,119 presently also known as the malaise or 
cytokine theory of depression.120,121  This inflammatory hypothesis emphasizes the role of 
psycho-neuroimmunological dysfunctions, which is based on several observations. The 
first one of these observations noted is that subsets of patients with major depression have 
an altered peripheral immune system, with impaired cellular immunity and increased 
levels of pro-inflammatory cytokines, including IL-6 and CRP.122,123  Furthermore, 
postmortem gene analyses in the prefrontal cortex of patients who had major depression 
have suggested up-regulation of various pro and anti-inflammatory cytokines.124  It is now 
known that cytokines can cross the blood-brain barrier and induce inflammation in the 
central nervous system and can influence neurotransmitter metabolism, neuroendocrine 
function and regional brain activity, all of which are relevant to depression.63 
3.5.1 Cytokine Administration Induces Depression 
It has been noted that chronic therapeutic administration of cytokines, mainly 
interferon-alpha (INF-α) for hepatitis C virus infection or cancer, can lead to depressive 
symptomatology in up to 50% of patients who will meet the criteria for major depression 
within 3 months of starting therapy;125 up to 90% receiving this therapy will display at 
least one or two significant depressive symptoms.126  Therefore, INF-α-induced depression 
has been used as a model to identify the specific changes in the immune system that may 
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play a role in the development of behavioral changes leading to depression.127  INF-α is a 
cytokine released by the innate immune system in response to viral infections; it has been 
shown to induce IL-6 production, which stimulates CRP production. Additionally, some 
evidence indicates that INF-α induced depression can be prevented and/or treated using 
selective serotonin reuptake inhibitor (SSRIs).125 Therefore, there is evidence supporting 
the directionality of inflammation leading to depression. 
3.5.2 Cytokines Alter Neurotransmitter Metabolism 
Numerous human and laboratory animal studies have demonstrated that multiple 
neurotransmitter systems, including monoamines, serotonin, dopamine, and glutamate, are 
affected by acute and chronic administration of cytokines.121  Serotonin has been the most 
studied neurotransmitter with regards to inflammation and depression. INF-α has been 
shown to attenuate the expression of 5HT1A, a serotonin receptor.128  Patients treated with 
INF-α have decreased serum serotonin, and this has been more pronounced in those who 
developed depression.129  Moreover, INF-α -associated increases in cerebrospinal fluid 
(CSF) levels of IL-6 have been inversely associated with the serotonin metabolite 5-
hydroxyindoleacetic acid (5-HIAA), indicating lowered brain serotonergic activity.130  The 
exact pathway affected is not clear, but it is know that the enzyme indoleamine 2,3-
dioxygenase (IDO) is activated by various cytokines alone or in combination.131  IDO 
catabolizes tryptophan, the primary amino acid precursor of serotonin, into kynurenine. 
Evidence of a role of IDO in cytokine-induced depression comes from several studies that 
demonstrated correlations between INF-α-induced depression and decreases in 
tryptophan accompanied by an increase in kynurenine and/or the kynurenine to 
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tryptophan ratio.131  Although much of the attention regarding IDO was initially focused on 
the depletion of tryptophan and therefore, of serotonin, several lines of evidence have 
started to challenge this pathway, and have focused more on the presence of increased 
kynurenine and its metabolites for immune-induced depression.131  
3.5.3 Effects of Inflammation on Neurogenesis and Neurotrophic Factors 
         Pro-inflammatory cytokines can influence neuronal functioning through changes in 
apoptosis, oxidative stress, and metabolic derangement, as well as by impairing processes 
of synaptic plasticity and neurogenesis.120,132  In humans, treatment with INF-α has been 
associated with reduced levels of peripheral brain-derived neurotrophic factor (BDNF), 
which are known to correlate well with BDNF availability in the CNS.133,134  Furthermore 
reduced BDNF during INF-α treatment has been found to correlate with increased 
depression.134  
Figure 1: Potential mechanisms linking inflammation to depression. 
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3.6 Epidemiology of Inflammation and Depression in Women 
Research on the association between inflammation and depression has mainly 
focused in elderly populations, but recent studies have included younger adults, children, 
and different at-risk populations, such as pregnant or post-partum women. The first large 
cross-sectional study to analyze the association between CRP and depression in a 
nationally representative sample using NHANES included 6,914 non-institutionalized men 
and women ages 18-39 years old (women sample size: 3,760). 55  Employing the Diagnostic 
Interview Schedule (DIS) depression questionnaire to assess depression, which was 
categorized into recurrent depression and severe depression within the last year and 
within their lifetime. Ford and colleagues found a higher proportion of women 
experiencing lifetime depression (11.7% vs 5.7%) compared to men. CRP was 
dichotomized at the limit of detection (0.21 mg/dL), and labelled as “low CRP” and “high 
CRP”. Almost a third (27.3%) of women were found to have high CRP levels compared to 
only 13% of men.  A history of major depression was associated with elevated CRP level 
(OR: 1.64, 95%CI 1.20, 2.24) in both men and women. When stratified by gender, no 
significant associations were found between depression and inflammation in women (past 
year depression OR=0.76, p=0.33; history of depression OR= 1.39, p=0.24). Among men, 
CRP levels were significantly higher in those experiencing a recent episode of depression 
(OR=3.00, 95% CI 1.39-6.48) and those with recurrent depression (OR= 3.55, 95% CI 1.55-
8.14) compared to their non-depressed counterparts.55 Despite having a large, nationally 
representative sample size, this study was limited by the low sensitivity of the CRP 
concentration detected by their assay, as 74.1% of the population fell below the limit of 
detection (0.21 mg/dL), therefore the study was forced to categorize CRP levels into 
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low/high based on the limit of detection (low CRP: <0.21 mg/dL and high: >0.21 mg/dL). In 
addition to the cross-sectional limitation of the study design, the severity of depression was 
not determined since the depression questionnaire only assessed the presence of major 
depression disorder in a yes/no manner, limiting the potential to assess the degree to 
which inflammation may be contributing to depression. 
In another study, Matthews et al. (2010) assessed the bi-directionality of the 
relationship between depression and CRP in the prospective Study of Women’s Health 
Across the Nation (SWAN) over a 7-year period.135  The Center for Epidemiological Studies 
Depression scale (CES-D) was used to assess depressive symptoms during the previous 
week in 1,781 women ages 42-52 years old on a yearly basis. Using multivariable 
longitudinal linear mixed regression model (woman-specific), they found that initial higher 
depression scores at time X predicted higher subsequent CRP levels and vice-versa over a 
7-year period.  After adjustment for BMI, physical activity, medications, and health 
conditions, higher CRP levels at year X significantly predicted higher depression scores in 
the subsequent year (p=0.03). Higher depressive symptoms also predicted higher CRP in 
the following year, but this association was not significant (p=0.10). In other words, they 
found that CRP remained a modest, yet statistically significant, predictor of subsequent 
depressive symptoms one year later, whereas the reverse association (depression as 
predictor of inflammation) only approached significance. Despite it being a strong study 
with multiple measurements of each exposure and outcome, and an ethnically-diverse 
population, this study was limited by its inclusion of only an older sample population of 
women. This is an important study because it sheds light on the directionality of this 
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association, suggesting that among women, inflammation is a predictor of depression, and 
not the other way around. 
Gimeno et al. (2008) assessed whether CRP predicted cognitive symptoms of 
depression or whether the symptoms of depression predicted inflammatory markers in the 
Whitehall II study in London.136  Participants consisted of office staff ages 35-55 from 20 
different London-based civil service departments. Baseline measurements took place in 
1991-1993, and follow-up assessment took place in 2002-2004 (mean follow-up was 11.8 
years). They excluded those with CRP >10 mg/L and those who reported a cold or flu in the 
2 weeks prior to assessments. The remaining sample size included 5,978 participants 
(1,803 women) for baseline and 3,339 for follow-up (951 women).  At baseline, women had 
significantly higher levels of both CRP and cognitive symptoms of depression compared to 
men (CRP: 0.91±3.2 vs 0.77±3.0 mg/L; p<0.001; Depression score: 1.17±1.9 vs 0.95±1.7; 
p<0.001, respectively).  However, in the cross-sectional analyses at baseline of 
inflammation and cognitive symptoms of depression, CRP (β=-0.067, p=0.011) was 
negatively associated with cognitive symptoms of depression among women, but not 
among men (p for sex interaction=0.025).  In longitudinal analyses of CRP and cognitive 
depression score, the association was statistically significant for the whole group (β=0.046, 
p=0.004). When the analysis was stratified by gender, men had a slight positive and 
significant association between CRP and depression (β=0.058, p=0.002), but this was no 
longer significant in women (β=0.02, p=0.522). It must be noted that 2,388 men were 
included in this analyses, whereas only 951 women were included.  Additionally, they 
showed that cognitive symptoms of depression at baseline did not predict CRP levels at 
follow-up (β= -0.013, p=0.341) for either gender.136  
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Some of the limitations of this study include an older sample population (mean age 
for women was 50.4±6.1 years) and no mention of menopausal status of the women, 
allowing for the possibility that menopausal state could bias the results towards the null, as 
younger women (including women with menstrual cycles) tend to have higher depression 
rates. Furthermore, for the longitudinal analysis, the long follow-up time (11.8 years) could 
actually be too long to be able to detect a true predictive association between inflammation 
at baseline and depression at follow-up.  
Overall, Ford et al found a significant association between lifetime history of major 
depression and elevated CRP levels in a nationally representative sample of US adults with 
a cross-sectional analysis.55  In longitudinal analysis, two studies found that inflammation 
predicts depression, but that depression does not predict inflammation.135,136  There is 
growing evidence that nutrition could be playing a very important role in both 
inflammation and the development or severity of depression, and none of the previous 
studies accounted for any biomarkers of nutritional status. 
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CHAPTER 4 
NUTRITIONAL STATUS: EMPHASIS ON VITAMINS D AND B6 
4.1 Micronutrients of Interest - Introduction 
Micronutrient status plays an important role in maternal and child health. Both 
vitamin D and B6 are considered micronutrients with a surprisingly large prevalence of 
insufficiency and deficiency in the female U.S. population, which can lead to increased risk 
of disease. This chapter will review the epidemiology of each micronutrient in the U.S. with 
an emphasis on women of reproductive age, followed by background information on 
metabolism, transport, food sources, and assessment of each. The association between each 
micronutrient and inflammation as well as depression will also be reviewed. 
4.1.2 Epidemiology of Vitamin D Status in the US 
  According to the National Center for Health Statistics, in 2001-2006, one third of 
individuals aged 1 year were at risk for vitamin D inadequacy or deficiency.141   
Furthermore, a recent publication using NHANES data shows that mean serum 25-hydroxy 
vitamin D (25-OHD) was lower in 2000-2004 compared to 1988-1994, suggesting a decline 
in either consumption of vitamin-D containing foods, cutaneous vitamin D synthesis, or 
both.141 
For women of childbearing age, maternal vitamin D malnutrition imposes multiple 
health impacts on both women and their offspring.142  Women with suboptimal vitamin D 
status are at increased risk for pre-eclampsia and eclampsia, gestational diabetes, and 
bacterial vaginosis.142  Furthermore, vitamin D deficiency during pregnancy or in the 
postpartum period has been associated with increased risk of rickets, type 1 diabetes, 
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allergies, asthma, and schizophrenia in the offspring as well as maternal depression.143 The 
potential consequences of vitamin D deficiency in women of reproductive age is 
particularly troublesome considering that a large proportion of this population within the 
U.S. has suboptimal levels of circulating vitamin D. Recent estimates found that 
approximately 78% of women have vitamin D insufficiency and 42% have vitamin D 
deficiency.144  Additionally, these proportions vary by ethnicity:  vitamin D levels are much 
lower in non-Hispanic Blacks, followed by Hispanics, and non-Hispanic White females. 
Eighty-six percent of African American women have vitamin D deficiency, followed by 60% 
of Hispanic and 26% of non-Hispanic White women. With regards to insufficiency, 99%, 
93% and 69% of non-Hispanic Blacks, Hispanics, and White women, respectively, have 
suboptimal levels of circulating vitamin D. 159,219   
4.2 Background on Vitamin D 
Vitamin D is both a hormone and a vitamin, known to have many functions in health 
maintenance and disease prevention. The term vitamin D refers collectively to the two 
major nutritionally relevant forms: vitamin D3 or cholecalciferol, which is formed in the 
skin following exposure to sunlight or ultraviolet light, and ergocalciferol or vitamin D2 
which is obtained by irradiation of plants, phytoplankton, yeast, invertebrates, and fungi 
containing ergosterol.145 
4.2.1 Uptake of Dietary Vitamin D 
Due to the fat-soluble nature of vitamin D, it is absorbed with other lipids in the 
intestine, a process facilitated by bile and pancreatic lipase. Following absorption, vitamin 
D is integrated into chylomicrons and enters the lymphatic system, which drains into the 
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main circulation. Lipoprotein lipase, particularly in adipose tissue, acts upon chylomicron 
lipids and may result in a portion of the vitamin D being taken up by fat cells. This 
observation suggests a mechanism whereby increased adiposity causes sequestering of 
vitamin D and is related to lower vitamin D status. 220  Vitamin D sequestration in adipose 
tissue is a nonspecific process, and these stores may not be actively used in periods of 
need.220  After depletion of triacylglycerols, the cholesterol-rich chylomicron remnants, 
which still contain a significant fraction of the absorbed vitamin D, are taken up by the 
liver. 
4.2.2 Endogenous Synthesis of Vitamin D 
Most vitamin D in serum comes from endogenous production in human skin, from 
the precursor, 7-Dehydrocholesterol (7-DHC).  Following exposure to sunlight, 7-DHC in 
the skin absorbs ultraviolet B (UVB) photons between the wavelengths of 290-320nm and 
is converted to pre-vitamin D3.221  At normal body temperature, pre-vitamin D3 undergoes 
thermal isomerization to form vitamin D3, which is more easily translocated from the skin 
cells to the bloodstream. In circulation, vitamin D3 travels bound to a specific α1-globulin 
known as vitamin D-binding protein (DBP), the major plasma carrier of all vitamin D 
metabolites. This complex then travels to the liver, where vitamin D metabolism starts. 
Toxic levels of vitamin D do not occur from prolonged sun exposure, which degrades into 
many inactive forms, such such as lumisterol and tachysterol. 222 
4.2.3 Metabolism of Vitamin D 
Vitamin D, as either D2 or D3, is considered biologically inactive until it undergoes 
two enzymatic hydroxylation reactions. Circulating vitamin D2 or D3 in chylomicron 
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remnants, as well as vitamin DBP-bound vitamin D3 from endogenous synthesis, are first 
taken up by the liver and hydroxylated by hepatic 25-hydroxylase (25-OH-ase) from the 
CYP27A gene to form 25-hydroxycholecalciferol (25-OHD). 25-OHD then circulates in the 
blood stream as a complex with DBP, and when the active form of vitamin D is required due 
to decrease in serum calcium or phosphate, 25-OHD is further hydroxylated by 1α-
hydroxylase (CYP27B1) in the kidneys. 223  This second hydroxylation converts 25-OHD to 
the biologically active form: 1,25-dihydroxyvitamin D (1,25-[OH]2D), also known as 
calcitriol. The 1α-hydroxylase gene is also expressed in several extra-renal tissues, but its 
contribution to the formation of the active form of vitamin D in these tissues is unknown. 
224  The enzymatic reaction producing 1,25-(OH)2D is tightly regulated by two 
counteracting hormones: up-regulation by parathyroid hormone (PTH) and down-
regulation via fibroblast-like growth factor-23 (FGF23).225 This control of vitamin D 
activation constitutes the basis of the vitamin D endocrine system that is central to 
maintaining calcium and phosphate homeostasis. Following its synthesis in the kidney, 
calcitriol binds to DBP to be transported to target organs. Catabolism of 1,25(OH)2D to 
more polar and readily excretable inactive metabolites, 24,25(OH)2D and 1α, 24,25(OH)2D, 
begins with the 24-hydroxylation of either 25-OHD or 1,25(OH)2D, respectively. Calcitriol 
induces its own destruction by stimulating these enzymes.226  
4.2.4 Assessment of Vitamin D Status 
Both 25-OHD and 1,25(OH)2D levels can be measured in serum or plasma.227 
However, circulating 25-OHD concentration is the best biomarker of vitamin D status 
because it reflects both increases in vitamin D intake and cutaneous production of vitamin 
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D3. Serum 25-OHD also has a longer half-life of approximately 15 days compared to the 
shorter half-life of 4-6 hours for 1,25(OH)2D.168  Furthermore, serum 1,25(OH)2D 
concentration is tightly controlled by PTH, calcium, and phosphate,168 and levels do not 
typically decrease until vitamin D deficiency is severe. 228 
The serum vitamin 25-OHD concentrations used to define deficiency, marginal 
deficiency, normal ranges, and toxic levels are somewhat controversial. Table 1 shows the 
Institute of Medicine (IOM)-proposed cut-offs for assessing vitamin D sufficiency, 
deficiency, and toxicity using serum 25-OHD concentrations. While these cutoffs serve as 
the more “traditional” reference guidelines, literature on the topic suggests that the optimal 
serum concentration of 25-OHD is probably much higher than the recommended 
concentration for adults. Table 2 shows the proposed alternate 25-OHD reference limits 
considered “acceptable” by leading researchers in the field. 229,230  
 
Table 1. Institute of Medicine (IOM) Rec 1 
Table 1: Institute of Medicine (IOM) Recommended                                              
Serum 25-Hydroxyvitamin D (25-OHD) 
25-OHD level 
(ng/mL)* 
25-OHD Level 
(nmol/L)** 
Health Status 
<12 <30 
Associated with vitamin D deficiency, leading to 
rickets in children and osteomalacia in adults 
12 to 20 30 to 50 Generally considered inadequate for bone and 
overall health in healthy individuals ≥20 ≥50 
>50 <125 
Emerging evidence links potential adverse effect 
to such high levels, particularly >150 nmol/L 
(>60 ng/mL) 
Source: Institute of Medicine, Food and Nutrition Board. Dietary Reference Intakes for 
Calcium and Vitamin D. Washington, DC. National Academy Press, 2010. 
*Serum concentrations of 25-OHD are reported in both nanomoles per liter (nmol/L) 
**1ng/mL = 2.496 nmol/L   
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Table 2: Alternate Recommendation of Different Levels of Serum 25-OHD 
25-OHD Level 
(ng/mL)* 
25-OHD Level 
(nmol/L)** 
Health Implication 
<20 50 Deficiency 
20-29.9 50-75 Insufficiency 
≥30 >75 Sufficiency 
>150 >374 Intoxication 
Source: Holick, Michael F. Vitamin D Deficiency. N Engl J Med 2007; 357:266-281 
*Serum concentrations of 25-OHD are reported in both nanomoles per liter 
(nmol/L) and nanograms per milliliter (ng/mL). 
**1ng/mL = 2.496 nmol/L 
 
4.2.5 Factors Affecting Vitamin D Status 
Many variables can affect cutaneous synthesis of vitamin D, making it a challenge to 
estimate average 25-OHD levels produced by sun exposure in North America.231 Cutaneous 
synthesis of vitamin D is affected by the amount of solar UVB radiation that reaches the 
earth’s surface, which depends on latitude, season of the year, and time of the day of sun 
exposure. At latitudes above 40o N below 40o S, the amount of vitamin D synthesized 
between November and February is extremely low because vitamin-D producing UVB 
photons pass through the ozone layer at an oblique angle, causing many to be absorbed by 
the ozone. More UVB photons penetrate the ozone layer in the spring, summer, and fall 
months because the sun is directly overhead. Studies suggest a seasonal change in serum 
25-OHD concentrations between the winter nadir and the summer zenith of approximately 
25 nmol/L.231 
The cutaneous synthesis of vitamin D, and its contribution to serum vitamin D 
levels, also depends upon the presence of 7-DHC in the skin. Aging, melanin pigmentation, 
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clothing, and use of sunscreen also affect cutaneous synthesis. 232  Aging decreases the 
synthesis of 7-DHC in skin, thereby reducing the production of vitamin D3 by approximately 
75% by age 70 years compared to younger adults. 232  The skin pigment melanin is a 
natural sunblock that competes with 7-DHC for UVB photons, therefore, darker-skinned 
persons require a much longer sun exposure in order to make the same amount of vitamin 
D as lighter-skinned individuals.233  Using sunscreen and wearing clothing that completely 
covers the body can also block UVB photons, reducing vitamin D synthesis. 240  
Obesity can affect the amount of dietary vitamin D that reaches the liver. While in 
chylomicrons, a portion of dietary vitamin D is sequestered in adipose tissue in a 
nonspecific manner, and these stores may not be actively used in periods of need. This 
suggests a mechanism whereby increased adiposity causes sequestering of vitamin D and is 
related to lower vitamin D status. 220  Therefore, obese individuals may require higher 
intakes of vitamin D to achieve serum concentrations of 25-OHD comparable to those 
observed among lean individuals.  For instance, Blum et al (2008) supplemented elderly 
subjects with 700 IU daily for a year, and found that serum levels of 25-OHD were 
approximately 10 nmol/L lower for every additional 15 kg of weight above “normal”. 235  
Available literature demonstrates that serum 25-OHD levels increase in response to 
increased vitamin D intake, although overall, it can be concluded that the relationship is 
non-linear rather than linear. A summary of 16 human trials suggested the following 
association between dietary vitamin D and 25-OHD concentration: for each additional 100 
IU of vitamin D3, serum 25-OHD concentrations increased by 1 to 2 nmol/L.236  However, 
this increase of serum 25-OHD differs based on the starting 25-OHD concentrations. Chung 
et al (2009) confirmed the association between increasing doses of vitamin D and 
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increasing net change in serum 25-OHD concentration in both adults and children, but 
concluded that the dose-response relationships differ depending on the subjects’ baseline 
serum 25-OHD levels (≤40 vs >40 nmol/L) and duration of the supplementation (≤3 vs >3 
months).237 There is evidence that increasing serum 25-OHD level above approximately 50 
nmol/L requires more vitamin D intake than does increasing serum 25-OHD levels when 
the starting point is less than 50 nmol/L.238 Furthermore, there have been reports that the 
rise in serum 25-OHD level for a given dose tends to stabilize by week 6 and does not vary 
with age at least up to 80 years of age. 239 
4.2.6 Dietary Sources & Recommended Dietary Allowance for Vitamin D 
The dietary sources of vitamin D include food and dietary supplements. Very few 
foods naturally contain vitamin D3. These include egg yolks and oily fish, such as salmon, 
mackerel and herring and liver oils from cod, tuna and shark. 173  Sun-dried mushrooms 
also contain some vitamin D2.  In the United States, the foods fortified with vitamin D (D2 or 
D3) include milk, breads and cereals, margarine, yogurts and cheeses, and some brands of 
orange juice.173   
 In recent years, dietary supplements containing vitamin D have become more 
common and have been more frequently consumed. 173  Traditionally, many supplements 
have contained 400 IU per daily dose, but levels in supplements have been increasing and 
can be found in the range of 1,000 to 5,000 IU of vitamin D3 per dose and even up to 50,000 
IU of vitamin D2 per dose.173  Recent findings suggest that vitamin D3 may be more efficient 
at increasing serum 25-OHD levels compared to vitamin D2.240 
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The current recommended dietary allowance (RDA) is the daily dose that should 
meet the nutritional needs of 98% of healthy individuals in the US for a specific nutrient. 
The RDA for vitamin D represents a daily intake that is sufficient to maintain normal 
calcium homeostasis and bone health in healthy individuals with minimal sun exposure. 
RDAs for vitamin D vary by age and gender. For women of reproductive age (14-50yrs), the 
RDA is set at 600 International Units (IUs) (15micrograms) per day.173  
4.2.7 Biological Activities of Vitamin D 
1,25(OH)2D is considered the biologically active hormonal form of vitamin D 
responsible for carrying out most, if not all, of the biological functions of vitamin D.  The 
biological actions of 1,25(OH)2D involve regulation of gene expression at the 
transcriptional levels and are mediated through binding to a vitamin D receptor (VDR), 
located primarily in the nuclei of target cells. 241  Until recently, the main known role of 
vitamin D was to control bone metabolism and calcium and phosphorus homeostasis. But 
in the past decade, the VDR has been discovered in many tissues throughout the body (e.g. 
gut, kidney, gonads, heart, muscle, brain, and skin), implying that 1,25(OH)2D may play a 
role in these organs. Furthermore, the specific vitamin D-responsive elements (VDREs) 
considered the hallmark of vitamin D action are present in a large number of human genes 
involved in a wide range of roles, such as modulation of cell growth, 242  neuromuscular243 
and immune function, including and reduction of inflammation, 244  to mention a few. 
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4.3 Vitamin B6 
4.3.1 Epidemiology of Vitamin B6 Status in the US 
A recent cross-sectional study on vitamin B6 status in the US population found that 
regardless of vitamin B6 supplementation, plasma Pyridoxal-5’phosphate (PLP) – the 
principal biomarker of vitamin B6– of women of childbearing age was significantly lower 
than those of comparably aged men. A fourth of women in the U.S. have insufficient vitamin 
B6 levels as defined plasma PLP levels <20 nmol/L.137  Among oral contraceptive users, 
seventy-five percent were found to have suboptimal vitamin B6 levels (Morris et al, 2008). 
These statistics are worry-some considering that maternal vitamin B6 levels may affect the 
neurological development of their offspring.138 Furthermore, clinical studies have shown 
that suboptimal vitamin B6 status decreases probability of conception139  and increases risk 
of pregnancy complications, including spontaneous abortions.140  
4.3.2 Vitamin B6: Background 
Vitamin B6 is a water-soluble vitamin that functions as a coenzyme in over 100 
enzymatic reactions involved in the metabolism of amino acids, carbohydrates, 
neurotransmitters and lipids.146  As of recently, it has also been coined a potent antioxidant 
that effectively quenches reactive oxygen species.147  Vitamin B6 currently refers to a 
collective of six biologically interconvertible 3-hydroxy-2-methylpyridine compounds: 
pyridoxine (PN), pyridoxal (PL), pyridoxamine (PM) and their respective 5’-phosphates: 
PNP, PLP and PM.148  In addition to the 6 forms of vitamin B6, there also is a glucoside form 
of pyridoxine that exists in variable amounts in plant foods.149    
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The most abundant and biologically active form of vitamin B6 is PLP, serving as a 
coenzyme in numerous biological processes that include tryptophan-niacin conversion, 
heme synthesis, gluconeogenesis, neurotransmitter synthesis, and amino acid 
metabolism.150  Given PLP’s wide range of functions, deficiency of vitamin B6 can have 
serious and diverse physiologic effects, including microcytic anemia, seborrheic dermatitis, 
epileptiform convulsions, depression, and confusion.148  
Although vitamin B6 is widely available in food such as fortified cereal products, 
fruits, vegetables, nuts, beans, legumes, and animal products, recent literature suggests that 
a larger portion of the population than previously thought may be at risk for low vitamin B6 
status, specifically women of childbearing age.137  This review will provide background on 
vitamin B6, its sources, metabolism, assessment in humans, and its connection with 
inflammation. 
4.3.3 Dietary Sources, Intake & DRI for Vitamin B6 
Vitamin B6 is widely available in foods such as whole grain products, meat, fish, 
poultry and non-citrus fruits in the American diet. Other rich sources include highly 
fortified cereals, beef liver, and other organ meats.148  The major forms in animal tissue are 
the coenzyme species PLP and PMP. In most fruits, vegetables and cereal grains, a 
significant fraction of vitamin B6 is pyridoxine-5’-β-D-glucoside, a form that is partially 
available as a source of vitamin B6.146  Vitamin B compounds, particularly PL and PLP, are 
light sensitive; furthermore large losses of food vitamin B6 can occur during heating and 
leaching of the vitamin during food preparation.148 
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The adequacy of vitamin B6 nutrition depends on the quantity of dietary B6 
consumed as well as its bioavailability, defined as the extent of intestinal absorption and 
metabolic utilization.146  Vitamin B6 is absorbed in the small intestine by a non-saturable 
passive diffusion mechanism.148  The bioavailability of B6 supplements or fortified foods in 
the form of pyridoxine is roughly 90%, whereas in the rest of non-fortified sources, it 
depends on the form of B6; bioavailability of non-glucoside forms of the vitamin in food is 
greater than 75% and the bioavailability of pyridoxine-5’-β-D-glucoside in food is about 
half as much.146   
4.3.4 Dietary Reference Intakes for Vitamin B6 
The main criterion used in setting the estimated average requirement (EAR) for 
vitamin B6 is plasma PLP value of at least 20 nmol/L.151  The EAR for vitamin B6 is 1.1 mg 
per day for adults ages 19-50 years old, and the RDA is 1.3 mg/day or 20% more than EAR 
to allow for variance in need.148  Data from NHANES 2001-2002 showed the median 
vitamin B6 dietary intake of U.S. women (19 years or older) is 1.45 mg/day. Intake of 
women ranges (5th to 95th percentile) from 0.79 to 2.51 mg/day. Recent evidence shows 
that a higher RDA may be prudent, especially for women. Data from NHANES 2003-2004 
suggests that a daily vitamin B6 intake of 3.0 to 4.9 mg/day is generally adequate to 
maintain an acceptable plasma PLP concentration, but a large portion of women of 
childbearing age, do not maintain adequate vitamin B6 status at that intake level.137  
4.3.5 Vitamin B6 Metabolism 
After consumption, the phosphorylated vitamers are dephosphorylated in the 
intestinal mucosa, and are absorbed rapidly by carrier-mediated diffusion.152  Most of the 
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absorbed non-phosphorylated B6 is taken up by the liver and metabolized to PLP, the major 
co-enzymatic form.148   PN, PL, and PM are converted to their respective 5’-phosphate 
derivatives by the enzyme PL kinase, which is present in all tissues, including erythrocytes. 
Non-phosphorylated forms of vitamin B6 can move freely in and out of tissues, whereas 
phosphorylation ensures metabolic trapping. Tissue concentrations of pyridoxal phosphate 
are controlled by the balance between phosphorylation and de-phosphorylation.152  Free 
pyridoxal either leaves the cells or is oxidized to 4-pyridoxic acid by aldehyde 
dehydrogenase (which is present in all tissues) and also by hepatic and renal aldehyde 
oxigenases.152  4-Pyridoxic acid is the inactive excretory metabolite, which is actively 
secreted by the renal tubules.    
At high intakes of vitamin B6, tissue-binding capacity may be exceeded and the free 
PLP is rapidly hydrolyzed to the non-phosphorylated PL, which is released by the liver and 
other tissues into circulation. However, product inhibition of the PNP oxidase by PLP 
renders the relationship between PN intake and PLP concentration in tissues and plasma 
non-linear.148 
4.3.6 Vitamin B6 Transport and Turnover 
Under normal conditions, most circulating vitamin B6 is present as PLP that is mainly 
Schiff base-linked to proteins, primarily albumin in plasma and hemoglobin in 
erythrocytes. Although 90% of vitamin B6 is plasma is present as PLP, the total is less than 
0.1% of the total body vitamin B6.153  Estimates of total body vitamin B6 stores in healthy 
adults range from approximately 400 µmol to 1,000 µmol (60 to 170 mg), and 80% to 90% 
of this is in muscle, primarily bound to glycogen phosphorylase.148  The overall body half-
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life of vitamin B6 is estimated to be roughly 25 days, with an estimated daily fractional 
turnover rate of less than 3%. However, this half-life could be longer given the slow 
turnover of the large pool of B6 bound to glycogen phosphorylase.148 
4.3.7 Assessment of Vitamin B6 Status 
A variety of biochemical indicators have been used to assess vitamin B6 status. Even 
though vitamin B6 status is most appropriately evaluated using a combination of direct (i.e., 
vitamin concentration in plasma or cells) and indirect (i.e., erythrocyte amino transferase 
saturation by PLP or tryptophan metabolites),153 plasma or serum PLP may be the best 
single indicator because it is a reflection of liver PLP and thus tissue stores.154 Circulating 
PLP concentration is normally measured by an enzymatic assay using the apoenzyme form 
of tyrosine decarboxylase or by high performance liquid chromatography.148  
A plasma or serum PLP level of less than 20 nmol/L is considered to reflect 
inadequate vitamin status in adults, although some support a threshold of 30 nmol/L for 
assessing sufficiency.148  However, there is no definite consensus for a value that 
unquestionably defines a deficient state of this nutrient.155  Plasma PLP increases 
approximately 12 nmol/L for each 1 mg/day increase in vitamin B6 intake.137  Indicators 
for assessing vitamin B6 status are shown in the table below (table 3).153  
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Table 3: Vitamin B6 Biomarkers. 
 
Source: McCormick, D. B. in Present Knowledge in Nutrition 1, 269–277 (International Life Sciences Institute, 2006).  
 
4.3.8 Factors that Can Affect Vitamin B6 Status 
There are several factors that have been shown to decrease plasma PLP status, 
including smoking, certain medications, oral contraceptives or hormone replacement 
therapy, pregnancy, renal failure, alcoholism and inflammation.197,198  Vitamin B6 deficiency 
my result from the prolonged use of drugs that are carbonyl-trapping reagents, and can 
form biologically inactive adducts with pyridoxal and pyridoxal phosphate.152 Such 
compounds include penicillamine, the antituberculosis drug isoniazid, and the anti-
Parkinsonian drugs benserazide and carbidopa.  
Several studies have found smokers to have lower plasma PLP levels presumably 
linked to smoker’s increased inflammation levels.137,157,158  With regards to alcohol intake, 
despite alcoholism being associated with nutritional deficiency of B-vitamins, a recent 
study found alcohol intake to be positively associated with higher plasma PLP in the Boston 
Puerto Rican Health Study.157     
Plasma PLP decreases during pregnancy more than can be accounted for by 
increased blood volume, with the most significant drop in the third trimester.159   This 
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reduction in plasma PLP may represent a normal physiological change in pregnant women 
as there have been no reports of clinical symptoms of deficiency in pregnant women with 
decreased status.159   There may be several reasons for this decrease, including fetal 
sequestration of plasma PLP or a shift in maternal distribution in favor of erythrocytes over 
plasma.153,160   However, Barnard and colleagues (1987) have shown that, despite the fall in 
plasma PLP in pregnancy, the plasma concentration of PLP plus pyridoxal is unchanged.161   
Renal failure and other conditions in which plasma alkaline phosphatase is elevated (i.e., 
pregnancy and metabolic bone disease) are associated with low plasma PLP and a 
corresponding increase in pyridoxal.153  
Obesity has also been noted to affect vitamin B6 status. In a cross-sectional study of 
morbidly obese adults in Norway, several vitamins including plasma B6, vitamin C, vitamin 
D and vitamin E, were found to be lower in morbidly obese men and women compared to 
healthy controls.162   Given that obesity is a state of chronic low-grade inflammation, it 
could be contributing to compromised B6 status via inflammation. Plasma PLP is also 
affected by acute phase responses, such as in inflammation and infection.163  This 
association will be further discussed in the following sections. 
4.3.8.1 Estrogens and Vitamin B6 Status 
The connection between vitamin B6 status and oral contraceptive use was first 
noted by Rose in 1966, when increased urinary excretion of xanthurenic acid, kynurenine, 
and 3-OH-kyurenine was observed following a tryptophan load test.164 Several studies 
followed with similar findings, where supplementation with high doses of vitamin B6 in the 
form of pyridoxine hydrochloride corrected the abnormal tryptophan metabolism in 
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women taking OCs.165–167  Although these studies may appear as evidence of estrogen-
induced vitamin B6 deficiency or depletion, when other indices of vitamin B6 nutritional 
status were measured, they seemed to be unaffected by contraceptive use, suggesting an 
effect on tryptophan metabolism, rather than on vitamin B6 nutritional status.152  These 
studies led to a general consensus that estrogen disrupts tryptophan metabolism 
independent of vitamin B6 status, rendering the tryptophan load test a poor indicator of 
vitamin B6 status in OC users.168  
 Although the association between OC use and tryptophan metabolism is well 
established, the potential effect of OC use on vitamin B6 status and requirements remains 
controversial.169  In a recent large-scale population-based study performed in the U.S. using 
the NHANES 2003-2004 cycle, plasma PLP concentration was found to be significantly 
lower (<20 nmol/L) in 75% of OC users who were not supplementing with vitamin B6.137  
Morris and colleagues also assessed current vitamin B6 intake and suggested that intakes 
higher than the current RDA may be necessary to maintain adequate vitamin B6 status in 
OC users.137   In another cross-sectional study in Italy, women who had not been taking OCs 
for at least 12 months had significantly higher vitamin B6 levels compared to current OC 
users.170  In a prospective studies of OC use and vitamin B6 status, an initial lowering of 
plasma PLP levels was observed three months after start of OC use; however, plasma PLP 
levels returned to pre-treatment levels by six months of OC use.171  These findings suggest 
that the effects of OC use on vitamin B6 concentrations may be transient. 
Although OC use may be associated with a reduction in plasma PLP levels, the 
mechanism by which OC use may lower plasma PLP concentration is not well defined, but 
some suggest that plasma PLP may redistribute into tissue in response to OC use.172 
 48 
 
Another possible explanation could be that OC use induces certain PLP-dependent 
enzymes, such as tryptophan oxygenase, causing an increased need for the vitamin in 
metabolism.172  A third explanation for the low plasma PLP concentrations observed in OC 
users involves inflammation.169  OC use is associated with increased serum CRP 
concentrations.67  Krintus and colleagues (2009) found three-fold higher CRP levels among 
OC users compared to non-OC users.173  Furthermore, Williams and colleagues found 
similar results in their study, which indicated that combined OC use was associated with 
increased CRP levels in women independent of other factors, such as obesity.174  
4.3.9 Biological Activities of Vitamin B6 
The metabolically active vitamer is pyridoxal phosphate, which serves as a 
coenzyme for over 100 reactions, primarily in amino acid metabolism, such as 
aminotransferases, decarboxylases, aldolases, racemases and dehydratases.148  The 
catabolism of nearly all amino acids involves transfer of their amino group to α-keto acids, 
which requires PMP.  Furthermore, decarboxylases are essential in the formation of many 
hormones and neurotransmitters, such as serotonin, epinephrine, and dopamine, rendering 
vitamin B6 essential for their synthesis. PLP is also a cofactor for mitochondrial δ-
aminolevulinate synthase which catalyzes the first and rate-limiting step in heme 
biosynthesis in the liver.148  The role of PLP in one-carbon metabolism may be especially 
important in nucleic acid biosynthesis and immune system function.168  In addition, PLP 
enzymes are also involved in lipid and carbohydrate metabolism, including in muscle 
glycogen phosphorylase and sphingolipid synthesis and may modulate glucocorticoid 
action.148  Figure 3 below shows a summary of the main metabolic actions of vitamin B6.153   
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4.4 Nutrients related to Depression 
4.4.1 Physiology of Vitamin D and Depression 
Several biological mechanisms may explain the link between vitamin D deficiency 
and depression. These proposed mechanisms are based on the presence of VDR and 1,α-
hydroxylase in the brain. First of all, calcitriol can cross the blood-brain barrier and is also 
synthesized in the brain.246  Secondly, VDRs have been found in many areas of the human 
brain, including the prefrontal cortex, hippocampus, cingulated gyrus, thalamus, 
hypothalamus, and substantia nigra – all of which have been previously linked to the 
physiology of depression. However, current experimental evidence does not fully satisfy 
criteria to establish causality. 247 
Vitamin D has the potential to regulate expression of many genes, including the 
expression of neurotrophins, which regulate neural development and also function in the 
adult brain. 248 Gene expression of three of the four neurotrophins present in mammalian 
brains (NGF, BDNF, NT-3, and NT4/5), are affected by vitamin D.247  Vitamin D could be 
playing an important role in the regulation of neurotransmission, neuroprotection, 
neuroimmodulation, and nerve growth factor synthesis. 250  Therefore, a vitamin D 
deficiency may be contributing to neuronal decline and disruption in neural 
transmission.249 
Another mechanism linking vitamin D to depression is vitamin D’s involvement in 
the neuroendocrinological system by modulating glucocorticoid signaling.251 
Glucocorticoid levels have been found to be higher in patients suffering from major 
depressive disorder. A malfunction in glucocorticoid signaling and the release of cortisol 
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may be a result of low vitamin D levels.251  However, the exact mechanism linking 
glucocorticoids, vitamin D and depression remains unknown.  
And lastly, since vitamin D is associated with higher levels of inflammatory 
cytokines, and inflammation has been linked with depression, compromised vitamin D 
status may be contributing to an inflammatory-induced depression. There is supporting 
evidence for a modulatory effect of vitamin D both in vivo and in vitro on proinflammatory 
cytokines. Firstly, treatment with vitamin D has resulted in decreased production of 
proinflammatory cytokines (or increased production of anti-inflammatory cytokines) in a 
variety of cell types including monocytes, microglia (an important source of 
proinflammatory cytokines in the brain), keratinocytes, and endothelial cells, among 
others.247  Furthermore several studies have found increased proinflammatory cytokine 
levels in individuals with compromised serum vitamin D.  
In summary, there are several mechanisms through which low vitamin D can be 
contributing to depression and there is ample biological evidence to suggest an important 
role for vitamin D in brain development and function, but the current experimental 
evidence base does not yet fully satisfy causal criteria. 247   
4.4.2 Epidemiology of Vitamin D and Depression 
The largest cross-sectional study of vitamin D concentrations and depression in 
adults in the US included 7,970 adults representing over 90 million US non-
institutionalized, civilian population, aged 15-39 from the NHANES III (1988-1994).252 
Vitamin D was categorized into deficient (<50 nmol/L), insufficient (50-75 nmol/L), and 
sufficient (>75 nmol/L). Depression was assessed using the Diagnostic Interview Schedule 
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(DIS), and categorized into major depression, depression episodes longer than two years, 
and current depression. The proportion of individuals with major depression did not vary 
by vitamin D status (p=0.86). However, the proportion of individuals with vitamin D 
deficiency was significantly higher among those who had experienced depression for over 
two years compared to those who had not experienced depression for over two years 
(24.7% vs 19.1%, p=0.039), and those with current depression compared to those without 
depression (27.4% vs 14.5%, p=0.003). In multivariable logistic model, they found that 
those with vitamin D deficiency have 1.85 times the odds of having current depression, 
compared to individuals with sufficient vitamin D levels (OR=1.85, p=0.021), after 
adjusting for age, gender, ethnicity, poverty income ratio, nutritional supplements, 
medication use, geographical location, BMI and serum creatinine. Additionally, they 
observed a higher prevalence of vitamin D deficiency in women, non-Hispanic Blacks, 
persons living below poverty, non-supplement consumers, those with higher BMI, and in 
those with current depression compared to their counterparts.252  A more recent secondary 
analysis of NHANES 2005-2006 focused solely on women ages 20 and over to assess the 
relationship between vitamin D and depression, using the same vitamin D assessment 
method, but the depression assessment tool used in this cycle was the Patient Health 
Questionnaire 9 (PHQ-9). None-the-less, they found a linear statistically significant 
relationship between circulating 25-OHD and depression score (p=0.002) after controlling 
for age, race, and education.175   
Even though most of the available epidemiological studies have been unable to 
establish causality due to their cross-sectional design, a randomized double-blind trial of 
vitamin D supplementation and depression by Jorde et al (2008) provided important 
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evidence for a possible causal relationship between vitamin D and depression. Participants 
in the randomized clinical trial included 334 overweight and obese men and women ages 
21 to 70 years old who were randomized to receive one of two doses of vitamin D (40,000 
IU/week, 20,000 IU/week) or a weekly placebo. Serum vitamin D and depression (using 
the Beck Depression Inventory) were assessed at baseline and at the end of the one year 
period. Even though they did not find continuous 25-OHD to be significantly correlated 
with depression scores at baseline, after participants were stratified by vitamin D status 
(sufficient vs insufficient, or <40 vs ≥40 nmol/L), those with insufficient 25-OHD had 
significantly higher total depression scores (6.0 vs 4.5, p<0.05) compared to those with 
sufficient vitamin D concentration. 253  There was also a modest, yet significant decrease in 
median total depression scores after 1 year of vitamin D supplementation with 40,000 IU 
(median score: 4.5 to 3.0, p<0.01), with 20,000 IU/week (median score: 5.0 vs 4.0, p<0.01). 
The placebo group did not have a significant decrease in depression score after 1 year 
(median score: 4.0 vs 3.8, p>0.05). However, this study was limited to overweight and/or 
obese individuals, and it is not clear whether these findings could be generalized to a 
normal-weight population; furthermore, the median baseline depression scores were low 
in this population, suggesting a very low number of clinically depressed participants. And 
finally, the effect of vitamin D supplementation with 400 IU/day on depression was 
evaluated in the Women’s Health Initiative, a large prospective study that included 36,282 
post-menopausal women. They employed the Burnham scale and current antidepressant 
use to assess depression status, which was assessed every two years.254 After 2 years 
follow-up, those who were randomized to consume daily vitamin D/calcium supplements 
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had an odds ratio of 1.16 (95% CI 0.86-1.56), suggesting that among this population, this 
level of supplementation had no beneficial effects on depression.  
Most epidemiological studies to date have been either cross-sectional or have had a 
small range of depression scores, as the number of individuals with clinically-significant 
depression have been small. The two studies that focused on a large female population did 
not limit their study to females of reproductive age, which are known to have higher rates 
of depression. Furthermore, very few have accounted for inflammation, which may be a 
strong confounder, as vitamin D affects inflammation status, and that, in turn, is 
contributing to the development of depression.  To date, two studies have examined if the 
association between vitamin D and depression is partially affected by CRP levels.222,223 
Although both studies found an inverse association between circulating vitamin D levels 
and depression, they did not find a significant difference in risk of depression among 
subjects with low vitamin D and elevated CRP,222 nor did they find CRP to mediate the 
association between vitamin D and depression. 223 However, these studies did not assess 
whether the association between vitamin D and depression was symptom specific, nor did 
they stratify by gender given that vitamin D and depression affect women 
disproportionately. 
4.4.3 Physiology of Vitamin B6 and Depression 
Even though the exact pathway linking vitamin B6 to depression is not entirely 
understood, two main theories/mechanisms have been proposed for the etiology of 
depression involving vitamin B6 and tryptophan metabolism. The first mechanism involves 
pyridoxal 5’-phosphate as a coenzyme in the tryptophan-serotonin pathway, and a lack of 
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B6 may theoretically cause depression by reducing serotonin levels.257  The second 
mechanism involves vitamin B6 as a key player in the kynurenine pathway which is thought 
to play an important role in the pathogenesis of inflammation-dependent depression. 258 
A link between tryptophan metabolism and depression first became evident with 
the development of serotonin reuptake inhibitor drugs, leading to the first theory, the 
Monoamine/serotonin (5-HT) Theory of Depression, which involves an alteration in 
tryptophan and other monoamine activities in the etiology of depression.259  Nevertheless, 
a direct connection between changes in monoaminergic neurotransmission such as 
serotonin and depression has not been definitely proven.258  
The alternative hypothesis is based on a shift in the tryptophan metabolism from 
serotonin synthesis to the generation of neuroactive metabolites, such as quinolinic acid 
and kynurenic acid, by the kynurenine pathway. The balance between serotonergic and 
kynurenine pathways is controlled by the expression of three rate-limiting enzymes that 
convert tryptophan to kynurenine: indolamine 2,3 dioxygenase (IDO1), IDO2, and 
tryptophan 2,3 dioxygenase (TDO2).258  The expression of these enzymes is tightly 
regulated by the innate immune system. The Macrophage Theory of Depression, first 
proposed in 1990, implicated elevated pro-inflammatory cytokines as a cause of 
depression. 260  With the discovery that several pro-inflammatory cytokines induce the 
expression of IDO1, the two theories were joined to form the new Kynurenine Theory of 
Depression, which ties activation of the immune system to a shift in tryptophan metabolism. 
261 
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4.4.4 Epidemiology of Vitamin B6 and Depression 
After it was first discovered that women taking oral contraceptives had 
compromised vitamin B6 status in the early 1970’s, studies sought to explore possible 
effects of vitamin B6 deficiency on female health. The link between vitamin B6 status and 
depression was first observed in the late 1970’s when an inverse association was found 
between pure pregnancy depression and serum B6 levels in 15 pregnant women. 262  This 
was thought to be due to the high levels of estrogen during pregnancy, which changed the 
brain metabolism increasing the need for pyridoxal 5’-phosphate. Furthermore, fetal 
sequestration of vitamin B6 was thought to contribute to vitamin B6 deficiency in this 
population, leading to depression in the perinatal period. That same year, Livingston and 
colleagues (1978) carried out a more complex study where they assessed the vitamin B6 
status of 40 non-pregnant women of reproductive age (control group), 30 pregnant 
women, 20 postpartum non-depressed, and 24 postpartum depressed women, to see 
whether vitamin B6 status differed by depression state and by pregnancy status. However, 
they found no evidence for vitamin B6 deficiency in women suffering from postpartum 
depression. 263 
Several studies have looked at the association between vitamin B6 and depression in 
the past decade, but the results have varied depending on whether vitamin B6 is measured 
in plasma or in diet. Hvas and colleagues (2004) examined the association between 
depression and vitamin B6 status using the Major Depression Inventory (MDI) and  plasma 
PLP in a small cross-sectional analysis of 140 individuals aged 19-92 years old.11  In this 
study of mostly an elderly population (mean age= 75 years old), they found plasma PLP 
concentration to be inversely associated with depression score after adjusting for age and 
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gender (r= -0.25, p=0.002). Individuals with PLP concentration below 30 nmol/L were also 
found to have higher depression scores compared to those with normal PLP levels after 
adjustment for age and sex (p=0.02; 95%CI 1.2-9.4); however, this study was limited by 
small sample size, older age of participants despite the range including adults aged 19 and 
older, and limited number of participants with depression.  
A study by Tucker and colleagues (2008) examined the association between both 
dietary vitamin B6 and plasma PLP in 618 participants from the Massachusetts Hispanic 
Elderly Study and a neighborhood based comparison group of 251 non-Hispanic Whites 
living in Massachusetts.264 Depressive symptoms were assessed using the Center for 
Epidemiologic Studies Depression Scale (CES-D) with the cutoff denoting depression set at 
16 or higher. Dietary vitamin B6 was assessed using a semi-quantitative food frequency 
questionnaire designed for this population. After adjusting for age, sex and ethnicity, they 
found plasma PLP to be significantly associated with lower CES-D score in the total sample 
(β= -0.12, p<0.05) and in non-supplement users (β= -0.14, p<0.05) as well as with 
depression in the total sample (OR=0.74, 95% CI 0.56, 0.99, after adjustment for folate) and 
in non-supplement users (OR= 0.71, 95% CI 0.52, 0.98). Furthermore, those who had 
plasma PLP levels below 20 nmol/L had almost twice the likelihood of having high 
depression score, compared to those with PLP levels above 20 nmol/L in the total sample 
(OR= 1.74, 95%CI 1.02, 2.89) and in non-supplement users (OR= 1.78, 95% CI 1.03, 3.09).  
However, even though total intake of vitamin B6 (dietary + supplements) was not 
associated with depression score, dietary intake of vitamin B6 alone was inversely 
associated with depression score in the total sample and in non-supplement users 
(p<0.001).264  In this particular study, dietary intake of vitamin B6 was more strongly 
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associated with depressive symptoms in an older cohort than total B6 intake or plasma PLP. 
They determined that for each additional log unit of dietary vitamin B6 intake, there was a 
40% reduction of high depressive symptomatology in this cohort. In the most recent study, 
higher plasma PLP was significantly associated with a decreased prevalence of depression 
(p-trend: 0.03) among 422 adults ages 21-67 years old in Japan.232 In cross-sectional 
analyses, they found that the odds of depression were 46% lower among those in tertiles 
two and three (PLP >25.5 nmol/L; OR: 0.54, 95% CI 0.31, 0.94 and OR: 0.54, 95% CI 0.30, 
0.96, respectively) compared to those in the lowest tertile of PLP (range: 8.1 to 25.5 
nmol/L) after adjusting for age, gender, office, smoking, alcohol intake, physical activity, job 
position, marital status, history of cancer, cardiovascular disease, or mental disease, dietary 
vitamin B12 intake, serum folate and homocysteine concentration, and depression score at 
baseline. However, this association was no longer significant in longitudinal analyses. 
Intervention studies with vitamin B6 supplementation on depression have been 
hard to interpret because most have either focused on supplementation with vitamin B 
complex.265,266 or have studied the effect of supplemental vitamin B6 on other aspects of 
mental health, such as pre-menstrual syndrome267 or anxiety or depression in 
schizophrenic patients268 or in post-stroke patients. 238 A more recent study by Almeida 
and colleagues (2014) found that even though supplemental B vitamins (including 25 mg of 
vitamin B6/day) did not increase anti-depressant efficacy in adults taking citalopram, it did 
enhance and sustain antidepressant response over 1 year, suggesting a potential for the a 
change in treatment guidelines of depression to incorporate B-vitamins.269  Little is known 
about the role of vitamin B6 in the development and severity of depression in adults, 
especially in women of reproductive age, who are at increased risk of depression. 
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The studies examining dietary vitamin B6 alone have yielded controversial results 
regarding the association between vitamin B6 intake and depression. 270,271 However, those 
assessing plasma vitamin B6 and depression have consistently shown an inverse 
association between plasma PLP and depression scores11,232,240  Studies on vitamin B6 and 
depression to date have been mostly limited by small sample size, age of population 
(mostly elderly), heterogeneity in the measure of depression, lack of assessment of possible 
confounders and none have taken inflammation into account.  
4.5 Nutrients Related to Inflammation 
The influence of infection-related inflammation on micronutrient status was first 
recognized in the 1960s by Scrimshaw et al, when changes in concentrations of circulating 
minerals and vitamins, including vitamin D, were observed following infection.176  Several 
decades later, the association between nutrition and inflammation remains an important 
research topic. A recent study attempting to shed light on the association between 
inflammation and nutritional status examined the relationship between c-reactive protein 
and micronutrient concentrations cross-sectionally in a cohort of 2,000 persons from the 
Scottish Trace Element and Micronutrient Reference Laboratory between 2001 and 
2011.177 C-reactive protein was categorized into 6 groups ranging from the lower limit of 
detection to over 80 mg/L.  With the exception of vitamin E and copper, all micronutrients 
tested (vitamins A, D, B6, and C) showed similar significant trends of decreasing plasma 
concentrations as CRP concentrations increased.177  However, due to the cross-sectional 
nature of this study, directionality could not be demonstrated. Even though the 
mechanisms for each of these associations may differ, the effects of inflammation on 
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micronutrient status can be, in part, mediated by pro-inflammatory cytokines that suppress 
hepatic production of many carrier proteins, increasing capillary permeability, and 
promoting sequestration of some micronutrients into the liver and other organs.178  There 
is also the possibility of reverse causation if individuals are sick and have systemic 
inflammation, their appetite may be diminished274 leading to limited dietary intake, and 
consequently, compromised micronutrient status.  
Many different micronutrient biomarkers have been studied with regards to 
inflammation, such as iron, vitamin A, vitamin E, selenium, copper, omega-3 fatty acids 
among others, but vitamin B6 and vitamin D are of special interest in light of inflammation 
and depression. Serum and plasma biomarkers of both of these vitamins are reduced in an 
inflammatory state, and a deficiency of both micronutrients has been associated with 
depression. It is of special interest to study these biomarkers in a female population of 
reproductive age, because both vitamin D and B6 deficiencies are highly prevalent in this 
group, and they are essential for healthy pregnancy outcomes. The following sections will 
provide a review of the literature on each of these vitamins with regards to inflammation. 
4.5.1 Physiology of Vitamin D and Inflammation 
There is considerable evidence for a modulatory effect of vitamin D treatment on 
proinflammatory cytokines both in vitro and in vivo. The vitamin D receptor has been 
identified in peripheral lymphocytes, macrophages, and thymus tissue.179  The biological 
actions of vitamin D are mediated by its binding to a high-affinity vitamin D receptor that 
acts as a ligand-activated transcription factor. Cell-based and animal studies have 
suggested that vitamin D influences inflammation by modulating the expression of several 
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cytokine genes controlled by the VDR. Vitamin D and its analogues inhibit production of 
proinflammatory cytokines (or increase production of anti-inflammatory cytokines) in a 
variety of cell types, including monocytes,180 microglia,181 keratinocytes,182 endothelial 
cells,183 and human benign prostatic hyperplastic cells.184  In addition to mediating the 
release of specific cytokines, vitamin D also increases the expression of cytokine 
receptors.275  Vitamin D promotes proliferation of immunosuppressive regulatory T cells 
towards a T-helper 2 type profile, which has an anti-inflammatory effect.185  VDR knock-out 
mice have higher levels of proinflammatory cytokines and are more susceptible to 
inflammatory diseases such as inflammatory bowel disease compared to normal mice.186  
In humans, vitamin D studies conducted in subjects with a wider range of serum vitamin D 
levels have shown variable results regarding the association of vitamin D and inflammatory 
cytokines. The following section summarizes recent studies on human populations. 
4.5.2 Epidemiology of vitamin D and Inflammation 
Low vitamin D status has been associated with increased risk for chronic disease in 
which inflammation is an underlying component.187  Even though most studies have 
examined the association between vitamin D status and inflammation in adults with acute 
or chronic illnesses, a few recent studies have examined the association between vitamin D 
status and CRP in healthy adults.188 Three recent cross-sectional studies evaluating the 
association between serum vitamin D and c-reactive protein found an inverse association 
in adults without acute illness.189–191 However, the available literature is conflicting. Three 
recent cross-sectional studies found no association between serum vitamin D and CRP192–
194 and two recent randomized clinical trials also found no association between vitamin D 
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supplementation and circulating CRP levels.195,196  However, a meta-analysis of ten 
randomized clinical trials of vitamin D supplementation found a significant inverse 
association between serum vitamin D levels and circulating hs-CRP.197   
Given the inconsistent results in the literature, Amer and Qayyam employed single-
knot spline regression at the median of serum vitamin D concentration to evaluate the 
shape of the association between inflammation and both low and high vitamin D levels in 
NHANES adults. Study participants (15,167 men and women) were divided into two 
groups: low vitamin D group (those with 25-OHD < 21 ng/mL) and high vitamin D group 
(those with 25-OHD ≥ 21 ng/mL). Mean CRP values in the lower and higher 25-OHD were 
2.2 and 1.7 mg/L, respectively.189  In univariate spline linear regression model among those 
in the low vitamin D group, CRP decreased as the serum 25-OHD level increased (p<0.001). 
However, in the high vitamin D group, an increase in 25-OHD was not associated with any 
statistically significant decrease in the CRP level (95%CI -0.11, 0.001; p=0.07). In 
multivariable linear regression, this inverse association seen between vitamin D and CRP in 
the low vitamin D group (< 21ng/mL) remained unchanged (p<0.001). However, in the 
high vitamin D group, the association between CRP and vitamin D reversed in multivariable 
regression, and CRP was positively associated with vitamin D levels.189  These results shed 
light on the potential interactions and mechanisms at play in the association between 
circulating vitamin D levels and inflammation. It is possible that vitamin D supplementation 
among healthy subjects with baseline vitamin D levels ≥21 ng/mL might not have 
additional effects on systemic inflammation.  A second study using restricted spline 
regression 86 found a U-shaped association between 25(OH)-vitamin D and CRP among 
healthy adults, with a nadir between 52-62 nmol/L (21-25 ng/mL), suggesting that below 
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these levels, 25(OH)-vitamin D may have an anti-inflammatory effect, but above these 
levels vitamin D may have a pro-inflammatory effect. 
In order to discern the association between vitamin D status, supplementation, and 
its effect on inflammation, Chen et al (2014) completed a meta-analysis of ten randomized 
controlled trials including a total of 924 participants. They found that vitamin D 
supplementation significantly decreased the circulating CRP level by 1.08 mg/L (95%CI -
2.13, -0.03). Furthermore, after subgroup analysis, they found a higher reduction of CRP by 
2.21 mg/L (95%CI -3.50,-0.92) among participants with baseline CRP level ≥5mg/L. 
Additionally, their analysis revealed that baseline CRP level, supplemental dose of vitamin 
D and intervention duration together may be attributed to the heterogeneity across 
studies.197  They concluded that vitamin D supplementation was indeed beneficial for the 
reduction of circulating CRP, but the results of studies should be interpreted with caution.  
The current literature suggests the mechanism by which vitamin D may influence 
inflammation may be more complex, and perhaps only those with very low vitamin D status 
may benefit from vitamin D supplementation. However, more research is needed to shed 
light on dosage required and vitamin D status adequate for improving inflammatory state.  
4.5.3 Physiology of Vitamin B6 and Inflammation 
In addition to functioning as a cofactor in a wide variety of enzymes involved in 
macronutrient metabolism and in neurotransmitter synthesis, vitamin B6 plays a critical 
role in both the innate and adaptive immune responses.198 Vitamin B6 is required for the 
production of cytokines,199 which are among the primary mediators of inflammation, as 
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well as for the proliferation and activation of lymphocytes that characterize the 
inflammatory response.200,201  
There are several hypotheses regarding the underlying mechanism for the 
association between low plasma PLP and inflammation. One hypothesis suggests that low 
dietary intake of vitamin B6 confers increased risk of inflammation; however, in most 
studies of inflammatory conditions such as rheumatoid arthritis (RA) where plasma PLP 
levels are low, vitamin B6 intakes correlate poorly with plasma PLP concentration.202 
Despite lower plasma PLP levels, RA patients have normal measures of other indicators of 
vitamin B6 status, such as erythrocyte aspartate transaminase (EAST) activity coefficient 
and erythrocyte PLP concentration,202 suggesting a functional deficiency rather than a 
frank deficiency. 
 A second hypothesis suggests increased vitamin B6 requirements during 
inflammation are due to catabolism of vitamin B6. In the study by Chiang et al (2003), 
urinary excretion of 4-pyridoxic acid, which is a measure of vitamin B6 metabolism, was not 
correlated with plasma PLP in RA patients, suggesting that low plasma PLP in this 
condition is not due to increased metabolism of vitamin B6.202  However, this idea remains 
in debate, as a new study by Ulvik and colleagues revealed that there was an increase in 
vitamin B6 catabolism during inflammation by assessing the substrate product ratio in 
plasma (pyridoxic acid to the addition of PL + PLP).277  This new approach to assess vitamin 
B6 catabolism may provide new insights into the potential mechanisms underlying the 
association between plasma vitamin B6 and inflammation. 
It appears the lower plasma PLP observed in inflammatory conditions is not linked 
to dietary inadequacy or to vitamin B6 deficiency in most cases, but rather is due to 
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metabolic phenomena inherent to inflammation.271   Among NHANES participants, the 
prevalence of low plasma PLP (<20nmol/L) is approximately 2.5 times higher in 
individuals with higher CPR (>10 mg/L) compared to those with CPR levels ≤3mg/L. 278 
These data suggest there is a higher need tor plasma PLP by the immune system during 
active inflammation.  
Current evidence points to the third hypothesis: that the inverse association 
between plasma PLP and inflammation is the result of mobilization of plasma PLP to sites 
of active inflammation for use by the PLP-dependent enzymes that play a role in the 
inflammatory response. 279  Because the PLP in muscle is phosphorylated, it is not easily 
released; thus, when there is an increased demand for PLP during inflammation or when 
intake is low, PLP is supplied by liver and plasma stores. This evidence comes from a study 
with an animal model of RA, which found that during bouts of inflammation, PLP levels fell 
in liver and plasma, but not in other tissues. 205 Hence, plasma PLP concentration would be 
highly susceptible to a sudden increase in PLP demand during an immune response.271   
This third hypothesis proposes that the lower plasma PLP levels observed during 
inflammation are due to the mobilization of PLP to the site of inflammation for degradation 
of tryptophan via the kynurenine pathway, metabolism of immunomodulatory 
sphingolipids, and the proliferation of immune cells.271   Degradation of tryptophan 
through the indoleamine 2,3-dioxygenase (IDO) pathway is a hallmark of inflammation.271  
Tryptophan metabolism through the kynurenine pathway includes two vitamin B6- 
dependent enzymes. These studies suggest that impaired vitamin B6 status in inflammation 
is not solely caused by either lower intake, malabsorption or excessive catabolism of the 
vitamin, but may be a result of metabolism mechanisms inherent to the inflammatory 
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process. The sequestration of PLP in the sites of inflammation may appear to be the most 
convincing hypothesis to date, but further studies are needed to rule out the remaining 
hypotheses and confirm the latter. 
4.5.4 Epidemiology of Vitamin B6 and Inflammation 
A number of population studies have shown that low plasma vitamin B6 levels are 
associated with typical chronic inflammatory diseases, such as rheumatoid arthritis and 
inflammatory bowel diseases,203 and are inversely related to markers of inflammation.163 
However, this association seems to be affected by several factors, such as OC use, age, and 
dietary supplementation.  
The first large study to investigate this association was carried out over a decade 
ago. Using the Framingham Heart Study cohort, Friso and colleagues examined the 
association between plasma PLP levels and CRP in 891 older adults.156  They found those 
with high CRP levels (≥6 mg/L) had significantly lower PLP levels (36.5 vs 55.8 nmol/L, p-
value<0.001) than individuals with low CRP values. Only 6.4% (n=57) of the study 
population had high CRP as defined by the cut-point used. Vitamin B6 intake did not differ 
between the CRP groups (2.4 vs 2.1 mg/day, p-value>0.2), therefore the lower PLP levels in 
one group were not due to diminished intake.156  
A larger, more recent cross-sectional study using the National Health and Nutrition 
Examination survey evaluated the relationship between both vitamin B6 intake and plasma 
PLP concentrations and serum CRP in 2,686 adults representative of the adult U.S. 
population.204 They investigated whether the vitamin B6 requirement is affected by 
inflammation by determining the vitamin B6 intake associated with minimal prevalence of 
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vitamin B6 inadequacy in different serum CRP categories. Vitamin B6 intake was assessed 
using two 24-hour diet recalls as well as from supplement use data. Those who were 
diabetic, pregnant, lactating, taking hormones or steroidal anti-inflammatory drugs were 
excluded. They found female gender, current smoking, and low albumin to be positively 
associated with higher inflammation and vitamin B6 deficiency (<20 nmol/L). After 
multivariable adjustment for demographics, smoking, BMI, alcohol use, antioxidant vitamin 
status, intakes of protein and energy, and serum concentrations of creatinine and albumin, 
high vitamin B6 intake was associated with protection against high CRP levels (>10 mg/L) 
compared with those with low CRP (≤3 mg/L). However, plasma PLP ≥20 nmol/L 
compared with <20 nmol/L was inversely related to serum CRP independently of B6 intake 
(p<0.001). Higher vitamin B6 intakes were found to be protective against inflammation, 
with higher vitamin B6 intakes associated with maximum protection against vitamin B6 
inadequacy in the presence of inflammation.204  This study confirmed the association 
between inflammation and low plasma PLP concentration, but challenged the notion that 
vitamin B6 intake is unrelated to inflammation. From these studies, it appears that 
suboptimal vitamin B6 status can be corrected via supplementation, but the amount of 
vitamin B6 intake needed to protect against vitamin B6 inadequacy may be elevated in the 
presence of inflammation.272 Vitamin B6 supplementation with 50 mg/day of pyridoxine for 
30 days may correct vitamin B6 deficiency,275 but higher levels (100mg/day) may be 
needed to improve inflammation among individuals with high inflammation levels, such as 
rheumatoid arthritis patients.276   
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CHAPTER 5 
 
RESEARCH GAP & PURPOSE OF THE STUDY 
 
 
Depression is the leading cause of disease burden among women of reproductive 
age. This population is at increased risk for both vitamin D and vitamin B6 deficiencies 
compared to men, as has been shown by previous NHANES analyses. Additionally, this 
population has been repeatedly shown to have higher inflammation levels compared to 
men. This is particularly interesting given that inflammation has been linked to the 
development and severity of depression since the early 1990s. Given all the evidence 
linking vitamin D and B6 to inflammation in numerous animal and population-based 
studies, it is surprising to see how little is known about how these factors may be 
connected, and how they may be contributing to depression severity or symptomatology. It 
is of special interest to find new avenues for depression prevention and treatment due to 
the low response rate of antidepressants.  
What was once coined the “macrophage theory of depression” may now be the basis 
for how low-grade inflammation could be contributing to compromised micronutrient 
status, and how the interaction between these factors could be an underlying cause for the 
depression seen in women of reproductive age. This knowledge gap prevents our 
understanding to what extent correcting micronutrient status and inflammation might be a 
simple, economic, and effective component of a prevention strategy aimed at reducing the 
risk of developing depression. 
The primary objective in the proposed study was to assess how inflammation is 
related to depression, while accounting for micronutrients numerous lifestyle and 
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behavioral factors, such as body mass index, leisure-time physical activity, sleep, and oral 
contraceptive use. Our study also considered different types of depressive symptoms, such 
as affective and somatic, in addition to individual depression symptoms, to determine how 
inflammation, vitamin D and B6 concentrations may be interacting and contributing to 
different dimensions of depression. The study findings shed light on potential mechanisms 
linking nutritional status and inflammation to different aspects of depression and 
depression severity. Findings may be used to create new approaches that include targeting 
nutritional status to prevent, treat, and help manage depression among women of 
reproductive age. 
5.1 Specific Aims and Hypotheses by Manuscript Title 
5.1.2 Study #1: Inflammation is associated with depression symptomatology among 
women of reproductive age from NHANES 2005-2008 
Our working hypothesis for this aim is that elevated inflammation is positively associated 
with depression in women of reproductive age. Our experimental approach was to 
investigate the association between high-sensitivity C-reactive protein (hs-CRP) and sum 
depression scores, as well as individual symptoms and depression subtypes measured with 
the PHQ-9 to determine the extent to which inflammation is associated with increased 
depression. We also explored which lifestyle and behavioral factors affected this 
association through moderation or mediation pathways in post-hoc analysis. 
 
5.1.2.1 Specific Aim #1: 
To assess the association hs-CRP and different dimensions of depression among non-
pregnant women of reproductive age from NHANES 2005-2008.  
 
5.1.2.2 Hypothesis #1a: 
Among women of reproductive age, hs-CRP will be positively associated with depression 
score and depression severity as determined by the PHQ-9. 
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5.1.2.3 Hypothesis #1b: 
Among women of reproductive age, the association between inflammation and depression 
will depend on the nature of the symptoms. 
5.1.3 Study #2. Does inflammation influence the association between vitamin B6 and 
depression in non-pregnant women ages 15-44 from NHANES 2005-2008 
Our working hypothesis for this aim is that elevated hs-CRP is modifying the association 
between vitamin B6 levels and depression in women of reproductive age. Our experimental 
approach was to investigate the association between vitamin B6 levels and depression 
scores among women with high and low inflammation levels to determine the extent to 
which inflammation influences the association between vitamin B6 status and different 
dimensions of depression. 
5.1.3.1 Specific Aim #2: 
To assess the association between vitamin B6 concentrations and different dimensions of 
depression, stratified by CRP categories, in women of reproductive age from NHANES 
2005-2008. 
5.1.3.2 Hypothesis #2a:  
Among women of reproductive age, hs-CRP will be inversely associated with serum vitamin 
B6 status. 
5.1.3.3 Hypothesis #2a: 
Among women of reproductive age, depression will be inversely associated serum vitamin 
B6 status, and this association will be strongest among women with elevated hs-CRP 
concentrations. 
5.1.4 Study #3. Do inflammation or lifestyle factors influence the association between 
vitamin D status and depression in non-pregnant women ages 15-44 from 
NHANES 2005-2008 
Our working hypothesis for this aim is that inflammation modifies the association between 
vitamin D status and depression in women of reproductive age. Our experimental approach 
was to investigate the association between vitamin D categories and depression scores 
measured with the PHQ-9 among women with high and low CRP levels to determine the 
extent to which hs-CRP influences the association between vitamin D and different 
dimensions of depression symptomology. We also explored which lifestyle and behavioral 
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factors affected this association through moderation or mediation pathways in post-hoc 
analysis. 
5.1.4.1 Specific Aim #3: 
To assess whether inflammation modifies the association between vitamin D and 
depression in non-pregnant women of reproductive age from NHANES 2005-2008. 
5.1.4.2 Hypothesis #3a: 
Among women of reproductive age, serum vitamin D status will be inversely association 
with depression. 
5.1.4.3 Hypothesis #3b:  
Among women of reproductive age, the association between vitamin D status and 
depression depends on inflammation. 
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CHAPTER 6 
 
STUDY DESIGN AND METHODS 
6.1 Study Design and Population 
 
We examined cross-sectional data from the 2005-2008 National Health and 
Nutrition Examination Survey (NHANES), which is national survey from the National 
Center for Health Statistics of the Centers for Disease Control and Prevention (CDC), 
designed to assess the health and nutritional status of the U.S. population. NHANES 
employs a complex, multistage, probability sampling design to select individuals 
representative of the civilian, non-institutionalized population, with oversampling of 
special sub-populations, such as racial and ethnic minorities. Detailed descriptions of the 
survey design and procedures are available at the study website.277  
Briefly, approximately 5,000 people are surveyed each year via in-person interviews 
and physical examinations. The interview, which is conducted in participants’ homes, 
includes demographic, socioeconomic, dietary, and health-related questions; the 
examination component is comprised of medical, dental, and physiological measurements, 
as well as laboratory tests, which take place in specially-designed and equipped mobile 
examination centers (MEC) that travel throughout the country. The National Center for 
Health Statistic’s Institutional Review Board has reviewed and approved the NHANES 
protocol. 282 
 Participants were eligible for our study if they were women of reproductive age 
(15-44 years old) who were not pregnant. From the initial sample of 2,609 eligible women, 
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we excluded those who were taking anti-inflammatory medications, including NSAIDs 
(n=70), those with acute inflammation denoted by CRP levels above 10 mg/L (n=201)277 
and those with missing data for either depression (n=506) or inflammation (n=104). 
Depression data for those younger than 18 years was not publicly available; therefore, our 
age range was restricted to women ages 18-44 years old. Women who reported current 
antidepressant use were additionally excluded (n=135).  
6.2 Exposure Assessment 
Fasting whole blood samples were collected during the medical examination. 
Venipuncture was performed using standard phlebotomy techniques by NHANES-trained 
personnel. Serum specimens were frozen at -20 degrees Celsius until biomarker 
assessment at varying laboratories designated by the Center for Disease Control. Further 
detailed instructions on specimen collection and processing can be found at NHANES 
website.21  A brief description for each biomarker assessment is provided below. 
Serum hs-CRP was assayed at the University of Washington Medical Center. Hs-CRP 
was quantified by latex-enhanced nephelometry using a Dade Behring Nephelometer II 
analyzer System (Dade Behring Diagnostics Inc, Somerville NJ). Monoclonal antibodies 
were used to detect serum CRP, and N rheumatology standard SL was used to standardize 
against the World Health Organization’s International Reference Preparation of CRP.  This 
high-sensitivity assay allowed for a minimum detection of 0.2 mg/L and does not have a 
maximum reportable limit. Further details can be found on the website. 277  CRP was 
modeled as three categories: no inflammation (CRP<1mg/L), low inflammation (CRP 
between 1-3 mg/L) and mid-high inflammation (CRP between 3-10 mg/L), following 
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guidelines for increased risk of cardiovascular disease set forth by the American Heart 
Association. 278 
Serum specimens for pyridoxal 5’-phosphate (PLP) were processed, stored and 
shipped to the Division of Environmental Health Laboratory Sciences, National Center for 
Environmental Health, Centers for Disease Control and Prevention in Atlanta, Georgia. 
Briefly, serum PLP, the main bioactive form of vitamin B6, was measured using reverse-
phase high performance liquid chromatography (HPLC) analysis using fluorometric 
detection at 325nm excitation and 425nm emission. Quantitation of PLP was based on 
analyte peak area interpolated against a five-point calibration curve from aqueous 
standards. This HPLC assay has a lower limit of detection compared to the enzymatic assay 
used in previous NHANES cycles (0.3 vs 10 nmol/L). 277  Serum PLP was also divided into 
categories indicating vitamin B6 deficiency (PLP <20nmol/L), insufficiency (PLP 20 to 29.9 
nmol/L) and sufficiency (PLP ≥30 nmol/L) following previously used cut-offs for vitamin 
B6 status. 277  
Measurements of serum 25(OH) vitamin D were performed with the DiaSorin RIA 
kit (Stillwater, MN) for NHANES 2001-2006, and with liquid chromatography-tandem mass 
spectrometry (LC-MS/MS) method for NHANES 2007-2008. 279  In order to use vitamin D 
data from these two different methods, NHANES converted the vitamin D data from 2001-
2006 assayed with the RIA method to equivalent 25(OH)D measurements from a 
standardized LC-MS/MS method using regression analysis. This was done to allow 
researchers to use vitamin D data that are equivalent to 25(OH)D measurements assayed 
with LC-MS/MS method. 279  Serum vitamin D was primarily categorized into variables 
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indicating vitamin D deficiency (<50nmol/L), insufficiency (50 to 75 nmol/L) and 
sufficiency ( >75 nmol/L) following previously used cut-offs for vitamin D status.165,280   
6.2.1 Laboratory Quality Assurance and Monitoring 
The NHANES quality control and quality assurance protocols meet the 1988 Clinical 
Laboratory Improvement Act mandates at all the locations. Quality control measures and 
device calibrations were performed daily for all laboratory procedures.277  
6.3 Depression Assessment 
The Patient Health Questionnaire-9 (PHQ-9)281 was administered during the MEC 
interview to assess depressive symptom severity over the past two weeks. Based on the 
diagnostic criteria for major depressive disorder in the Diagnostic and Statistical Manual 
Fourth Edition (DSM-IV), the PHQ-9 employs a 4-point scale (0=not at all, 1= several days, 
2= more than half the days, 3= nearly every day) to determine the frequency with which 
respondents experienced the following nine symptoms of major depressive disorder: 
anhedonia, depressed mood, sleep disturbance, fatigue, appetite changes, low self-esteem, 
concentration problems, psychomotor retardation/agitation, and suicidal ideation. Total 
depression scores range from 0 to 27, and scores of 10 or higher indicative of clinical 
depression.282 The PHQ-9 has been shown to be a reliable and valid questionnaire as 
indicated by its high internal consistency and good sensitivity (88%) and specificity (88%) 
for identifying cases of major depressive disorder in community samples.283–285  
In addition to the total depression score, we calculated somatic and cognitive-affective 
depression subscale scores. The somatic depression subscale was calculated by adding the 
scores for frequency of somatic depression symptom from the PHQ-9 (sleep disturbance, 
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fatigue, appetite changes, and psychomotor retardation/agitation) and the cognitive-
affective subscale score was calculated adding the scores for non-somatic symptoms 
(anhedonia, depressed mood, low self-esteem, concentration problems and suicidal 
ideation).287 While previous factor analyses supported a one-factor model with all nine 
items,288,289 recent confirmatory factor analyses have found that subscales of depression 
dimensions may provide a better fit to the data.290,291  It has also been argued that given the 
heterogeneity of symptoms for depression, individual symptoms should be analyzed.29 We 
included a separate analysis for individual depressive symptoms, coded as continuous 
variables (scores ranging from 0-3) and as binary variables. To dichotomize the variable, 
those items with responses “more than half the days” and “nearly every day” indicated the 
presence of the symptom.292,293  
6.4 Covariate Assessment 
We considered as possible covariates a selected set of demographic, lifestyle, and 
socioeconomic factors available through data collected during the demographic or 
household section of the NHANES questionnaire. The National Center for Health Statistics 
(NCHS) standard definitions for ethnicities were used, and ethnicities were categorized as 
non-Hispanic whites, non-Hispanic blacks, Mexican-Hispanics, other Hispanics, and other 
race. Educational attainment was measured as the highest completed grade of school 
regardless of age, and categorized into four levels: less than high school, high school 
equivalent, some college, and college graduate or above. The smoking assessment for 
respondents aged 18-19 years (MEC) was not identical to that for respondents aged 20+ 
years (household interview). For respondents aged 20+ years, we classified as current 
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smokers those who reported smoking at least 100 cigarettes during their lifetime and 
reported that they now smoke cigarettes every day or some days. For respondents ages 18-
19 years, we classified as current smokers those who reported smoking 15 or more day in 
the last 30 days. To determine a smoking dose from current smokers, we classified those 
who reported smoking <15 days per month or “some days” as medium dose smoking, and 
those who smoked more than 15 days per month or “every day” as high dose smokers. To 
create the alcohol groups, we used data obtained during the alcohol use interview at the 
MEC and calculated the drinks per day as suggested by Case and Stewart.294  Alcohol 
consumption, which was only available for participants of legal drinking age (21 and older), 
was categorized into abstainer, one or fewer drinks/day and more than one drink per day.  
Leisure-time physical activity (LTPA) was assessed by asking participants about their 
involvement in 48 specific recreation activities of moderate or vigorous intensity. 
Frequency was first multiplied by the duration in hours and divided by 4.3 to obtain hours 
of LTPA per week. To calculate MET hrs/week, each activity was multiple by its MET level 
per NHANES physical activity codes.295  Participants were then categorized into quartiles of 
physical activity. Sleep duration was assessed by asking participants how many hours of 
sleep they usually get on a weekday/workday, and those who reported sleeping 12 or more 
hours were labeled as sleeping 12 hours/night. Oral contraceptive use was determined by 
self-report of current use, with “past” or “never” users classified as not currently using oral 
contraceptives (OC). Body mass index (BMI) (calculated as kg/m2) was computed from 
height and weight measurements and categorized into four standard categories: 
underweight (BMI<18.5 kg/m2), normal weight (18.5 ≤ BMI<25), overweight (25≤ 
BMI<30) and obese (BMI≥30 kg/m2).  
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6.5 Statistical Analysis Plan 
The complex survey design used for NHANES data collection was incorporated into 
all data analyses using the “svy” command with appropriate weighting in Stata 12.0 
(StataCorp LP, College Station, TX). Detailed information on the procedures for taking into 
account survey sampling weights have been described elsewhere.296  
Descriptive statistics were calculated for the overall sample using frequency 
distributions for categorical variables and means and standard errors for continuous 
variables. Natural logarithmic transformations were performed on hs-CRP, PLP, and 
vitamin D to normalize the distribution, and their geometric means and 95% confidence 
intervals are presented. Bivariate analyses were carried out for each covariate and each 
exposure as well as outcome using weighted ANOVAs, Chi square tests and 2-sample t-test 
as appropriate. In linear regression models, all covariates that changed the estimated 
coefficient for the primary predictor of interest by more than 10% were retained in the 
multivariable model. In addition, known risk factors for depression were retained in the 
model as well as those that were associated with both the predictor and the outcome.  
To examine whether each exposure was more strongly related with certain 
depression symptoms, we conducted a series of linear regression analyses involving total 
depression score, somatic depression score, and non-somatic depression score as well as 
each individual depression symptom as outcome. A similar series of logistic regression 
analyses was also completed for dichotomous individual depressive symptoms. For all the 
individual depression symptoms, we also adjusted for the remaining depression symptom 
scores to account for any potential overlap between different symptoms and reduce the 
probability of Type I error. Logistic regression analyses were carried out for depression 
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PHQ-9 score of 10 or greater. The command “mfpigen” was used to assess all possible 
interactions among variables in the full models. 
For each study, several lifestyle variables were assessed as potential mediators by 
running Sobel mediation tests and the Preacher and Hayes test of indirect effects to 
quantify their effects on any observed relationships between exposure and 
depression.297,298  Effect modification was assessed by stratified regression analyses and by 
including multiplicative interaction terms in the multivariable analysis. Final model fit was 
assessed using goodness of fit tests. All linear and logistic regression estimates were 
weighted using NHANES sample weights, which account for the complex survey design, 
survey nonresponse, and post-stratification. All analyses were considered significant at an 
alpha of 0.05. 
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CHAPTER 7 
“THE ASSOCIATION BETWEEN C-REACTIVE PROTEIN AND DEPRESSIVE SYMPTOMS 
AMONG WOMEN OF REPRODUCTIVE AGE IS MODERATED BY BODY MASS INDEX” 
7.1 Abstract 
Depression is the leading cause of disability world-wide, and women in their 
childbearing years make up the largest group of Americans with depression. Recent 
evidence indicates that inflammation is associated with depression, and this relationship 
may differ by gender and by depression symptoms. We conducted a secondary data 
analysis to evaluate the association between c-reactive protein (CRP) and different 
dimensions of depressive symptomatology in non-pregnant women ages 18-44 years from 
the cross-sectional National Health and Nutrition Examination Survey (NHANES) 2005-
2008. Depression scores were calculated based on the Patient Health Questionnaire-9 
(PHQ-9) and categorized into total depression, somatic and non-somatic depression. High 
depression score (PHQ-9≥10) was also used as an outcome, as were individual symptoms 
of depression.  High-sensitivity CRP was quantified by latex-enhanced nephelometry. To 
account for NHANES’ complex survey design sample, we incorporated the sampling 
weights to analyze 1,489 observations. CRP was positively related to total (p=0.006), 
somatic (p=0.01) and non-somatic depression scores (p=0.01) in unadjusted models. 
However, in the multivariable adjusted models, CRP was positively associated with 
depression scores (total depression, p=0.001; somatic depression, p=0.001; non-somatic 
depression, p=0.007) only among those who were underweight (BMI<18.5 kg/m2). BMI 
accounted for 44.8% of the association between CRP and total depression scores (p<0.05). 
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When individual depression symptoms were examined, BMI was negatively associated 
with abnormal appetite score among women with no inflammation (CRP<1mg/L), but BMI 
was positively associated with appetite score among those with moderate inflammation 
(CRP 3-10mg/L). BMI appears to play a role in the association between inflammation and 
depression symptoms among women. Further research is needed determine whether 
changes in biomarkers of inflammation predict changes in specific dimensions of 
depression in this population, and whether lifestyle modification can be used to prevent 
depression or as adjuvant treatment for depression among women.  
 
7.2 Introduction 
Depression is common in the United States, with approximately 16% of adults 
experiencing clinical depression at some point in their lives.1  Women are two- to three- 
times more likely than men to experience depression.2,3  Depression is a multifaceted 
phenomenon with a large range of symptoms, and different subtypes of depression have 
been proposed based on specific combinations of symptoms.4  Research into the etiology of 
depression needs to account for the heterogeneous nature of the condition and requires 
developing methods to characterize and objectively assess the severity of depression and 
to classify depression into its different subtypes.5 In order to address the issue of symptom 
diversity, subtypes of depressive symptoms have been proposed based on specific 
combination of symptoms. Somatic depression, characterized by sleep disturbance, fatigue, 
or changes in appetite,  has been found to be more prevalent in females compared to 
males,6  and other evidence suggests that gender differences may account for heterogeneity 
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in depression symptoms and that the involvement of inflammation in the etiology of 
depression may be affected by lifestyle factors.7  
Several observational studies reported that increases in inflammatory biomarkers 
are associated with increased risk for depression; however, conflicting findings exist 
regarding the directionality of the association, and the underlying mechanisms are not fully 
understood. Recent research has specifically focused on the association between high 
sensitivity c-reactive protein (hs-CRP), interleukin-6 (IL-6), tumor necrosis factor α (TNF- 
α), and other markers of systemic inflammation and depression.8,9 However, very few 
studies have investigated depression subtypes, including somatic and 
cognitive/affective,6,10–14 and no studies have examined whether the association between 
inflammation and depression among women is symptom-specific. Individual depression 
symptoms differ in their biological correlates, which underscores the heterogeneous nature 
of depression and may explain the lack of progress in validating depression diagnoses with 
biomarkers.15  Assessing the association between inflammation and specific symptoms 
offers opportunities to investigate potential biological factors that may be related to 
specific syndromes but may be masked by aggregate scoring; individuals with similar total 
depression scores often have drastically different clinical conditions.16 The analysis of 
individual symptoms could reveal patterns that are currently missed. 
The purpose of this study was to further explore the relationship between 
inflammation and depression among U.S. reproductive-age women and to determine 
whether CRP, a marker of inflammation, is associated with depression subtypes or 
individual symptoms of depression among this population. Our goal was to determine 
whether serum CRP levels in the low-grade inflammation range are associated with 
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particular subtypes of depressive symptoms among 1,489 women, aged 18-44 years, from 
the National Health and Nutrition Examination Survey (NHANES) 2005-2008 and to assess 
whether body mass index (BMI) and other lifestyle factors potentially modify this 
association.  
7.3 Methods 
7.3.1 Study Design and Study Population 
We analyzed cross-sectional data from the 2005-2008 National Health and Nutrition 
Examination Survey (NHANES), which is a national survey from the National Center for 
Health Statistics of the Centers for Disease Control and Prevention (CDC), designed to 
assess the health and nutritional status of the U.S. population.  NHANES employs a complex, 
multistage, probability sampling design to select persons representative of the civilian, 
non-institutionalized population, with oversampling of special sub-populations, such as 
racial and ethnic minorities. Detailed descriptions of the survey design and procedures are 
available at the NHANES website.16  
Briefly, approximately 5,000 people are surveyed each year via in-person interviews 
and physical examinations. The interview, which is conducted in participants’ homes, 
includes demographic, socioeconomic, dietary, and health-related questions; the 
examination component is comprised of medical, dental, and physiological measurements, 
as well as laboratory tests, which take place in specially-designed and equipped mobile 
examination centers (MEC) that travel throughout the country. The National Center for 
Health Statistic’s Institutional Review Board has reviewed and approved the NHANES 
protocol. 
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 Participants were eligible for our study if they were women of reproductive age 
(15-44 years old) who were not pregnant. From the initial sample of 2,609 eligible women, 
we excluded those who were taking anti-inflammatory medications, including NSAIDs 
(n=70); those with acute inflammation denoted by CRP levels above 10 mg/L (n=201);17 
those reporting antidepressant use (n=135) and those with missing data for either 
depression (n=506) or inflammation (n=104). Depression data for those younger than 18 
years was not publicly available; therefore, our age range was restricted to women ages 18-
44 years old. The remaining sample contained 1,489 observations. 
 7.3.2 Assessment of Depression Status 
The Patient Health Questionnaire-9 (PHQ-9)18 was administered during the MEC 
interview to assess depressive symptom severity over the past two weeks. Based on the 
diagnostic criteria for major depressive disorder in the Diagnostic and Statistical Manual 
Fourth Edition (DSM-IV), the PHQ-9 employs a 4-point scale (0=not at all, 1= several days, 
2= more than half the days, 3= nearly every day) to determine the frequency with which 
respondents experienced the following nine symptoms of major depressive disorder: 
anhedonia, depressed mood, sleep disturbance, fatigue, appetite changes, low self-esteem, 
concentration problems, psychomotor retardation/agitation, and suicidal ideation. Total 
depression scores range from 0 to 27, and scores ≥10 represent clinically significant 
depressive symptoms.18  The PHQ-9 has been shown to be a reliable and valid 
questionnaire as indicated by its high internal consistency and good sensitivity (88%) and 
specificity (88%) for identifying cases of major depressive disorder in community 
samples.19–21  
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In addition to the total depression score, we calculated somatic and cognitive-
affective depression subscale scores. The somatic depression subscale was calculated by 
adding the scores for frequency of somatic depression symptom from the PHQ-9 (sleep 
disturbance, fatigue, appetite changes, and psychomotor retardation/agitation), and the 
cognitive-affective subscale score was calculated adding the scores for non-somatic 
symptoms (anhedonia, depressed mood, low self-esteem, concentration problems and 
suicidal ideation).10  While previous factor analyses supported a one-factor model with all 
nine items,22,23 recent confirmatory factor analyses have found that subscales of depression 
dimensions may provide a better fit to the data.24,25  Some also argue that given the 
heterogeneity of symptoms for depression, individual symptoms should be analyzed.15 We 
also included a separate analysis for individual depressive symptoms, coded as continuous 
variables (scores ranging from 0-3) and as binary variables. To dichotomize the variable, 
those items with responses “more than half the days” and “nearly every day” indicated the 
presence of the symptom.26,27 
7.3.3 C-Reactive Protein 
Fasting whole blood samples were collected during the medical examination. 
Venipuncture was performed using standard phlebotomy techniques by NHANES-trained 
personnel. Serum specimens were frozen at -20 degrees Celsius until biomarker 
assessment at the University of Washington Medical Center. Serum high-sensitivity CRP 
was quantified by latex-enhanced nephelometry using a Dade Behring Nephelometer II 
analyzer System (Dade Behring Diagnostics Inc, Somerville NJ). Monoclonal antibodies 
were used to detect serum CRP, and N rheumatology standard SL was used to standardize 
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against the World Health Organization’s International Reference Preparation of CRP.  This 
high-sensitivity assay allowed for a minimum detection of 0.2 mg/L and does not have a 
maximum reportable limit. Further details can be found on the website.16  Given that hs-
CRP was not normally distributed, it was converted to its natural logarithm to improve 
normality. In additional analyses, CRP was modeled as three categories: no inflammation 
(CRP<1mg/L), low inflammation (CRP between 1-3 mg/L) and moderate inflammation 
(CRP between 3-10 mg/L), following guidelines for increased risk of cardiovascular disease 
set forth by the American Heart Association.17 
7.3.4 Covariates and Confounders 
We considered as possible covariates a selected set of demographic, lifestyle, and 
socioeconomic factors available through data collected during the demographic or 
household section of the NHANES questionnaire. The National Center for Health Statistics 
(NCHS) standard definitions for ethnicities were used, and ethnicities were categorized as 
non-Hispanic whites, non-Hispanic blacks, Mexican-Hispanics, other Hispanics, and other 
race. Educational attainment was measured as the highest completed grade of school 
regardless of age, and categorized into four levels: less than high school, high school 
equivalent, some college, and college graduate or above. The smoking assessment for 
respondents aged 18-19 years (MEC) was not identical to that for respondents aged 20+ 
years (household interview). For respondents aged 20+ years, we classified those who 
reported smoking at least 100 cigarettes during their lifetime and reported that they now 
smoke cigarettes every day or some days as current smokers. For respondents ages 18-19 
years, we classified those who reported smoking 15 or more day in the last 30 days as 
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current smokers. To create the alcohol groups, we used data obtained during the alcohol 
use interview at the MEC and calculated the drinks per day as suggested by Case and 
Stewart.13  Alcohol consumption, which was only available for participants of legal drinking 
age (21 and older), was categorized into abstainer, one or fewer drinks/day and more than 
one drink per day.  Oral contraceptive use was determined by self-report of current use, 
with “past” or “never” users classified as not currently using oral contraceptives (OC). 
Body mass index (BMI), leisure-time physical activity (LTPA), and sleep duration 
have been associated with both C-reactive protein and depression7,28,29 and were examined 
as potential mediators/confounders of the relationship between CRP and depressive 
symptoms.  BMI (kg/m2) was computed from height and weight measurements and 
categorized into four standard categories: underweight (BMI<18.5 kg/m2), normal weight 
(18.5 ≤ BMI<25), overweight (25≤ BMI<30) and obese (BMI≥30 kg/m2). LTPA was 
assessed by asking participants about their involvement in 48 specific recreation activities 
of moderate or vigorous intensity. Frequency was first multiplied by the duration in hours 
and divided by 4.3 to obtain hours of LTPA per week. To calculate MET hrs/week, each 
activity was multiplied by its MET level according to NHANES physical activity codes.30  
Participants were then categorized into quartiles of physical activity. Sleep duration was 
assessed by asking participants how many hours of sleep they usually get on a 
weekday/workday; those who reported sleeping 12 or more hours were labeled as 
sleeping 12 hours/night. 
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7.3.5 Data Analysis 
The complex survey design used for NHANES data collection was incorporated into 
all data analyses using the “svy” command with appropriate weighting in Stata 12.0 
(StataCorp LP, College Station, TX). Detailed information on the procedures for taking into 
account survey sampling weights have been described elsewhere.31  
Descriptive statistics were calculated for the overall sample using frequency 
distributions for categorical variables and means and standard errors for continuous 
variables.  Because hs-CRP was logarithmically transformed when analyzed as a continuous 
variable, geometric means (antilogarithms of the transformed means) and their 95% 
confidence intervals are presented.  Bivariate analyses were carried out for each covariate 
and log-transformed hs-CRP and CRP categories as well as for covariates and total 
depression, somatic/non-somatic depression and binary depression variables, using 
weighted ANOVAs, Chi square tests and 2-sample t-tests, as appropriate. In linear 
regression analyses, all covariates that changed the estimated coefficient for the primary 
predictor of interest by more than 10% were retained in the multivariable model. In 
addition, known risk factors for depression, such as smoking and education levels, were 
retained in the model as were risk factors were associated with both the predictor and the 
outcome (e.g. BMI, LTPA, OC use).  
To examine whether hs-CRP was more strongly related to certain depression 
symptoms, we conducted a series of linear regression analyses involving total depression 
score, somatic depression score, and non-somatic depression score as well as each 
individual depression symptom as outcome. Individual symptom analysis was repeated via 
logistic regression for dichotomous symptoms. For all the individual depression symptoms, 
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we also adjusted for the remaining depression symptom scores to account for any potential 
overlap between different symptoms. Logistic regression analyses were carried out for 
depression PHQ-9 score of 10 or greater.  Model adequacy was assessed using goodness of 
fit tests.   
BMI, LTPA and sleep were assessed as potential mediators by running Sobel 
mediation tests and the Preacher and Hayes test of indirect effects to quantify the effects of 
BMI, LTPA, and sleep on any observed relationships between hs-CRP and depression.32,33  
Effect modification was assessed by stratified regression analyses and by including 
multiplicative interaction terms in the multivariable analyses. 
7.4 Results 
Description of Study Cohort.  The mean age of the 1,489 women included in our 
sample was 31.7 years.  The majority of women were white (63.5%), married or living with 
a partner (60.4%,) did not use oral contraceptives (80.8%), reported an average of seven 
hours of sleep per night, and were nonsmokers (76.3%). Almost eight percent (n=132) of 
our sample reported moderate to severe depression symptoms indicative of clinically 
significant depression, denoted by a score of 10 or higher on the PHQ-9 (Table 4). 
In bivariate analysis, depression scores were positively associated with BMI (p-
trend <0.02 for all) and negatively associated with education (p<0.001) and with LTPA 
(p<0.001). Depression score was higher for both somatic and non-somatic subtypes for 
women who were not currently taking oral contraceptives (p=0.05 and p=0.01, 
respectively) and for smokers (p<0.001 for all).  Women with high depression scores slept 
less (6.1 vs 7.0 hours/night, p<0.001) compared to those with low depression scores. The 
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prevalence of depression was significantly higher among women who were separated or 
divorced, who smoked, and those who reported the lowest levels of LTPA. The prevalence 
of a high depression score was lower among women who reported current oral 
contraceptive use compared to non-OC users (4.5% vs 8.0%, p=0.09; Table 4). 
Just over a quarter of women (27.8%) had hs-CRP levels between 3-10 mg/L, 
indicative of moderate inflammation. CRP was positively associated with BMI, with 
moderate inflammation being much more prevalent among obese (55.4%) or overweight 
(27.0%) women compared to normal weight (13.8%) or underweight women (6.6%; 
p<0.001). We found a negative association between educational attainment and hs-CRP 
(p<0.001). Hs-CRP levels were higher in oral contraceptive users compared to non-users 
(2.1 vs 1.1 mg/L, p<0.001), and only 21% of current users had hs-CRP levels <1mg/L 
compared to 43.3% of non-contraceptive users (p<0.001).  Those in the lower quartile of 
LTPA had higher circulating hs-CRP concentration compared to the rest of the quartiles 
(p=0.05), with some evidence of an LTPA dose response (p for trend=0.02). CRP 
concentration did not vary by age, smoking status or marital status (Table 5). 
Association of hs-CRP with depression. In univariate linear regression, hs-CRP was 
positively associated with total depression score (β: 0.32, p=0.006), somatic depression 
score (β:0.17, p=0.01) and non-somatic depression score (β:0.14, p=0.01). After adjustment 
for demographics and behavioral characteristics, hs-CRP remained statistically significantly 
associated with all three depression scores, although the betas and p values were 
somewhat attenuated. Upon further adjustment for sleep duration, BMI and LTPA, the 
association of hs-CRP with total depression and depression subtypes was attenuated and 
no longer significant (Table 6).   
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To determine which depression symptoms were associated with hs-CRP, we first 
estimated bivariate associations, and found that hs-CRP was significantly higher among 
those experiencing trouble sleeping (1.70 vs 1.24 mg/L, p=0.009) or those with abnormal 
appetite (1.85 vs 1.24, p<0.001) (Table 8). We also estimated linear and logistics regression 
models for continuous and dichotomized symptoms. In linear regression analyses of 
individual depression symptoms, hs-CRP was significantly associated with sleep 
disturbance, abnormal appetite, psychomotor abnormalities (somatic symptoms) and with 
anhedonia, depressed mood, and trouble concentrating (non-somatic symptoms). 
However, after adjustment for age, race/ethnicity, marital status, education, smoking, 
sleep, BMI and LTPA, as well as mutual adjustment for remaining depression symptoms, 
these associations were no longer significant (Table 9).  In univariate logistic regression, 
hs-CRP was significantly associated with sleep disturbances (OR:1.32 p=0.01) and 
abnormal appetite (OR:1.42, p<0.001) (Table 10). After adjustment for age, ethnicity, 
education, marital status, smoking, OC use, LTPA, sleep duration, and BMI, as well as 
mutual adjustment for the remaining depressive symptom score, a one standard deviation 
increase in log-transformed CRP was significantly associated with a 31% higher odds of 
sleep disturbance (OR: 1.31, p=0.05), and marginally associated with an 82% higher odds 
of suicidal ideation (OR: 1.82%, p=0.06). No other significant associations remained. 
To examine BMI as a potential modifier of the hs-CRP-depression association, we 
first ran the linear regression model adjusting for BMI, which attenuated the association 
between hs-CRP and total depression as well as the association with subtypes of 
depression (Table 7). This addition did not change the direction of the association. 
Adjustment for BMI did not change the direction of the association. Addition of an 
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interaction term between continuous BMI and continuous hs-CRP into the multivariable 
model did not result in any significant changes (not shown). To further assess how BMI 
may be influencing the association between hs-CRP and depression, we carried out a series 
of linear regressions using each one of the nine depression symptoms from the PHQ-9 
questionnaire as the main outcome (Table 9).  This analysis revealed the following 
symptoms of somatic depression to be affected by addition of the interaction term for BMI 
and CRP: fatigue (β:-0.26, p=0.07) and changes in appetite (β: -0.23, p=0.02). The 
interaction terms for continuous BMI x CRP for these two symptoms were significant 
(p=0.04 and p=0.02, respectively). To better understand how the outcome of changes in 
appetite may relate to BMI and CRP, we plotted this interaction with predictive margins to 
visualize the score for abnormal appetite for those with no inflammation, low 
inflammation, and mid-high inflammation (using the mean CRP for each category) based on 
BMI levels. We found that among those with CRP levels below 1 mg/L, BMI was negatively 
associated with abnormal appetite score, but among those with CRP levels between 3-10 
mg/L, BMI was positively associated with predicted appetite score (Figure 3).  
Furthermore, we stratified our analysis by BMI category and found that after 
adjustment in our final model, an increase in one standard deviation of log transformed hs-
CRP was associated with an increase in total depression score (β:1.60, p=0.001), somatic 
(β:1.07, p=0.001), and non-somatic depression score (β:0.49, p=0.007) only among those 
who were underweight. This association was not significant in any other BMI category 
(Table 7). 
To assess whether BMI, LTPA or sleep were potential mediators or confounders of 
the association between hs-CRP and depression, we ran a series of Sobel tests and Preacher 
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and Hayes tests of indirect effects with total depression score, somatic depression score 
and non-somatic depression score as the main outcomes (Figure 2).  For total depression, 
44.8% of the total effect was significantly mediated by BMI (p<0.05); for somatic 
depression, 43.8% of the total effect was mediated by BMI (p<0.05) and for non-somatic 
depression, 45.8% of the total effect was mediated by BMI (p=0.09). LTPA also attenuated 
the association between hs-CRP and depression variables, but these indirect effects were 
not statistically significant (all p>0.09). For total depression, the standardized CRP effect 
size was reduced by 16.9% (p=0.03) upon addition of sleep to the model; for somatic 
depression, the effect size was reduced by 20.7% (p=0.03), and for non-somatic depression, 
it was reduced by 12.4% (p=0.05).  We also conducted analyses to test hs-CRP x sleep 
(p>0.16 for all) and hs-CRP x LTPA (p>0.20 for all) interactions for the full models for total 
depression, somatic and non-somatic depression, all of which were not significant.  
In univariate logistic regression, an increase in one standard deviation in log-
transformed hs-CRP was associated with an 18% increase in the odds of having depression, 
and this was borderline significant (OR: 1.18, 95% CI 0.98, 1.41, p=0.07) (data not 
shown).  No significant interactions were evident in logistic regression analyses.   
Association between Sleep and Physical Activity and Depression. Sleep duration was 
inversely associated with total depression score (β:-0.41, p<0.001), somatic depression 
score (β:-0.31, p<0.001) and non-somatic depression score (β:-0.11, p=0.04) in the final, 
multivariable linear regression model (data not shown). In multivariable logistic 
regression, sleeping more than seven hours was associated with a 53% lower odds of 
having high depression score (OR:0.47, p=0.005). LTPA was inversely associated with total 
depression, somatic and non-somatic depression in multivariable linear regression as well 
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in multivariable logistic regression (data not shown). Being in the lowest quartile of LTPA 
was significantly associated with higher total depression score (β:1.4, p<0.001), somatic 
depression score (β:0.82, p=0.001) and non-somatic depression score (β:0.58, p=0.001). In 
multivariable logistic regression, the relative odds of a high depression score (OR: 2.8, 
p=0.01) was significantly higher among women in the lowest quartile of LTPA compared to 
those with more activity.  
7.5 Discussion 
In this large representative sample of reproductive age US women, we found that hs-
CRP was positively associated with total depression, somatic depression, and non-somatic 
depression after adjustment for demographic and behavioral characteristics. 
However, these associations were attenuated and were no longer significant after 
adjustment for BMI, sleep, and LTPA, suggesting that the association between inflammation 
and depression may be mediated or confounded by these lifestyle factors. Although 
previous studies have also reported an association between higher levels of inflammatory 
biomarkers such as hs-CRP and increased depressive symptoms,8,14,34–37 our study is the 
first to investigate how these lifestyle factors may influence the association between 
inflammation and various dimensions of depression among women of reproductive age. 
Body mass index significantly attenuated the association between CRP and depression 
among women in our analysis, and this finding is consistent with, and expands upon the 
result of a recent analysis by Liu et al (2014), where CRP was significantly associated with 
depression among men, but not among women after adjustment for BMI.7  We observed a 
similar pattern among our sample of women of reproductive age, suggesting that BMI, a 
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proxy for adiposity, partially explained the association observed between CRP and total 
depression score in unadjusted models. Adipose tissue functions as a key endocrine gland, 
releasing adipokines, which can have pro- or anti-inflammatory activities, depending on 
the adipose storage site.38 Pro-inflammatory adipokines, such as leptin and IL-6, are 
upregulated in proportion to adipose tissue and increase transcription of hs-CRP.39 
Compared to men, women generally have greater body fat content,40 which is associated 
with higher BMI and higher leptin levels. BMI may be masking the association between CRP 
and depression given that adiposity is associated with higher inflammation and, in some 
studies, predicts future depression.41 However, given that our study is cross-sectional, and 
depression has also been found to predict weight gain through emotional eating and weight 
gain,42 we cannot rule out the possibility that BMI may be operating as a mediator instead 
of a confounder.  
Although the association between obesity and depression seems clearly established, 
conflicting evidence remains regarding the shape of the relationship between body weight 
and depression when considering the full range of BMI, including those who are 
underweight.43–45 Some suggest the relationship between body weight and depression is U-
shaped, with those who are underweight and overweight or obese having higher odds of 
depression.7 We observed a positive association between CRP and depression scores, 
evident only among those who were underweight (BMI <18.5 kg/m2), suggesting that BMI 
modifies the CRP-depression association. It is possible that inflammation originating from 
non-adipose tissue is strongly related to depression among those with lower levels of 
adiposity. Among those with higher levels of adiposity, adipokine-derived inflammation 
may be attenuating this association. These results are consistent with recent findings from 
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a cross-sectional analysis of the relationship between log-transformed CRP and depression 
scores among an elderly Chinese population, where Qin et al. (2017) found that CRP was 
significantly associated with total depression score, somatic depression score, and non-
somatic depression score among underweight individuals after adjustment for age, sex, 
education, marital status, smoking, and alcohol consumption.46 Similarly, they did not 
observe any significant association between CRP and any type of depression in their full 
sample after adjustments or in the normal, overweight, or obese BMI categories. 
Additionally, they found a lower prevalence of depression among those in the higher BMI 
categories, whereas we found that the prevalence of depression increased with increasing 
BMI. This inverse association between BMI and depression is not a new phenomenon 
among Asian populations, as obesity may be thought to protect middle-aged and elderly 
Chinese against depression.47  Given the demographic and cultural differences between 
these two populations, the similarities in results need to be examined further to determine 
whether different mechanisms are involved. 
Previous studies indicate that inflammation is more strongly related to somatic 
symptoms of depression.6,11,13,14,25 We did not see a significant difference between CRP and 
somatic vs non-somatic depression scores. However, when analyzing individual symptoms 
of depression, CRP was significantly associated with sleep disturbances and changes in 
appetite.  Previous studies have also reported that CRP is significantly associated with 
sleep disturbances26,27 and appetite changes,27 in addition to other somatic symptoms 
(fatigue and low energy) after adjustment for age, gender, ethnicity and the sum of 
remaining depression symptoms.  In some cases,26,27 the associations between CRP and 
additional symptoms of depression could be due to including participants with acute 
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inflammation (CRP>10 mg/L) as well as including men and women in the analysis. One of 
the studies27 found that, relative to the lowest quartiles, those in the highest quartile of CRP 
(range: 3.31-157.50 mg/L) have higher odds of all the somatic symptoms they assessed; 
these relationships were not significant among lower quartiles of CRP.  In support of 
immune-to-brain-pathways, sleep disturbance is one of the sickness symptoms found to be 
mediated by increases in circulating pro-inflammatory cytokines.48  Therefore, our finding 
that inflammation was associated with higher odds of sleep disturbance, even after 
adjustment for sleep and other potential confounders, is consistent with previous 
studies,28,49 and adds to the evidence that sleep disturbances may be one of the primary 
manifestations of inflammation-associated depression, which may be more evident among 
women even at lower inflammation levels. 
The occurrence of appetite change was the only other somatic symptom associated with 
inflammation, although this relationship showed evidence of effect modification by BMI. 
BMI was negatively associated with abnormal appetite score among those with CRP levels 
below 1mg/L, but was positively associated with predicted appetite score among those 
with CRP levels between 3-10mg/L. These findings suggest that baseline inflammation 
levels can affect how BMI is associated with appetite changes, and BMI can either be 
protective or increase the risk of experiencing this somatic symptom of depression. 
However, interpretation can be challenging due to the ambiguity in the question used to 
assess changes in appetite (“Over the past two weeks, how often have you been bothered by 
poor appetite or overeating?”), which asks about both negative or positive changes in 
appetite that could relate to either melancholic/typical depression (characterized by 
decreased appetite and weight loss) or to atypical depression (characterized by overeating 
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and weight gain). Some evidence indicates that atypical depression is more strongly 
associated with inflammation and BMI than is melancholic depression.50  
From a physiologic perspective, endocrine changes in adipose-related hormones can 
partially explain how inflammation may be related to changes in appetite among 
individuals with different BMI levels. Leptin, an adipocyte-derived hormone also serves as 
a feedback signal to control energy intake and regulate hunger.51  Increased leptin signaling 
associated with weight gain or excess adipose tissue increases energy expenditure and 
suppresses food intake, whereas decreased leptin signaling elicits anabolic activities by 
reducing energy expenditure and increasing food intake.51  Leptin levels are proportional 
to fat mass, but sustained high levels can lead to leptin resistance, which is a hallmark of 
obesity. Elevated CRP levels can also lead to leptin resistance.52 Therefore, leptin may play 
a more influential role in controlling changes in appetite and weight, but among those with 
elevated CRP, hunger and appetite regulation through leptin may be compromised if leptin 
resistance is present.  A recent study53  found that rats treated with a leptin receptor 
antagonist showed depressive-like symptoms accompanied by peripheral inflammation, 
demonstrating that leptin resistance can induce an obesity phenotype in healthy rats that is 
characterized by immune changes and depressive like behaviors. These observations 
support the idea that comorbid obesity and depressive illness develop are a joint response 
to changes in peripheral endocrine and metabolic environment.  
Our results are consistent with findings that show an inverse association between 
regular physical activity and serum concentration of inflammatory markers, suggesting 
that physical activity may have anti-inflammatory properties.54,55 The most sedentary 
women in our analysis had slightly higher mean hs-CRP levels, and LTPA was inversely 
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associated with total depression. These findings agree with previous suggestions of 
physical activity as a prevention or treatment for depression.56,57 Although little to no LTPA 
appeared to increase the odds of depression in this cross-sectional study, we cannot rule 
out a possible reverse causation, where those with high depression scores are more 
sedentary. Suarez et al (2013) found that high depression scores may inhibit the anti-
inflammatory effects of LTPA.29 
Our study has important strengths, including a large, diverse sample of women 
representative of the US population, the use of a validated, multidimensional depressive 
symptom measure, and the testing of multiple candidate mediators such as BMI, physical 
activity, and sleep. We also adjusted for sleep duration to avoid potential confounding by 
conditions such as sleep apnea or insomnia. Furthermore, we excluded those who are 
currently taking antidepressants to prevent nondifferential misclassification of outcome, 
given that some of the common side effects of antidepressants reported by patients are the 
very symptoms that are used to measure depression, such as insomnia, hypersomnia, 
agitation, restlessness, fatigue, somnolence, weight gain or weight loss, and decreased or 
decreased appetite.58 This overlap of antidepressant side-effects and depression symptoms 
provides a compelling reason for analyzing symptoms separately from total depression 
scores.15  
Our study also has important limitations. First, due to the cross-sectional nature of 
NHANES study design, we were unable to determine the directionality of the association 
between hs-CRP and depression symptoms. It is reasonable to speculate that the impact of 
depression may affect inflammation-reducing activities, such as healthy eating or exercise, 
and may lead to increased adiposity through weight gain. Prospective studies are 
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warranted to establish directionality and experimental models are needed to understand 
causality. The lack of additional markers of inflammation can also be considered a 
limitation; however, CRP is considered the best marker of systemic inflammation.59  In 
healthy young adults CRP is relatively stable, with a median concentration of around 0.8 
mg/L, a 90th percentile of around 3 mg/L and a 99th percentile of approximately 10 mg/L.60  
We excluded those with CRP levels higher than 10 mg/L, in order to avoid spurious 
associations between depression and acute inflammation due to current infections. 
Although CRP levels tend to remain stable in the general population, they can vary 
significantly across the menstrual cycle, as reported by Gaskins et al (2012), who observed 
a larger portion of women with CRP levels above 3 mg/L during menses compared to other 
phases of the menstrual cycle.61  There is evidence that inflammation markers are 
associated with menstrual symptoms and PMS,62 so it may also help to standardize CRP 
measurements to menstrual cycle phase in reproductive aged women. In addition, 
depending on the phase of the menstrual cycle our participants were currently in when 
they were interviewed, their symptoms of depression as measured by the PHQ-9 may have 
been higher or lower if they experienced pre-menstrual syndrome. These issues of 
misclassification of exposure or outcome may have biased our results towards the null. 
Data on menstrual cycle phase would have allowed us to discern whether depression 
symptoms were related to hormonal changes or PMS. And finally, this survey from a non-
institutionalized population may represent only less severe depression, because those who 
may be experiencing severe depression may either be institutionalized or 
disproportionately chose not to participate in the survey. Therefore, our results might not 
be generalizable to women with severe depression or major depressive disorder. 
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7.6 Conclusion 
 In summary, we found that the relationship between CRP and depressive symptoms 
varies by BMI; among those who are underweight, CRP was positively associated with 
depressive symptoms. Furthermore, the relationship between inflammation and changes in 
appetite and sleep disturbance may underlie previous findings that somatic depression is 
more prevalent among women. The current study expands our understanding of how 
systemic inflammation may contribute to depression symptoms among women of 
reproductive age. Understanding how inflammation and BMI may affect depression 
symptoms among women can help identify potential novel treatment avenues that may 
benefit from changes in lifestyle to promote greater efficacy and remission. 
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Table 4: Distribution of covariates by depression in women of reproductive age from NHANES 2005-2008 (N=1489) 
    
Total              
Population 
Total PHQ-9 Score 
(range 0-27) 
Somatic                           
Depression Score 
(range 0-12) 
Non-Somatic 
Depression Score 
(range 0-15) 
High Depression Score                       
(PHQ-9 score ≥10) 
    No Yes   
    N % Mean SE p-value Mean SE p-value Mean SE p-value N  % N % p-value 
Total population sample 1489   2.9 0.1 -- 1.8 0.1 -- 1.1 0.1 -- 1357 92.5 
13
2 7.5 -- 
C-reactive protein (mg/L)* 1.3 1.2, 1.4 -- -- -- 1.3 1.2, 1.4 1.6 1.3, 1.9 0.09 
Age, years (mean, SE) 31.7 0.3 -- -- -- 31.7 0.3 32 0.8 0.48 
Sleep per night, hours (mean, SE) 6.9 0.1 -- -- -- 7.0 0.1 6.1 0.2 <0.01 
Body Mass Index (kg/m2)         0.06     0.13     0.08         0.43 
  less than 18.5 49 3.5 2.5 0.5   1.6 0.3   0.9 0.2   47 97.1 2 2.9   
  18.5 to 24.9 593 44.4 2.6 0.1   1.7 0.1   1.0 0.1   543 93.3 50 6.7   
  25-29.9 423 26.3 3.0 0.3   1.9 0.2   1.1 0.1   385 91.5 38 8.5   
  30 or greater 422 25.9 3.4 0.3   2.1 0.1   1.4 0.1   380 91.4 42 8.6   
  p-trend         0.01     0.02     0.01           
Marital Status         0.12     0.15     0.08         2E-04 
  Single/Never Married 553 29.2 3.0 0.2   1.9 0.1   1.0 0.1   508 93.6 45 6.4   
  Married/with partner 783 60.4 2.7 0.1   1.7 0.1   1.0 0.1   718 93.5 65 6.5   
  Divorced/Separated/Widowed 153 10.2 4.0 0.5   2.4 0.3   1.7 0.3   131 83.5 22 16.5   
Education         <0.001     <0.001     <0.001         <0.01 
  Less than Highschool 369 15.6 4.1 0.3   2.4 0.2   1.7 0.1   317 86.0 51 14.0   
  Highschool or GED 354 20.6 3.5 0.3   2.1 0.2   1.4 0.2   317 89.1 37 10.9   
  Some college 482 36.0 2.9 0.2   1.8 0.1   1.1 0.1   446 93.0 36 7.0   
  College graduate 284 27.8 2.0 0.2   1.4 0.1   0.6 0.1   276 97.9 8 2.1   
  p-trend         <0.01     <0.001     <0.001           
Race/Ethnicity         0.27     0.37     0.27         0.26 
  Non-Hispanic White 557 63.5 2.8 0.2   1.8 0.1   1 0.1   508 92.9 49 7.1   
  Mexican Hispanic 364 10.2 3.2 0.2   1.9 0.1   1.3 0.1   336 92.5 28 7.5   
  Other Hispanic 141 6.6 3.6 0.4   2.1 0.2   1.5 0.2   122 89.4 19 10.6   
  Non-Hispanic Black 348 12.6 3.4 0.3   2.1 0.1   1.3 0.1   315 89.7 33 10.3   
  Other Race 79 7.2 2.9 0.3   1.7 0.2   1.2 0.1   76 96.2 3 3.8   
Oral Contraceptive use         0.01     0.05     0.01         0.09 
  Not currently using 1231 80.8 3.0 0.1   1.9 0.1   1.2 0.1   1118 92.0 
11
3 8.0   
  Currently using  213 19.2 2.3 0.3   1.5 0.2   0.8 0.2   201 95.5 12 4.5   
Smoke         <0.001     <0.001     <0.001         <0.01 
  Not current smokers 1126 76.3 2.5 0.1   1.6 0.1   0.9 0.1   1057 95.3 69 4.7   
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  Current smokers 324 23.7 4.4 0.4   2.7 0.2   1.8 0.2   263 83.4 61 16.6   
Alcohol Consumption         0.57     0.63     0.81         0.24 
  none 386 24.3 2.8 0.2   1.8 0.1   1.1 0.1   351 92.5 35 7.6   
  <1 drink/day 901 75.0 3.0 0.2   1.9 0.1   1.1 0.1   818 92.4 83 7.6   
  >1 drink/day 10 0.7 4.4 2.0   2.4 1.0   2.0 1.0   6 75.8 4 24.2   
  p-trend         0.47 0.43 0.56           
Leisure Time Physical Activity         <0.001     <0.001     <0.001         <0.01 
  Q1 (0-64 MET minutes/week) 386 25.1 4.2 0.3   2.5 0.2   1.7 0.2   321 84.5 65 15.5   
  Q2 (65-594 MET min/week) 302 24.8 2.5 0.2   1.6 0.1   0.9 0.1   283 95.2 19 4.9   
  Q3 (595-1560 MET min/week) 270 23.9 2.3 0.2   1.6 0.1   0.8 0.1   258 96.3 12 3.7   
  Q4 (>1560 MET min/week) 321 26.3 2.2 0.3   1.4 0.2   0.8 0.1   306 95.9 15 4.1   
  p-trend         <0.001     <0.001     <0.001           
Weighted regression and  t-tests for continuous depression scores and design-based Pearson chi square for categorical depression variables. *Geometric mean and 95% 
CI for ln-transformed CRP. 
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Table 5: Distribution of covariates by inflammation (hs-CRP) in women of reproductive age                                                                   
from NHANES 2005-2008 (N=1,489) 
    
hs-CRP* 
hs-CRP Category 
    CRP<1mg/L 1<CRP<3mg/L 3<CRP<10mg/L   
    
Geometric 
mean 
95% CI p-value N  % N % N % p-value 
Total population sample 1.3 1.16, 1.42 -- 553 38.7 492 33.6 444 27.8 -- 
Depression Score (PHQ-9)  -- 2.6 0.2 2.9 0.2 3.4 0.3 <0.05 
Age, years (mean, SE) -- 31.9 0.4 31.9 0.6 32.6 0.4 0.42 
Sleep per night, hours (mean, SE) -- 7.1 0.1 6.9 0.1 6.8 0.1 0.05 
Body Mass Index (kg/m2)     <0.001             <0.001 
  less than 18.5 0.5 0.33, 0.78   32 72.6 12 20.9 5 6.5   
  18.5-24.9 0.8 0.66, 0.87   336 56.6 172 29.6 85 13.8   
  25-29.9 1.6 1.9, 1.75   137 31.6 171 41.3 115 27.0   
  30 or greater 3.0 2.63, 3.40   48 10.5 135 34.1 239 55.4   
  p-trend     <0.001               
Marital Status     0.10             0.66 
  Single/Never Married 1.3 1.14, 1.47   221 38.8 175 34.3 157 29.2   
  Married/Living with partner 1.3 1.10, 1.43   283 39.6 260 32.4 240 27.8   
  Divorced/Separated/Widowed 1.5 1.27, 1.79   49 32.6 57 38.2 47 29.2   
Education     0.005             0.002 
  Less than High school 1.6 1.35, 1.95   122 30.5 117 34.3 129 35.2   
  High school or GED 1.5 1.24, 1.71   128 36.5 119 32.2 107 31.4   
  Some college 1.3 1.12, 1.47   176 36.1 165 35.9 141 28.0   
  College graduate 1.0 0.88, 1.23   126 48.00 91 31.3 67 20.7   
  p-trend     <0.001               
Race/Ethnicity     0.009             0.05 
  Non-Hispanic White 1.3 1.10, 1.44   216 39.3 195 34.7 146 26.1   
  Mexican Hispanic 1.6 1.33, 1.99   118 31.6 121 34.2 125 34.2   
  Other Hispanic 1.4 0.99, 2.09   52 36.1 47 30.3 42 33.7   
  Non-Hispanic Black 1.5 1.33, 1.71   126 34.8 105 30.3 117 34.9   
  Other Race 0.8 0.58, 1.10   41 52.6 24 31.6 14 15.8   
Oral Contraceptive use     <0.001             <0.001 
  Not current user 1.1 1.02, 1.27   501 43.3 394 31.7 336 25.0   
  Current user 2.1 1.73, 2.49   42 21.0 82 40.8 89 38.2   
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Smoke     0.13             0.49 
  Not a current smoker 1.3 1.12, 1.40   425 39.5 369 32.9 332 27.7   
  Current smoker 1.4 1.22, 1.62   109 35.7 114 36.1 101 28.2   
Alcohol Consumption      0.09             0.02 
  None 1.6 1.29, 1.91   121 33.9 120 29.8 145 36.3   
  <1 drink/day 1.2 1.09, 1.37   339 39.8 318 34.8 244 25.3   
  >1 drink/day 1.4 0.73, 2.64   3 33.2 5 52.2 2 14.6   
  p-trend     0.04               
Leisure Time Physical Activity     0.05             0.03 
  Q1 (0-64 MET min/week) 1.5 1.33, 1.78   116 29.4 144 38.7 126 32.0   
  Q2 (65-594 MET min/week) 1.1 0.88, 1.42   126 44.7 90 30.0 86 25.3   
  Q3 (595-1560 MET min/week) 1.2 1.01, 1.39   113 43.3 84 33.3 73 23.4   
  Q4 (>1560 MET min/week) 1.2 1.05, 1.37   125 40.8 110 34.5 86 24.8   
  p-trend     0.02               
  
*ln-transformed hs-CRP, with geometric means and 95% confidence intervals. Weighted regression and t-test for continuous hs-
CRP and chi square test for categorical CRP.  
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Table 6: Association of total depression score and depression subtypes with 
inflammation in women of reproductive age from NHANES 2005-2008 (n=1489) 
Per 1 S.D. increase                   
in hs-CRP: 
Depression defined as: 
Total PHQ-9 score 
(range 0-27) 
Somatic                      
Depression score 
(range 0-12) 
Non-somatic 
Depression score 
(range 0-15) 
β                                
(95% CI) 
p-value 
β                                
(95% CI) 
p-value 
β                                
(95% CI) 
p-value 
Unadjusted Model 
0.32 0.006 0.17 0.01 0.14 0.01 
(0.10, 0.54)   (0.04, 0.30)   (0.04, 0.25)   
Model 1 
0.24 0.03 0.13 0.04 0.11 0.05 
(0.02, 0.46)   (0.006, 0.26)   (0.002, 0.22)   
Model 2 
0.11 0.43 0.06 0.48 0.05 0.42 
(-0.16, 0.37)   (-0.11, 0.22)   (-0.08, 0.18)   
Model 1 adjusted for age, race/ethnicity, education, marital status, smoking and oral contraceptive use. Model 2 
includes those variables adjusted in Model 1 plus sleep, leisure-time physical activity and body mass index 
categories. 
 
Figure 2: Linear regression analysis assessing mediators/confounders of the relationship between hs-CRP and (a) total 
depression score, (b) somatic depression score and (c) non-somatic depression score among of reproductive age from NHANES 
2005-2008.  
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Table 7: Association of total depression score and depression subtypes with inflammation in 
women of reproductive age from NHANES 2005-2008 stratified by Body Mass Index categories 
Per 1 S.D. increase                   
in hs-CRP: 
Depression defined as: 
Total PHQ-9 score 
(range 0-27) 
Somatic                      
Depression score         
(range 0-12) 
Non-somatic                 
Depression score          
(range 0-15) 
β                                
(95% CI) 
p-value 
β                                
(95% CI) 
p-value 
β                                
(95% CI) 
p-value 
BMI <18.5 kg/m2             
  Unadjusted 0.51 0.09 0.27 0.23 0.24 0.16 
    (-0.08, 1.10)   (-0.18, 0.73)   (-0.10, 0.57)   
  Adjusted 1.60 0.001 1.07 0.001 0.49 0.007 
    (0.74, 2.47)   (0.47, 1.66)   (0.15, 0.84)   
BMI 18.5-24.9 kg/m2             
  Unadjusted 0.15 0.36 0.08 0.51 0.08 0.27 
    (-0.18, 0.49)   (-0.16, 0.32)   (-0.06, 0.21)   
  Adjusted 0.01 0.95 -0.03 0.72 0.05 0.60 
    (-0.34, 0.36)   (-0.23, 0.16)   (-0.14, 0.24)   
BMI 25-29.9 kg/m2             
  Unadjusted 0.13 0.62 0.06 0.65 0.06 0.64 
    (-0.39, 0.64)   (-0.22, 0.35)   (-0.20, 0.32)   
  Adjusted 0.15 0.66 0.06 0.77 0.09 0.58 
    (-0.55, 0.86)   (-0.35, 0.47)   (-0.24, 0.43)   
BMI ≥30 kg/m2             
  Unadjusted 0.20 0.51 0.12 0.52 0.08 0.60 
    (-0.41, 0.80)   (-0.25, 0.49)   (-0.23, 0.39)   
  Adjusted 0.29 0.40 0.24 0.19 0.03 0.85 
    (-0.40, 0.98)   (-0.12, 0.60)   (-0.34, 0.41)   
Adjusted models include age, race/ethnicity, marital status, education, smoking, oral contraceptive use, physical 
activity, sleep and continuous body mass index. 
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Table 8: Distribution of c-reactive protein and CRP categories by dichotomized individual depression symptoms among women 
  
Serum hs-CRP* 
C-Reactive Protein Categories 
<1 mg/L 1-3mg/L 3-10 mg/L   
Mean 95% CI p-value N  % N % N % p-value 
  Trouble sleeping**     0.009             0.07 
    No 1.24 (1.1, 1.4)   492 91.4 421 86.1 380 86.3   
    Yes 1.70 (1.4, 2.1)   61 8.7 71 13.9 64 13.7   
  Fatigue     0.31             0.56 
    No 1.27 (1.1, 1.4)   464 85.1 418 85.4 360 82.4   
    Yes 1.41 (1.2, 1.7)   89 14.9 74 14.6 84 17.6   
  Abnormal appetite**     <0.001             <0.001 
    No 1.24 (1.1, 1.4)   508 93.2 454 93.2 388 86.3   
    Yes 1.85 (1.6, 2.2)   45 6.8 38 6.8 56 13.7   
  Moving or speaking too slow or too fast     0.09             0.35 
    No 1.28 (1.2, 1.4)   539 98.2 475 96.9 427 96.6   
    Yes 1.75 (1.3, 2.5)   14 1.8 17 3.1 17 3.4   
  Anhedonia     0.35             0.10 
    No 1.28 (1.2, 1.4)   526 96.4 459 94.2 418 95.3   
    Yes 1.4 (1.1, 1.8)   27 3.6 33 5.8 26 4.7   
  Depressed mood     0.17             0.39 
    No 1.27 (1.1, 1.4)   516 95.3 463 94.2 407 92.7   
    Yes 1.56 (1.2, 2.0)   37 4.7 29 5.8 37 7.3   
  Low self-esteem     0.27             0.48 
    No 1.27 (1.2, 1.4)   527 96.0 467 94.7 414 94.1   
    Yes 1.56 (1.1, 2.2)   26 4.0 25 5.3 30 5.9   
  Trouble concentrating     0.18             0.19 
    No 1.27 (1.2, 1.4)   530 96.2 472 96.7 418 93.9   
    Yes 1.66 (1.1, 2.4)   23 3.8 20 3.3 26 6.1   
  Suicidal ideation     0.29             0.31 
    No 1.28 (1.2, 1.4)   545 99.4 488 99.6 436 98.8   
    Yes 1.83 (0.9, 3.7)   8 0.6 4 0.4 8 1.2   
Weighted t-tests and design-based Pearson chi square for categories of CRP. *Natural log transformed hs-CRP. **Significant trend test for weighted proportions.  
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Table 9: Linear regression of total depression score and individual depression symptoms with hs-CRP in women of 
reproductive age from NHANES 2005-2008 
Per 1 S.D. 
increase                   
in hs-CRP: 
Total PHQ-9 score 
Somatic Depression Symptoms 
Sleep disturbance Fatigue* Abnormal appetite* 
Psychomotor 
abnormalities 
β                                
(95% CI) 
p-value 
β                                
(95% CI) 
p-value 
β                                
(95% CI) 
p-value 
β                                
(95% CI) 
p-value 
β                                
(95% CI) 
p-
value 
Unadjusted 
0.38 0.003 0.06 0.04 0.02 0.51 0.07 0.001 0.03 0.03 
(0.14, 0.62)   (0.002, 0.11)   (-0.04, 0.08)   (0.03, 0.11)   (0.003, 0.05)   
Model 1 
0.15 0.25 0.04 0.21 0.01 0.72 -0.009 0.73 0.01 0.44 
(-0.11, 0.42)   (-0.02, 0.10)   (-0.06, 0.09)   (-0.06, 0.04)   (-0.02, 0.04)   
Model 2 
-0.27 0.46 0.09 0.46 -0.27 0.07 -0.23 0.02 0.03 0.52 
(-0.99, 0.46)   (-0.16, 0.34)   (-0.55, 0.02)   (-0.41, -0.04)   (-0.07, 0.14)   
Model 3 -- 
0.03 0.27 -0.0004 0.99 -0.02 0.25 0.007 0.69 
(-0.02, 0.08)   (-0.06, 0.06)   (-0.07, 0.02)   (-0.03, 0.04)   
Per 1 S.D. 
increase                   
in hs-CRP: 
Non-somatic Depression Symptoms 
Anhedonia Depressed mood Low Sef-esteem Trouble concentrating Suicidal Ideation 
β                                
(95% CI) 
p-value 
β                                
(95% CI) 
p-value 
β                                
(95% CI) 
p-value 
β                                
(95% CI) 
p-value 
β                                
(95% CI) 
p-
value 
Unadjusted 
0.03 0.02 0.04 0.05 0.03 0.17 0.04 0.01 0.008 0.18 
(0.006, 0.06)   (0.001, 0.07)   (-0.01, 0.07)   (0.009, 0.07)   (-0.004, 0.02)   
Model 1 
0.01 0.63 0.002 0.92 0.01 0.66 0.02 0.26 0.01 0.17 
(-0.02, 0.04)   (-0.04, 0.05)   (-0.04, 0.06)   (-0.01, 0.05)   (-0.005, 0.03)   
Model 2 
-0.008 0.91 0.06 0.53 -0.08 0.41 -0.07 0.30 0.04 0.16 
(-0.14, 0.13)   (-0.13, 0.24)   (-0.26, 0.11)   (-0.20, 0.06)   (-0.02, 0.09)   
Model 3 
-0.003 0.83 -0.01 0.56 -0.001 0.96 0.01 0.47 0.01 0.22 
(-0.03, 0.02)   (-0.04, 0.02)   (-0.04, 0.04)   (-0.02, 0.04)            (-0.006, 0.03)   
β= standardized beta coefficient for increase in 1 standard deviation in log-transformed hs-CRP. Model 1 is adjusted for age, race/ethnicity, marital status, education, 
smoking, oral contraceptive use, sleep, antidepressant use, leisure-time physical activity, and body mass index.  Model 2 is model 1 plus an interaction term for 
BMIxCRP. Model 3 is additionally adjusted for the sum of the remaining depression items (mutually adjusted associations). *Interaction term for BMIxCRP is statistically 
significant 
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Table 10: Logistic regression of association of total depression score and individual depression symptoms with 
hs-CRP in reproductive-aged women from NHANES 2005-2008 
Per 1 S.D. 
increase                   
in hs-CRP: 
High depression 
score 
Somatic Depression Symptoms 
Sleep disturbance Fatigue Abnormal appetite 
Psychomotor 
abnormalities 
OR                              
(95% CI) 
p-value 
OR                              
(95% CI) 
p-value 
OR                              
(95% CI) 
p-value 
OR                              
(95% CI) 
p-value 
OR                              
(95% CI) 
p-value 
Unadjusted 
1.18 0.07 1.32 0.01 1.1 0.31 1.42 <0.001 1.31 0.11 
(0.98, 1.41)   (1.07, 1.62)   (0.91, 1.32)   (1.21, 1.67)   (0.94, 1.85)   
Model 1 
--   1.23 0.07 0.94 0.64 1.36 0.002 1.12 0.61 
    (0.98, 1.5)   (0.73, 1.22)   (1.12, 1.64)   (0.72, 1.73)   
Model 2 
--   1.31 0.05 1.03 0.88 0.91 0.53 1.03 0.90 
    (1.01, 1.71)   (0.71, 1.48)   (0.68, 1.22)   (0.62, 1.73)   
Per 1 S.D. 
increase                   
in hs-CRP: 
Non-somatic Depression Symptoms 
Anhedonia Depressed mood Low Self-esteem 
Trouble 
concentrating 
Suicidal Ideation 
OR                              
(95% CI) 
p-value 
OR                              
(95% CI) 
p-value 
OR                              
(95% CI) 
p-value 
OR                              
(95% CI) 
p-value 
OR                              
(95% CI) 
p-value 
Unadjusted 
1.10 0.36 1.19 0.18 1.19 0.29 1.25 0.20 1.37 0.33 
(0.90, 1.34)   (0.92, 1.54)   (0.86, 1.64)   (0.88, 1.79)   (0.72, 2.61)   
Model 1 
0.88 0.28 1.02 0.90 0.99 0.97 1.11 0.60 1.13 0.74 
(0.70, 1.11)   (0.74, 1.40)   (0.67, 1.48)   (0.74, 1.66)   (0.54, 2.34)   
Model 2 
0.91 0.55 0.99 0.94 1.19 0.46 1.14 0.49 1.82 0.06 
(0.67, 1.24)   (0.69, 1.42)   (0.74, 1.92)   (0.78, 1.66)   (0.97, 3.40)   
Model 1 is mutually adjusted for the sum of other depressive symptoms. Model 2 is model 1 plus age, race/ethnicity, marital status, education, smoking, oral contraceptive use, sleep 
duration, leisure-time physical activity, and body mass index. 
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Figure 3: The effect of BMI on abnormal appetite score (item 5 of the PHQ-9) for women 
with no inflammation (CRP=0.4 mg/L), low and moderate inflammation (CRP=1.9mg/L and 
CRP=5.6mg/L, respectively). 
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CHAPTER 8 
“THE ASSOCIATION BETWEEN SERUM PYRIDOXAL 5’-PHOSPHATE AND DEPRESSION 
VARIES BY INFLAMMATION AND DEPRESSION SYMPTOMS AMONG WOMEN OF 
REPRODUCTIVE AGE FROM NHANES 2005-2008” 
 
8.1 Abstract 
Depression is the leading cause of disease burden in U.S. women of reproductive 
age. Inflammation is associated with depression, yet the mechanism for this association 
remains unclear. Vitamin B6 status is reportedly compromised during inflammation and 
has been linked to depression. In secondary data analyses, we evaluated the association 
between vitamin B6 status, inflammation, and depression in 1,489 non-pregnant women 
(18-44 yrs) from NHANES 2005-2008. Depression scores were calculated based on the 
Patient Health Questionnaire-9 (PHQ-9) and categorized into total depression, somatic and 
non-somatic depression. High depression score (PHQ-9 ≥10) was also used as an outcome, 
as were individual symptoms of depression. Vitamin B6, as serum pyridoxal-5'phosphate 
(PLP), was categorized as deficient (<20 nmol/L), insufficient (20-29.9 nmol/L) or normal 
(≥30 nmol/L). Low inflammation was defined as a C-reactive protein (CRP) concentrations 
between 1-3 mg/L and moderate inflammation as CRP between 3-10 mg/L. Overall, 7.5% 
of women had a high depression score, but this proportion varied by inflammation and 
vitamin B6 status. When stratified by CRP categories, the prevalence of depression was 
higher among those with vitamin B6 deficiency (21%) than among those with vitamin B6 
insufficiency (10%) or those with normal vitamin B6 status (5%), although this trend was 
only significant among those with moderate inflammation (p-trend=0.02). A similar trend 
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of increased depression with lower vitamin B6 concentration was observed among women 
with CRP levels between 1-3 mg/L, but not among those with CRP <1 mg/L. In 
multivariable models including individual depression symptoms, PLP levels below 30 
nmol/L were associated with higher odds of experiencing suicidal ideation (OR: 7.33, 
p=0.01 and OR: 3.5, p=0.06 for B6 deficiency and insufficiency, respectively) and depressed 
mood (OR: 3.12, p=0.004 for B6 insufficiency). Among those with elevated CRP, vitamin B6 
deficiency was associated with a higher score for psychomotor abnormalities (p=0.02). 
Understanding the mechanism linking inflammation and vitamin B6 to various dimensions 
of depression could lead to new approaches to prevent and treat depression.   
8.2 Introduction 
Depression is common in the United States; approximately 16% of adults experience 
clinical depression at some point in their lives.1  Women are two- to three-times more 
likely than men to experience depression,2,3 and among women, depression is the leading 
source of disease burden.2–4  Numerous risk factors for depression have been identified, 
among them vitamin B6 deficiency.5–8   Population-based studies estimate that a quarter of 
U.S. women of childbearing age have suboptimal vitamin B6 concentrations, and the 
prevalence may be even higher among women currently taking oral contraceptives (78%).9  
In addition to a potential link with depression, these numbers are alarming considering 
that suboptimal maternal vitamin B6 status has been shown to adversely affect other health 
outcomes, including conception rates10 and  pregnancy complications such as spontaneous 
abortions,11 and may affect the neurological development of the offspring.12 
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Serum pyridoxal 5’-phosphate (PLP), the bioactive form of vitamin B6, serves as a 
coenzyme in numerous metabolic reactions, including the tryptophan-serotonin pathway, 
and a lack of vitamin B6 may lead to depression by reducing serotonin levels.13 Studies 
examining dietary vitamin B6 alone have yielded conflicting results regarding the 
association between vitamin B6 intake and depression.14,15 However, studies assessing 
serum PLP and depression have consistently shown an inverse association.6–8  To date, 
most studies of vitamin B6 and depression have been limited by small sample size, use of an 
elderly population, heterogeneity in the measures of depression, or failure to account for 
inflammatory biomarkers. Inflammation is an important consideration because, in addition 
to functioning as a cofactor in neurotransmitter synthesis, vitamin B6 plays an important 
role in the production of cytokines, the primary mediators of inflammation.16  Lower serum 
PLP concentrations are associated with inflammation,17,18 which may not necessarily be 
linked to dietary vitamin B6 inadequacy in some cases, but rather could be due to metabolic 
phenomena inherent to inflammation.19  During inflammation, tryptophan metabolism 
shifts from serotonin synthesis to generation of neuroactive metabolites, such as quinolinic 
acid and kynurenic acid, through the kynurenine pathway.20  This shift in utilization of 
vitamin B6 could potentially contribute to depression. To date, no studies have investigated 
how inflammation may affect the association between vitamin B6 status and depression. 
The purpose of this study was to further explore the relationship between vitamin 
B6 status and depression among U.S. reproductive-age women and to determine whether 
high sensitivity C-reactive protein (hs-CRP), a marker of inflammation, modifies the 
association between vitamin B6 and depression subtypes or individual symptoms of 
depression among reproductive-age women.  
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8.3 Methods 
8.3.1 Study Design and Study Population 
We analyzed cross-sectional data from the 2005-2008 National Health and Nutrition 
Examination Survey (NHANES), which is national survey from the National Center for 
Health Statistics of the Centers for Disease Control and Prevention (CDC), designed to 
assess the health and nutritional status of the U.S. population. The NHANES employs a 
complex, multistage, probability sampling design to select persons representative of the 
civilian, non-institutionalized US population, with oversampling of special sub-populations, 
such as racial and ethnic minorities. Detailed descriptions of the survey design and 
procedures are available at the NHANES website.21  
Briefly, approximately 5,000 people are surveyed each year via in-person interviews 
and physical examinations. The interview, which is conducted in participants’ homes, 
includes demographic, socioeconomic, dietary, and health-related questions; the 
examination component is comprised of medical, dental, and physiological measurements, 
as well as laboratory tests, which take place in specially-designed and equipped mobile 
examination centers (MEC) that travel throughout the country. The National Center for 
Health Statistic’s Institutional Review Board has reviewed and approved the NHANES 
protocol. 
 Participants were eligible for our study if they were women of reproductive age 
(15-44 years old) who were not pregnant. From the initial sample of 2,609 eligible women, 
we excluded those with missing data for either depression (n=506) or serum pyridoxal 5’-
phosphate (n=7). Depression data for individuals younger than 18 years old was not 
publicly available; therefore, our age range was restricted to women ages 18-44 years old. 
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Also excluded were women with acute inflammation denoted by CRP levels above 10 mg/L 
(n=201),22  those who were taking anti-inflammatory medications, including NSAIDs 
(n=70), and those who reported current antidepressant use (n=135). The remaining 
sample contained 1,489 women. 
 8.3.2 Assessment of Depression Status 
The Patient Health Questionnaire-9 (PHQ-9)23 was administered during the MEC 
interview to assess depressive symptom severity over the past two weeks. Based on the 
diagnostic criteria for major depressive disorder in the Diagnostic and Statistical Manual 
Fourth Edition (DSM-IV), the PHQ-9 employs a 4-point scale (0=not at all, 1= several days, 
2= more than half the days, 3= nearly every day) to determine the frequency with which 
respondents experienced the following nine symptoms of major depressive disorder: 
anhedonia, depressed mood, sleep disturbance, fatigue, appetite changes, low self-esteem, 
concentration problems, psychomotor retardation/agitation, and suicidal ideation. Total 
depression scores range from 0 to 27, with scores of 10 or higher indicative of clinical 
depression.24 The PHQ-9 has been shown to be a reliable and valid questionnaire as 
indicated by its high internal consistency and good sensitivity (88%) and specificity (88%) 
for identifying cases of major depressive disorder in community samples.25–27  
In addition to the total depression score, we calculated somatic and cognitive-
affective depression subscale scores. The somatic depression subscale was calculated by 
adding the scores for frequency of somatic depression symptom from the PHQ-9 (sleep 
disturbance, fatigue, appetite changes, and psychomotor retardation/agitation) and the 
cognitive-affective subscale score was calculated adding the scores for non-somatic 
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symptoms (anhedonia, depressed mood, low self-esteem, concentration problems and 
suicidal ideation).28 While previous factor analyses supported a one-factor model with all 
nine items,29,30 recent confirmatory factor analyses have found that subscales of depression 
dimensions may provide a better fit to the data.31,32  Some have also argued that given the 
heterogeneity of symptoms for depression, individual symptoms should be analyzed.33 We 
included a separate analysis for individual depressive symptoms, coded as continuous 
variables (scores ranging from 0-3) and as binary variables. To dichotomize the variable, 
those items with responses “more than half the days” and “nearly every day” indicated the 
presence of the symptom.34,35  
8.3.3 Serum Pyridoxal 5’-Phosphate  
Fasting whole blood samples were collected during the medical examination. 
Venipuncture was performed using standard phlebotomy techniques by NHANES trained 
personnel. Serum specimens were processed, stored and shipped to the Division of 
Environmental Health Laboratory Sciences, National Center for Environmental Health, 
Centers for Disease Control and Prevention in Atlanta, Georgia. Further detailed 
instructions on specimen collection and processing can be found at NHANES website.21  
Briefly, serum PLP, the main bioactive form of vitamin B6, was measured using reverse-
phase high performance liquid chromatography (HPLC) analysis using fluorometric 
detection at 325nm excitation and 425nm emission. Quantitation of PLP was based on 
analyte peak area interpolated against a five-point calibration curve from aqueous 
standards. This HPLC assay has a lower limit of detection compared to the enzymatic assay 
used in previous NHANES cycles (0.3 vs 10 nmol/L).21  Given that PLP was not normally 
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distributed, PLP measures were converted to their natural logarithm to improve normality. 
Serum PLP was also divided into categories indicating vitamin B6 deficiency (PLP 
<20nmol/L), insufficiency (PLP 20 to 29.9 nmol/L) and sufficiency (PLP ≥30 nmol/L) 
following previously used cut-offs for vitamin B6 status.36–38  
8.3.4 Covariates and Confounders 
We considered as possible covariates a selected set of demographic, lifestyle, and 
socioeconomic factors using responses to the demographic and household sections of the 
NHANES questionnaire. The National Center for Health Statistics (NCHS) standard 
definitions for ethnicities were used; ethnicities were categorized as non-Hispanic whites, 
non-Hispanic blacks, Mexican-Hispanics, other Hispanics, and other race. Educational 
attainment was measured as the highest grade of school completed, and categorized into 
four levels: less than high school, high school equivalent, some college, and college graduate 
or above. The smoking assessment for respondents aged 18-19 years (MEC) was not 
identical to that for respondents aged 20+ years (household interview). For respondents 
aged 20+ years, we classified those who reported smoking at least 100 cigarettes during 
their lifetime and reported that they now smoke cigarettes every day or some days as 
current smokers. For respondents ages 18-19 years, we classified as current smokers those 
who reported smoking 15 or more day in the last 30 days. To create the alcohol groups, we 
used responses to the alcohol use interview at the MEC and calculated the drinks per day as 
suggested by Case and Stewart.39  Alcohol consumption, which was only available for 
participants of legal drinking age (21 and older), was categorized into abstainer, one or 
fewer drinks/day and more than one drink per day.  Leisure-time physical activity (LTPA) 
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was assessed by asking participants about their involvement in 48 specific recreation 
activities of moderate or vigorous intensity. Frequency was first multiplied by the duration 
in hours and divided by 4.3 to obtain hours of LTPA per week. To calculate MET hrs/week, 
each activity was multiplied by its MET level per NHANES physical activity codes.40  
Participants were then categorized into quartiles of physical activity. Sleep duration was 
assessed by asking participants how many hours of sleep they usually get on a 
weekday/workday, and those who reported sleeping 12 or more hours were labeled as 
sleeping 12 hours/night. Oral contraceptive use was determined by self-report of current 
use, with “past” or “never” users classified as not currently using oral contraceptives (OC). 
Body mass index (BMI) and high-sensitivity C-reactive protein (CRP) have been 
associated with both vitamin B6 levels and depression9,17,41,42 and were examined as 
potential confounders/mediators of the relationship between PLP and depression.  BMI 
(kg/m2) was computed from height and weight measurements and grouped into four 
standard categories: underweight (BMI<18.5 kg/m2), normal weight (18.5 ≤ BMI<25), 
overweight (25≤ BMI<30) and obese (BMI≥30 kg/m2). High-sensitivity c-reactive protein 
was quantified using latex-enhanced nephelometry using a Dade Behring Nephelometer 
(Dade Behring Diagnostics Inc, Somerville, NJ). CRP was classified into three categories: 
those with no inflammation (CRP <1 mg/L), low inflammation (CRP 1-3 mg/L) and 
moderate inflammation (CRP 3-10 mg/L) following previously used guidelines.22  
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8.3.5 Data Analysis 
The complex survey design used for NHANES data collection was incorporated into 
all data analyses using the “svy” command with appropriate weighting in Stata 12.0 
(StataCorp LP, College Station, TX). Detailed information on the procedures for taking into 
account sampling weights have been described elsewhere.43  
Descriptive statistics were calculated for the overall sample using frequency 
distributions for categorical variables and means and standard errors for continuous 
variables. Because both PLP and hs-CRP were logarithmically transformed when analyzed 
as continuous variables, geometric means (antilogarithms of the transformed means) and 
their 95% confidence intervals are presented for serum PLP and hs-CRP. Bivariate analyses 
were carried out for each covariate and ln-transformed PLP and vitamin B6 categories as 
well as for covariates and total depression, somatic/non-somatic depression and binary 
depression variables, using weighted ANOVAs, Chi square tests and 2-sample t-test as 
appropriate. T-tests and chi-square tests were performed to assess crude differences in 
PLP and vitamin B6 status by individual depressive symptom. Adjusted analyses were 
performed using multivariable linear regression. In linear regression models, all covariates 
that changed the estimated coefficient for the primary predictor of interest by more than 
10% were retained in the multivariable model. In addition, known risk factors for 
depression were retained in the model as well as those that were associated with both the 
predictor and the outcome.  
To explore variation in the association of vitamin B6 status with dimensions of 
depression, we conducted a series of linear regression analyses in which total depression 
score, somatic depression score, non-somatic depression score and each individual 
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depression symptom served as an outcome variables. A similar series of logistic regression 
analyses was also completed for dichotomized individual depressive symptoms. For all the 
individual depression symptoms, we adjusted for the remaining depression symptoms to 
account for any potential overlap between different symptoms and to reduce the 
probability of type I error. Logistic regression analyses were also carried out for depression 
PHQ-9 score of 10 or greater. The command “mfpigen” was used to assess all possible 
interactions among variables in the full models. 
C-reactive protein and BMI were assessed as potential mediators or effect modifiers 
by running mediation tests, stratifying regression analyses, and by including multiplicative 
interaction terms in the multivariable analysis. To quantify the effects of CRP and BMI on 
any observed relationships between vitamin B6 status and depression, we carried out Sobel 
mediation tests and Preacher and Hayes bootstrap tests of indirect effects.44,45  All linear 
and logistic regression estimates were weighted using NHANES sample weights, which 
account for the complex survey design, survey nonresponse and post-stratification. 
8.4 Results 
 Description of Study Cohort. The characteristics of the 1,489 women who comprised 
our final sample are shown in table 11.  The mean age of our sample was 31.7 years. The 
majority of women were white (63.5%), married or living with a partner (60.4%,), did not 
use oral contraceptives (80.8%), reported an average of seven hours of sleep per night, and 
were nonsmokers (76.3%).  Almost eight percent (n=132) of women in our sample 
reported moderate to severe depression symptoms indicative of clinically significant 
depression, denoted by a score of 10 or higher on the PHQ-9 (Table 11). 
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In bivariate analysis, depression scores were positively associated with BMI (p-
trend <0.02) and hs-CRP (p-trend<0.02) and negatively associated with education 
(p<0.001) and LTPA (p<0.001) (Table 12). Depression scores were higher for both somatic 
and non-somatic subtypes among women who were not currently taking oral 
contraceptives (p=0.05 and p=0.01, respectively) compared to OC users and for smokers 
(p<0.001) compared to non-smokers.  Women with high depression scores slept less (6.1 
vs 7.0 hours/night, p<0.001) compared to those with low depression scores. The 
prevalence of depression defined as a PHQ-9 score of 10 or greater was significantly higher 
among women who were separated or divorced compared to women who were 
married/living together with partner or who were single/not married; for those who 
smoked compared to non-smokers; and those who reported the lowest levels of LTPA 
compared to the rest of the LTPA quartiles. The prevalence of a high depression score was 
lower among women who reported current oral contraceptive use compared to non-OC 
users (4.5% vs 8.0%, p=0.09). 
Approximately one third of women (32%) had suboptimal vitamin B6 levels and 
10% percent had biochemical evidence of vitamin B6 deficiency (PLP<20 nmol/L). Serum 
PLP was negatively associated with BMI (p-trend <0.001), CRP levels (p-trend <0.001), and 
smoking dose (p-trend<0.001), and positively associated with LTPA (p-trend <0.001) and 
education (p-trend<0.001). Those with vitamin B6 deficiency slept less than those with 
insufficient and sufficient vitamin B6 levels (p=0.003). Vitamin B6 concentration did not 
vary by age or oral contraceptive use (Table 12). 
Association of PLP with depression scores. Mean serum PLP was lower among women who 
had high depression scores compared to those who had low depression scores (34.4 vs 
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47.1 nmol/L, p=0.004), and total depression score was higher for women who had vitamin 
B6 deficiency compared to those who had insufficiency or sufficiency (4.4 vs 3.2 vs 2.6 
points, respectively; p=0.003). In univariate analyses, vitamin B6 deficiency was associated 
with a higher total depression score (β: 1.7, p=0.001), somatic depression score (β: 0.99, 
p<0.001), and non-somatic depression score (β: 0.72, p=0.02). These associations were 
attenuated and no longer significant after adjustment for demographics, lifestyle and 
behavioral factors (data not shown).  
To assess whether inflammation affects the association between vitamin B6 status 
and depression, we first visualized the relationship using bar graphs (Figure 4). Depression 
scores tended to increase with increasing CRP level, especially among those with vitamin 
B6 deficiency (p-trend=0.04). When stratified by CRP categories (<1 mg/L, 1-3 mg/L and 3-
10 mg/L), the prevalence of depression was highest among those with vitamin B6 
deficiency, followed by those with vitamin B6 insufficiency; however, this trend was only 
significant among those with moderate inflammation (CRP levels 3-10 mg/L ; p-
trend=0.02), and borderline significant among those with low inflammation (p-trend=0.07) 
(Figure 5). A similar pattern was found in linear regression models stratified by CRP levels. 
Vitamin B6 deficiency was associated with higher total depression score (β: 1.48, p=0.01 
and β:2.52, p=0.01) and somatic depression score (β:0.93, p=0.008; β:1.33, p=0.004) 
among those with low or moderate inflammation, but not among those with CRP levels 
below 1 mg/L in unadjusted analyses. Once again, adjustment for covariates completely 
attenuated these results (data not shown). 
To assess whether BMI or CRP were potential mediators or confounders of the 
association between PLP and depression, we ran a series of Sobel mediation tests followed 
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by bootstrap analysis for the Preacher and Hayes test of indirect effect.44,45 For total 
depression score, 7.9% of the total effect was significantly mediated by CRP (p=0.045) 
(Figure 6); BMI also attenuated the association between PLP and depression variables. For 
total depression, the standardized PLP effect size was reduced by 10.8% upon addition of 
BMI to the model (p=0.02); the effect of PLP on somatic and non-somatic depression was 
also reduced by 9% and 13.5%, and these mediations were significant (p=0.03 and p-0.04, 
respectively). 
To determine which depression symptoms were associated with vitamin B6 status, 
we estimated the bivariate associations, and then fit a series of linear and logistic 
multivariable models for continuous and dichotomized symptoms. In bivariate analysis, 
PLP was significantly lower among those experiencing most symptoms of depression, 
except for moving or speaking too slow or too fast (p=0.13). The prevalence of vitamin B6 
deficiency was significantly higher among those experiencing most individual depression 
symptoms, except for low self-esteem (p=0.25) and trouble concentrating (p=0.17) (Table 
13). In linear regression with individual depression symptoms, vitamin B6 deficiency was 
significantly associated with a higher score for most of the symptoms of depression 
(sleeping problems β: 0.30, p=0.001; fatigue β: 0.33, 0.001, abnormal appetite β: 0.27, 
0.002; anhedonia β:0.18, p=0.03; depressed mood β: 0.22, p=0.008; low self-esteem β: 0.12, 
p=0.05; suicidal ideation β: 0.07, p=0.05), but these associations were attenuated after 
mutual adjustment and adjustment for demographics, behavioral, and lifestyle factors. 
Compared to somatic symptoms, vitamin B6 deficiency was associated with fewer non-
somatic symptoms in unadjusted analysis among those with low inflammation levels 
(anhedonia, low self-esteem) and moderate inflammation (depressed mood and suicidal 
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ideation) in unadjusted analysis (data not shown). In univariate logistic regression with 
dichotomized individual symptoms of depression, vitamin B6 deficiency was significantly 
associated with all somatic symptoms (Table 14), and some non-somatic symptoms (Table 
15). In the fully adjusted models, those with vitamin B6 deficiency had much higher odds of 
experiencing suicidal thoughts (OR: 7.33, 95% CI 1.59-33.9), and those with vitamin B6 
insufficiency had three times the odds of experiencing depressed mood (OR: 3.12, 95% CI 
1.49-6.52) after adjustments. 
High depression score was only associated with vitamin B6 deficiency in unadjusted 
analyses (data not shown). There were no significant interactions between any variables 
and vitamin B6. When stratified by CRP level, vitamin B6 deficiency was only crudely 
associated with higher odds of high depression score among those with CRP levels between 
1-10 mg/L (data not shown).  
8.5 Discussion 
 
In this large representative sample of reproductive age women, we found that 
suboptimal vitamin B6 levels were associated with several dimensions of non-somatic 
depression, including depressed mood and suicidal ideation. When considering 
inflammation, the association of vitamin B6 deficiency with a higher score for the somatic 
symptom of psychomotor agitation was observed among women with moderate 
inflammation.  Although previous studies have reported an association between lower 
vitamin B6 status and increased depressive symptoms,6–8,15 our study is the first to examine 
how inflammation may influence the association between vitamin B6 status and various 
dimensions of depression among women of reproductive age. 
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A role for suboptimal vitamin B6 levels in depression is supported by three previous 
studies. The first, conducted in an elderly Danish population, found that plasma PLP 
concentration was inversely associated with depression score after adjusting for age and 
gender.6  A second study examined the association between plasma PLP in an elderly 
population from the Boston Puerto Rican Study. They found that plasma PLP was inversely 
associated with depression scores (β: -0.12, p<0.05), with vitamin B6 deficiency (PLP< 20 
nmol/L) associated with an almost doubling of the odds of depression in multivariable 
models (OR: 1.74, 95% CI 1.02, 2.89).7 In the most recent study, higher plasma PLP was 
significantly associated with a decreased prevalence of depression (p-trend: 0.03) among 
422 adults ages 21-67 years old in Japan.8  In cross-sectional analyses, they found that the 
odds of depression were 46% lower among those in tertiles two and three (PLP >25.5 
nmol/L; OR: 0.54, 95% CI 0.31-0.94 and OR: 0.54, 95% CI 0.30-0.96, respectively) 
compared to those in the lowest tertile of PLP (range: 8.1 to 25.5 nmol/L), after adjusting 
for numerous covariates (age, gender, office, smoking, alcohol intake, physical activity, job 
position, marital status, history of cancer, cardiovascular disease, or mental disease, dietary 
vitamin B12 intake, serum folate and homocysteine concentration, and depression score at 
baseline). However, the association between PLP and depression was no longer significant 
in longitudinal analyses. 8  
Our results for total depression scores and high depression were only significant prior 
to adjustments for sociodemographic, behavioral, and lifestyle factors, suggesting that 
these covariates play a role in the relationship between vitamin B6 and depression. Because 
of the cross-sectional design of NHANES, we cannot determine whether higher PLP levels 
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are protective against depression or whether depression somehow leads to lower vitamin 
B6 levels. 
When investigating the association between PLP and different subtypes of depression, 
we found that vitamin B6 deficiency (PLP <20 nmol/L), but not B6 insufficiency (20 <PLP 
<30 nmol/L), was significantly associated with both higher somatic and non-somatic 
depression scores in unadjusted analysis. This grouping of depression symptoms into 
subtypes, although shown to be a better fit for data in factor analysis than the total sum 
score of depression symptoms,28 may still be masking the association between vitamin B6 
deficiency and specific symptoms of depression. Previously, vitamin B6 was associated with 
depression among a Japanese population, but the association only reached statistical 
significance when using a higher depression cut-off point of 19 instead of the usual cut-off 
point of 16 in the Center for Epidemiological Studies Depression screener (CES-D).8  It is 
possible that low vitamin B6 levels are only associated with more severe cases of 
depression. In our analysis using dichotomized symptoms of depression, vitamin B6 
deficiency was associated with higher odds of experiencing suicidal thoughts, a symptom 
typically experienced by those with severe cases of depression (with PHQ-9 score of 15 or 
higher).46  Furthermore, compared to women without suicidal thoughts, those experiencing 
suicidal ideation also had the lowest mean serum PLP level of all the groups (21 vs 46.3 
nmol/L, p<0.001). However, given the wide confidence intervals in regression analyses, 
these results should be interpreted with caution, and a larger study with more cases of 
depression may be necessary to get a more precise estimate of effect of vitamin B6 
deficiency on symptoms of severe depression. 
 133 
 
Although the pathway linking vitamin B6 to depression is not entirely understood, a role 
of vitamin B6 in tryptophan metabolism has been suggested. Vitamin B6, as PLP, serves as a 
coenzyme in the tryptophan-serotonin pathway, and some suggest that a lack of vitamin B6 
may cause depression by reducing serotonin levels.13  In addition, vitamin B6 also serves as 
a key player in the kynurenine pathway, which is thought to play an important role in the 
pathogenesis of inflammation-dependent depression.20  The shift in PLP metabolism to the 
kynurenine pathway from its role in tryptophan-to-serotonin would result in lowered 
serotonin levels, but the second pathway would also coincide with heightened circulating 
inflammatory biomarkers. After stratifying by different levels of CRP, in unadjusted models, 
vitamin B6 deficiency was associated with most dimensions of depression among those 
with some degree of inflammation (denoted by CRP >1 mg/L), but not among those with no 
inflammation (CRP <1mg/L).  However, after adjustment for demographic, behavioral and 
lifestyle factors, most of these associations were attenuated and no longer significant, 
except for psychomotor retardation/agitation. Vitamin B6 deficiency was associated with a 
higher score for psychomotor abnormalities (β: 0.14, p=0.02) among those with elevated 
CRP (3-10mg/L) compared to those with normal PLP levels. Some evidence indicates that 
inflammation may be related more to somatic symptoms of depression,47 which are more 
pronounced in women than in men, rather than to non-somatic (affective) symptoms.48  
These findings suggest that PLP may play a role in the activation of muscle synergy, which 
is presumed to be modulated by neural command signals.49  Pyridoxine is a cofactor in the 
metabolism and production of many neurotransmitters involved in regulation of mobility, 
including serotonin, dopamine, and gamma-aminobutyric acid (GABA).50   Vitamin B6 
deficiency may contribute to impaired motor performance given PLP’s indirect role in 
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neural control of movement.  It is possible that this motor impairment may be heightened 
in the context of very low PLP levels and an additional trigger, such as the presence of 
inflammation, but no studies to date have examined this possibility. Studies are needed to 
investigate the kinetics and regulation of vitamin B6 vitamers and enzymes in different 
compartments in the presence of inflammation.51 
Our results suggest that CRP may act as an effect modifier in the association 
between vitamin B6 status and depression. This conclusion is supported by our finding that 
the crude association between vitamin B6 deficiency and depression was only evident 
among those who have CRP levels above 1 mg/L, and it was more pronounced among those 
with CRP levels above 3 mg/L. The question remains as to whether inflammation leads to 
low PLP levels or whether low PLP levels enhance inflammation, but both scenarios would 
probably be associated with higher depression scores.  
There is evidence supporting an inflammation-to-vitamin B6 deficiency pathway, 
since induced vitamin B6 deficiency did not lead to subsequent inflammation among a 
group of healthy adults who underwent a 28-day vitamin B6 restriction study.52  Although 
we cannot determine directionality of depression with either vitamin B6 or inflammation in 
this cross-sectional study, we found the prevalence of depression (PHQ-9 score of 10 or 
higher) did not vary significantly based on CRP levels (p=0.15). However, the prevalence of 
depression did vary by vitamin B6 status, with a higher prevalence among those with lower 
B6 levels (15.4% among those with B6 deficiency, 8.8% for B6 insufficiency and 5.9% among 
those with normal B6 status, respectively, p=0.004). Although events of depression did not 
vary significantly by CRP in this population, when stratified by CRP, the prevalence of 
depression was mostly evident among those with higher levels of CRP and suboptimal B6 
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status. If inflammation depletes circulating PLP levels due to increased demand for B6 for 
the kynurenine pathway, then inflammation-reducing treatments may result in improved 
vitamin B6 levels, and consequently, improved serotonin levels, which would theoretically 
translate to lowered rates of depression. Many selective serotonin reuptake inhibitors 
(SSRI) possess anti-inflammatory properties, and this is thought to be one of the 
mechanisms by which SSRIs alleviate depression symptoms.53  
We limited our study to biomarkers of vitamin B6 because studies examining dietary 
vitamin B6 have yielded controversial findings on the association between vitamin B6 and 
depression.14,15,54  However, those assessing circulating PLP concentrations and depression 
have consistently shown an inverse association between plasma PLP and depression 
scores. A possible reason for these inconsistencies may be the low correlation between 
dietary vitamin B6 intake and plasma PLP that has been consistently observed in various 
studies.7,8,55–58  Several non-dietary factors can affect circulating PLP concentration, 
including body mass index, inflammation, smoking, and oral contraceptive use.9,56,59,60  In 
our study, we controlled for all of these variables. Vitamin B6 supplements, on the other 
hand, are positively correlated with circulating PLP levels,9,56,58 confirming that suboptimal 
vitamin B6 status can be corrected via supplementation, but the amount of vitamin B6 
intake needed to protect against vitamin B6 inadequacy may be elevated in the presence of 
inflammation.17  Vitamin B6 supplementation with 50 mg/day of pyridoxine for 30 days 
may correct vitamin B6 deficiency,61 but higher levels (100 mg/day) may be needed to 
resolve inflammation among individuals with high inflammation levels, such as rheumatoid 
arthritis patients.62  Longitudinal studies are needed to determine whether vitamin B6 
supplementation alters inflammation and affects depression symptomatology or severity. 
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Understanding these relationships will help to determine to what degree vitamin B6 
supplementation could protect against inflammation-associated depression.  
Almost a fifth of our sample reported current OC use, and contrary to previous 
studies,9,63 oral contraceptive use was not related to a higher prevalence of vitamin B6 
deficiency or depression in our sample. Current OC users had a slightly lower mean 
depression score and lower prevalence of depression, which is also contrary to recent 
findings from a large population-based study in the Netherlands, where OC use was 
associated with increased risk of depression.63 Our findings are in agreement with a recent 
randomized controlled trial that found OCs were associated with improvements in 
depression among young women in the premenstrual phase.64 The prevalence of vitamin 
B6 deficiency was 8.3% among OC users, compared to 11% among non-users (p=0.53), and 
this is much lower than the calculations from Morris et al (2008) from NHANES 2003-2004 
where up to 78% of current OC users had vitamin B6 deficiency.9  This could be due to more 
routine vitamin B6 supplementation in OC users or analytical changes in PLP assessment 
between the NHANES 2003-2004 and more recent cycles, where the previously used 
enzymatic assay was changed to an HPLC method, which has a higher sensitivity.21  Two 
more recent studies also failed to observe higher rates of vitamin B6 deficiency among OC 
users.58,65 
Our study has important strengths, including a large, diverse sample of women 
representative of the US population, the use of a validated, multidimensional depressive 
symptom measure, and the testing of multiple candidate mediators/confounders. We also 
adjusted for sleep duration to avoid potential confounding by conditions such as sleep 
apnea or insomnia. Furthermore, we excluded those who were currently taking 
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antidepressants to prevent nondifferential misclassification of outcome, given that some of 
the common side effects of antidepressants reported by patients are the very symptoms 
that are used to measure depression, such as insomnia, hypersomnia, agitation, 
restlessness, fatigue, somnolence, weight gain or weight loss, and decreased or decreased 
appetite.66  This overlap of antidepressant side effects and depression symptoms provides 
a compelling reason for analyzing symptoms separately from total depression scores.33  
Our study also has important limitations. First, due to the cross-sectional nature of 
the NHANES study design, we were unable to determine the directionality of the 
association between PLP and depression symptoms. Both directions are plausible. Of the 
three previous studies on PLP and depression, no significant prospective associations were 
found between PLP and depression. One study,8 however, observed lower depression 
scores after three years among those with better baseline vitamin B6 status (both PLP and 
dietary), suggesting that vitamin B6 may decrease the risk of depression, rather than low 
vitamin B6 level is the result of depression.  Additionally, vitamin B6 can also act as an 
antioxidant,67 so it is possible that adequate nutritional status and optimal vitamin B6 levels 
could be protective against depression by reducing oxidative stress that may be associated 
with inflammation-associated depression. And finally, this survey from a non-
institutionalized population may only capture those with less severe depression, because 
those with severe depression may either be institutionalized or disproportionately unlikely 
to participate in the survey. Therefore, our results might not be generalizable to women 
with severe depression or major depressive disorder. 
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8.6 Conclusion 
In summary, vitamin B6 deficiency may be associated with symptoms experienced 
among those with more severe cases of depression in this population, such as suicidal 
ideation. When stratified by inflammation, we observed a pattern of increasing effect size 
for vitamin B6 deficiency on individual somatic symptom scores with increasing CRP levels, 
which was not evident for non-somatic symptoms. Although these patterns were only 
observed in crude analyses, it remains possible nonetheless that inflammation may affect 
vitamin B6 levels via the shift in PLP from the tryptophan-serotonin pathway to the 
kynurenine pathway, and these two coexisting conditions may be contributing to somatic 
symptoms rather than cognitive/affective symptoms of depression. Inflammation and 
compromised vitamin B6 status may play important roles in the manifestation of 
depression, but longitudinal studies are needed to better understand how vitamin B6 or 
inflammation may affect the development or severity of depression symptoms. The 
heterogeneity of depression also warrants further research based on symptoms in order to 
identify potential treatments that may focus on vitamin B6 status for patients with different 
dimensions of depression.   
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Table 11: Distribution of covariates by depression in women of reproductive age from NHANES 2005-2008 (N=1,489) 
    Total              
Population 
Total PHQ-9 Score                  
(range 0-27) 
Somatic                           
Depression Score 
(range 0-12) 
Non-Somatic 
Depression Score 
(range 0-15) 
High Depression Score                                      
   (PHQ-9 score ≥10) 
    No Yes   
    N % Mean SE 
p-
value Mean SE 
p-
value Mean SE p-value N  % N % p-value 
Total population sample 1489   2.9 0.1 -- 1.8 0.1 -- 1.1 0.1 -- 1357 92.5 132 7.5 -- 
Serum PLP (nmol/L)** 46.3 
43.2, 
49.6 -- -- -- 47.1 
44.0, 
50.5 34.4 
27.8, 
42.5 0.004 
Age, years (mean, SE) 31.7 0.3 -- -- -- 31.7 0.3 32.3 0.8 0.48 
Sleep per night, hrs (mean, 
SE) 6.9 0.1 -- -- -- 7.0 0.1 6.1 0.2 <0.001 
Body Mass Index (kg/m2)         0.06     0.13     0.08         0.43 
  less than 18.5 49 3.5 2.5 0.5   1.6 0.3   0.9 0.2   47 97.1 2 2.9   
  18.5 to 24.9 593 44.4 2.6 0.1   1.7 0.1   1.0 0.1   543 93.3 50 6.7   
  25-29.9 423 26.3 3.0 0.3   1.9 0.2   1.1 0.1   385 91.5 38 8.5   
  30 or greater 422 25.9 3.4 0.3   2.1 0.1   1.4 0.1   380 91.4 42 8.6   
  p-trend         0.005 0.02 0.009           
Inflammation Categories         0.05     0.08     0.05         0.15 
  hs-CRP <1 mg/L 553 38.7 2.6 0.2   1.7 0.1   1.0 0.1   509 94.2 44 5.8   
  hs-CRP 1-2.99 mg/L 492 33.6 2.9 0.2   1.8 0.1   1.1 0.1   446 91.6 46 8.5   
  hs-CRP 3-10 mg/L 444 27.8 3.4 0.3   2.1 0.1   1.4 0.1   402 91.3 42 8.7   
  p-trend         0.001 0.02 0.01           
Marital Status         0.12     0.15     0.08         <0.001 
  Single/Never Married 553 29.2 3.0 0.2   1.9 0.1   1.0 0.1   508 93.6 45 6.4   
  Married/with partner 783 60.4 2.7 0.1   1.7 0.1   1.0 0.1   718 93.5 65 6.5   
  Divorced/Separated/Widowed 153 10.2 4.0 0.5   2.4 0.3   1.7 0.3   131 83.5 22 16.5   
Education         <0.001     <0.001     <0.001         <0.001 
  Less than High school 369 15.6 4.1 0.3   2.4 0.2   1.7 0.1   317 86.0 51 14.0   
  High school or GED 354 20.6 3.5 0.3   2.1 0.2   1.4 0.2   317 89.1 37 10.9   
  Some college 482 36.0 2.9 0.2   1.8 0.1   1.1 0.1   446 93.0 36 7.0   
  College graduate 284 27.8 2.0 0.2   1.4 0.1   0.6 0.1   276 97.9 8 2.1   
  p-trend         <0.001 <0.001 <0.001           
Race/Ethnicity         0.27     0.37     0.27         0.26 
  Non-Hispanic White 557 63.5 2.8 0.2   1.8 0.1   1 0.1   508 92.9 49 7.1   
  Mexican Hispanic 364 10.2 3.2 0.2   1.9 0.1   1.3 0.1   336 92.5 28 7.5   
  Other Hispanic 141 6.6 3.6 0.4   2.1 0.2   1.5 0.2   122 89.4 19 10.6   
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  Non-Hispanic Black 348 12.6 3.4 0.3   2.1 0.1   1.3 0.1   315 89.7 33 10.3   
  Other Race 79 7.2 2.9 0.3   1.7 0.2   1.2 0.1   76 96.2 3 3.8   
Smoke         <0.001     <0.001     <0.001         <0.001 
  Not current smokers 1126 76.3 2.5 0.1   1.6 0.1   0.9 0.1   1057 95.3 69 4.7   
  Current smokers 324 23.7 4.4 0.4   2.7 0.2   1.8 0.2   263 83.4 61 16.6   
Leisure Time Physical 
Activity         <0.001     <0.001     <0.001         <0.001 
  Q1 (0-64 MET min/week) 386 25.1 4.2 0.3   2.5 0.2   1.7 0.2   321 84.5 65 15.5   
  Q2 (65-594 MET min/wk) 302 24.8 2.5 0.2   1.6 0.1   0.9 0.1   283 95.2 19 4.9   
  Q3 (595-1560 MET min/wk) 270 23.9 2.3 0.2   1.6 0.1   0.8 0.1   258 96.3 12 3.7   
  Q4 (>1560 MET min/wk) 321 26.3 2.2 0.3   1.4 0.2   0.8 0.1   306 95.9 15 4.1   
  p-trend         <0.001 <0.001 <0.001           
Oral Contraceptive use         0.01     0.05     0.01         0.09 
  Not currently using 1231 80.8 3.0 0.1   1.9 0.1   1.2 0.1   1118 92.0 113 8.0   
  Currently using  213 19.2 2.3 0.3   1.5 0.2   0.8 0.2   201 95.5 12 4.5   
Weighted regression and  t-tests for continuous depression scores and design-based Pearson chi square for categorical depression variables 
* ln-transformed PLP, presenting geometric means and 
95% CI.                           
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Table 12:Distribution of covariates by vitamin B6 (Pyridoxal 5'-Phosphate) variables in women of 
reproductive age from NHANES 2005-2008 (N=1,489) 
    
Serum PLP* 
Serum PLP Category 
    
Deficiency                 
(PLP<20 
nmol/L) 
Insufficiency      
(PLP 20-
29.9) 
Sufficiency                
(PLP≥30 
nmol/L)   
    Mean 95% CI p-value N  % N % N % p-value 
Total population 46.0 42.9, 49.4 -- 183 10.7 327 21.3 972 68.0 --- 
Depression Score (PHQ-9) -- 4.4 0.4 3.2 0.3 2.6 0.2 0.003 
Sleep duration(hr), mean(SE) -- 6.6 0.1 6.8 0.1 7.0 0.1 0.003 
Body Mass Index (kg/m2)     <0.001             0.003 
  less than 18.5 44.9 33.5, 60.1   6 11.5 11 26.9 32 61.6   
  18.5 -24.9 53.4 48.1, 59.3   58 8.8 110 17.7 421 73.5   
  25-29.9 44.8 40.7, 49.3   53 11.1 84 17.7 285 71.2   
  30 or greater 36.8 33.7, 40.3   66 13.6 121 30.3 233 56.1   
  p-trend     <0.001               
Inflammation Categories     <0.001             0.0001 
  hs-CRP <1 mg/L 54.6 50.0, 59.6   40 6.3 94 16.5 415 77.2   
  hs-CRP 1-3 mg/L 42.7 30.0, 47.9   69 12.1 114 23.4 307 64.5   
  hs-CRP 3-10 mg/L 39.8 35.3, 44.8   74 15.1 119 25.5 250 59.4   
  p-trend     <0.001               
Education     <0.001             0.0007 
  Less than Highschool 36.5 32.7, 40.8   57 16.9 82 23.0 229 60.2   
  Highschool or GED 42.1 38.7, 45.8   49 13.6 87 24.8 214 61.7   
  Some college 46.0 42.8, 49.4   52 9.3 108 21.9 320 68.9   
  College graduate 56.3 42.8, 49.4   24 6.8 50 17.1 209 76.2   
  p-trend     <0.001               
Race/Ethnicity     0.008             0.07 
  Non-Hispanic White 48.1 43.0, 53.9   75 10.7 118 21.0 361 68.3   
  Mexican Hispanic 41.3 38.7, 44.0   34 9.5 79 23.1 251 67.4   
  Other Hispanic 47.6 42.9, 52.8   11 5.3 30 23.4 98 71.3   
  Non-Hispanic Black 38.3 35.0, 42.0   55 16.1 88 24.6 204 59.4   
  Other Race 48.8 41.7, 57.2   8 8.1 12 13.6 58 78.3   
Smoke     <0.001             <0.001 
  Not a current smoker 50.4 46.7, 54.4   107 7.7 238 19.8 775 72.5   
  Yes 34.6 30.6, 39.1   75 20.6 78 26.0 170 53.4   
Leisure Time Physical 
Activity     <0.001             0.0003 
  Q1 (0-64 MET minutes/week) 39.5 35.4, 43.9   59 13.9 92 24.6 231 61.5   
  Q2 (65-594 MET minutes/week) 45.1 41.0, 49.5   37 12.0 54 6.5 211 71.5   
  Q3 (595-1560 MET minutes/wk) 48.8 42.8, 55.6   27 7.4 58 22.1 184 70.5   
  Q4 (>1560 MET minutes/week) 60.3 52.9, 68.7   20 3.9 68 19.1 231 77.1   
  p-trend     <0.001               
Oral Contraceptive use     0.10             0.53 
  not a current user 45.6 42.6, 48.8   152 11.0 266 21.3 807 67.8   
  current user 52.9 44.4, 62.9   23 8.3 48 20.2 141 71.5   
*natural log transformed serum PLP and 95% Confidence Intervals. Weighted ANOVA and linear regression 
for p-trend for continuous serum PLP; Weighted Pearson chi-square for categorical PLP. 
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Figure 4: Higher depression scores are evident among those with vitamin B6 deficiency, 
and an increasing trend is statistically significant as CRP levels increase. P-trend is 
significant for increasing depression score as CRP increases only among those with vitamin 
B6 deficiency (p-trend=0.04) 
 
 
 
Figure 5: Prevalence of depression is highest among those with higher CRP levels, and 
decreases with improving vitamin B6 status. Chi square results are only significantly 
different for higher prevalence of depression with decreasing vitamin B6 concentrations 
among women with elevated CRP (p=0.02), but not among women with CRP 1-3mg/L 
(p=0.07) or CRP <1mg/L (p=0.92) 
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Figure 6: Linear regression analysis assessing mediators/confounders of the relationship between PLP and (a) total depression 
score, (b) somatic depression score and (c) non-somatic depression score among women of reproductive age from NHANES 
2005-2008 
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Table 13:Distribution of serum pyridoxal 5'-phosphate and vitamin B6 categories by individual depression symptoms 
among women of reproductive age from NHANES 2005-2008 (N=1,489) 
  
Serum PLP* 
Serum PLP Category 
Deficiency 
(PLP<20 
nmol/L) 
Insufficiency      
(PLP 20-29.9) 
Sufficiency 
(PLP≥30 
nmol/L)   
Mean 95% CI p-value N  % N % N % p-value 
  Trouble sleeping**     <0.001             0.0005 
    No 47.9 44.5, 51.5 148 77.3 280 86.2 860 90.6 
    Yes 34.2 28.9, 40.3 35 22.7 47 13.2 112 9.5 
  Fatigue**     0.03             0.04 
    No 47.3 43.9, 51.1 140 76.1 271 83.5 826 86.2 
    Yes 39.6 34.1, 46.0 43 23.9 56 16.5 146 13.8 
  Abnormal appetite**     0.003             0.002 
    No 47.2 44.2, 50.4 156 82.2 297 89.9 891 93.1 
    Yes 35.6 29.2, 43.4 27 17.8 30 10.1 81 6.9 
  Moving or speaking too slow or too fast     0.13             0.03 
    No 46.4 43.2, 49.8 171 93.9 319 98.3 945 97.6 
    Yes 36.1 26.3, 49.6 12 6.1 8 1.7 27 2.4 
  Anhedonia     0.04             0.02 
    No 46.6 43.4, 50.0 166 90.1 309 95.7 922 96.1 
    Yes 36.4 28.7, 46.2 17 9.9 18 4.3 50 3.9 
  Depressed mood**     <0.001             0.0001 
    No 47.2 43.9, 50.7 161 88.2 297 90.4 922 96.3 
    Yes 30.7 27.1, 34.8 22 11.8 30 9.6 50 3.7 
  Low self-esteem     0.006             0.25 
    No 46.6 43.6, 49.8 169 92.7 308 94.2 925 95.7 
    Yes 36.1 29.4, 44.3 14 7.3 19 5.8 47 4.3 
  Trouble concentrating     0.04             0.17 
    No 46.6 43.3, 50.1 172 92.1 310 96.1 932 96.3 
    Yes 35.8 28.6, 44.8 11 7.9 17 3.9 40 3.7 
  Suicidal ideation     <0.001             0.002 
    No 46.3 43.3, 49.5 178 97.4 321 99.0 963 99.7 
    Yes 21.0 14.8, 29.8 5 2.6 6 1.0 9 0.3 
Weighted t-tests and design-based Pearson chi square for categories of plasma PLP. *ln-transformed PLP. **Significant trend test for weighted proportions. 
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Table 14: Logistic regression analysis of the association of individual somatic depressive symptoms 
(dichotomous) with serum pyridoxal 5'-phosphate in women (n=1,489)  
  
Somatic Depression Symptoms 
Sleeping problems Fatigue Abnormal appetite 
Psychomotor 
abnormalities 
OR                                
(95% CI) 
p-value 
OR                                
(95% CI) 
p-
value 
OR                                
(95% CI) 
p-
value 
OR                                
(95% CI) 
p-
value 
Unadjusted Model 
                
  PLP <20nmol/L 2.82 <0.001 1.96 0.001 2.94 <0.001 2.63 0.04 
    (1.68, 4.72)   (1.33, 2.90)   (1.68, 5.13)   (1.04, 6.65)   
  PLP 20-29.9 1.45 0.13 1.24 0.42 1.53 0.14 0.71 0.46 
    (0.89, 2.37)   (0.73, 2.11)   (0.86, 2.72)   (0.27, 1.83)   
  PLP ≥30 nmol/L ref   ref   ref   ref   
Adjusted Model                  
  PLP <20nmol/L 1.60 0.40 0.96 0.85 0.79 0.69 2.02 0.35 
    (0.52, 4.90)   (0.58, 1.58)   (0.25, 2.57)   (0.45, 9.09)   
  PLP 20-29.9 1.10 0.73 0.68 0.32 1.11 0.73 0.21 0.10 
    (0.63, 1.94)   (0.31, 1.48)   (0.60, 2.07)   (0.03, 1.34)   
  PLP ≥30 nmol/L ref   ref   ref   ref   
Adjusted model includes age, ethnicity, smoking, oral contraceptive use, sleep duration, physical activity, body mass 
index, CRP and mutually adjusted for the sum of the remaining depression items.  
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Table 15: Logistic regression analysis of the association of individual non-somatic depressive symptoms (dichotomous) with 
serum pyridoxal 5'-phosphate in women (n=1,489)  
  Non-somatic Depression Symptoms 
Anhedonia Depressed mood Low self-esteem 
Trouble 
concentrating 
Suicidal ideation* 
OR                               
(95% CI) 
p-
value 
OR                               
(95% CI) 
p-
value 
OR                               
(95% CI) 
p-
value 
OR                               
(95% CI) 
p-
value 
OR                               
(95% CI) 
p-
value 
Unadjusted Model                     
  PLP <20nmol/L 2.71 0.009 3.46 0.001 1.74 0.08 2.21 0.07 8.46 0.006 
    (1.31, 5.61)   (1.78, 6.73)   (0.93, 3.25)   (0.92, 5.29)   (1.94, 36.86)   
  PLP 20-29.9 1.12 0.79 2.76 <0.001 1.36 0.38 1.05 0.91 3.32 0.08 
    (0.49, 2.57)   (1.70, 4.48)   (0.67, 2.75)   (0.45, 2.45)   (0.85, 12.92)   
  PLP ≥30 nmol/L ref   ref   ref   ref   ref   
Adjusted Model                      
  PLP <20nmol/L 0.29 0.08 1.22 0.76 0.49 0.34 0.68 0.56 7.33 0.01 
    (0.07, 1.18)   (0.33, 4.52)   (0.11, 2.19)   (0.18, 2.60)   (1.59, 33.9)   
  PLP 20-29.9 0.53 0.17 3.12 0.004 1.05 0.92 0.76 0.62 3.50 0.06 
    (0.21, 1.32)   (1.49, 6.52)   (0.39, 2.83)   (0.24, 2.37)   (0.93, 13.1)   
  PLP ≥30 nmol/L ref   ref   ref   ref   ref   
Adjusted model includes age, ethnicity, smoking, oral contraceptive use, sleep duration, physical activity, body mass index, CRP and 
mutually adjusted for the sum of the remaining depression items. *Suicidal ideation not adjusted for education due to collinearity. 
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CHAPTER 9 
“VITAMIN D, DEPRESSION, AND INFLAMMATION AMONG WOMEN OF 
REPRODUCTIVE AGE FROM NHANES 2005-2008” 
 
9.1 Abstract 
Depression is the leading cause of disability world-wide, and women in their 
childbearing years make up the largest group of Americans with depression. Recent 
evidence indicates that vitamin D deficiency, which is more prevalent among 
women, may be associated with mood and depression, but much remains unknown 
concerning how inflammation, lifestyle and behavioral factors may influence this 
association. We conducted a secondary data analysis to evaluate the effects of 
inflammation, sleep, oral contraceptive use and body mass index on the association 
between serum vitamin D [as 25(OH) vitamin D] with depression in non-pregnant 
women ages 18-44 from the cross-sectional National Health and Nutrition 
Examination Survey (NHANES) 2005-2008. Depression scores were calculated 
based on the Patient Health Questionnaire-9 (PHQ-9) and categorized into total 
depression, somatic and non-somatic depression. High depression score (PHQ-9 ≥ 
10) use was also used as an outcome, as well as individual symptoms of depression. 
Serum 25(OH) vitamin D was categorized into deficiency (<50 nmol/L), 
insufficiency (50-75 nmol/L) and sufficiency (>75 nmol/L). To account for NHANES’ 
complex survey design sample, we incorporated the sampling weights in the 
analysis of 1,397 observations. Mean 25(OH) vitamin D did not differ by depression 
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(56.7 vs 60 nmol/L, p=0.27), but suboptimal vitamin D levels were significantly 
associated with higher odds for depression among women who had elevated CRP 
(ORdeficiency: 6.55, p=0.02 and ORinsufficiency: 9.54, p=0.001).  We observed a significant 
trend for decreasing depression score with increasing vitamin D level for total 
depression (p-trend:0.02) and somatic depression (p-trend: 0.006). When stratified 
by BMI, vitamin D was positively associated with depression scores (p=0.01) among 
underweight women. Among women who reported sleeping 7 or more hours per 
night, vitamin D was inversely associated with depression, whereas the opposite 
was true among women who slept less than 7 hours/night (p-interaction=0.01). 
Sleep appeared to significantly modify the association between vitamin D and 
depression among women. Further research is needed to determine how changes in 
inflammation or sleep may contribute to vitamin D deficiency, and how altogether, 
these lifestyle and behavioral factors may be used to prevent or treat depression 
among women. 
9.2 Introduction 
Depression is common in the United States, with approximately 16% of 
adults experiencing clinical depression at some point in their lives.1   Numerous 
biological, psychological, and environmental risk factors for depression have been 
proposed,2  among them vitamin D deficiency.3   Although vitamin D is mainly known 
for its role in maintaining calcium homeostasis and bone health,4  brain 
development and function also depend on vitamin D; 5–8   vitamin D receptors found 
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in several regions of the brain may play a role in serotonin synthesis9   and have 
been linked to mood regulation and affective disorders.10–12    
Women are two- to three-times more likely than men to experience 
depression, and among women, it is the leading source of disease burden.13–15  
Recent national estimates indicate that suboptimal vitamin D status is common in 
women, affecting up to 78% of U.S. women of childbearing age, although the 
prevalence  is even higher among non-Hispanic Black and Hispanic women.16   
Suboptimal maternal vitamin D status poses multiple health risks for both women 
and their offspring. Vitamin D deficiency during pregnancy or in the postpartum 
period has been associated with increased risk of rickets, type 1 diabetes, allergies, 
asthma, and schizophrenia in the offspring17  and with preeclampsia, gestational 
diabetes, bacterial vaginosis and perinatal depression in the mother.18–22   Better 
understanding of the role of vitamin D in depression among reproductive age 
women could lead to additional treatment options.  
Most studies investigating vitamin D and depression have produced 
inconsistent results.23  In part, this may have been due to differences in populations, 
heterogeneity of depression assessment, or the lack of inclusion of several lifestyle 
and behavioral factors that may affect the association between vitamin D and 
depression, such as inflammation, sleep, body mass index, and oral contraceptive 
(OC) use. Inflammation has been linked to vitamin D deficiency in numerous in vitro 
and in vivo studies24   since vitamin D receptors were discovered in cells of the 
immune system. In humans, vitamin D supplementation decreases circulating C-
reactive protein (CRP), a pro-inflammatory marker.25  Inflammation has also been 
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implicated as a potential risk factor for depression,26–28  and given vitamin D’s 
immunomodulatory potential, the association between vitamin D and depression 
may be affected by the presence of inflammation. To date, two studies have 
examined whether  the association between vitamin D and depression is partially 
affected by CRP levels.29,30  Although both studies found an inverse association 
between circulating vitamin D levels and depression, they did not find a significant 
difference in risk of depression among subjects with low vitamin D and elevated 
CRP,29  nor did they find CRP to mediate the association between vitamin D and 
depression.30  However, these studies did not assess whether the association 
between vitamin D and depression was symptom-specific, nor did they stratify by 
gender, although vitamin D deficiency and depression both affect women 
disproportionately.  
Several lifestyle factors have been previously associated with inflammation, 
vitamin D, and depression separately. Sleep duration has also been associated with 
both vitamin D deficiency31,32  and depression;75 yet, to date, no studies have 
assessed how sleep may affect the association between vitamin D and depression.  
OC use is related to increased vitamin D levels,33  yet OC use  has been found to both 
increase34  or decrease35  risk of depression in different studies. And finally, BMI, a 
proxy for adiposity, is linked to lower vitamin D levels36  and higher depression 
score37,38  in several studies, but to date, its effect on the association between 
vitamin D and depression has not been examined thoroughly. Therefore, 
investigating the association between vitamin D, various lifestyle and behavioral 
factors that may be more common among women, and individual symptoms of 
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depression in addition to total depression scores offers an opportunity to explore 
potential biological factors related to the etiology of depression that may not be 
evident among mixed populations or when aggregate scoring is used. 
The purpose of this study was to explore the relationship between vitamin D 
status and depression among U.S. reproductive-age women and to determine 
whether inflammation and other lifestyle factors modify the association between 
circulating serum vitamin D levels and depression subtypes or individual symptoms 
of depression among 1,397 women, aged 18-44 years, from the National Health and 
Nutrition Examination Survey (NHANES) 2005-2008. 
9.3 Methods 
9.3.1 Study Design and Study Population 
 
We analyzed cross-sectional data from the 2005-2008 National Health and 
Nutrition Examination Survey (NHANES), which is national survey from the 
National Center for Health Statistics of the Centers for Disease Control and 
Prevention (CDC), designed to assess the health and nutritional status of the U.S. 
population. NHANES employs a complex, multistage, probability sampling design to 
select persons representative of the civilian, non-institutionalized US population, 
with oversampling of special sub-populations, such as racial and ethnic minorities. 
Detailed descriptions of the survey design and procedures are available at the study 
website.39   
Briefly, approximately 5,000 people are surveyed each year via in-person 
interviews and physical examinations. The interview, which is conducted in 
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participants’ homes, includes demographic, socioeconomic, dietary, and health-
related questions; the examination component is comprised of medical, dental, and 
physiological measurements, as well as laboratory tests, which take place in 
specially-designed and equipped mobile examination centers (MEC) that travel 
throughout the country. The National Center for Health Statistic’s Institutional 
Review Board has reviewed and approved the NHANES protocol. 
  Participants were eligible for our study if they were women of reproductive 
age (15-44 years old) who were not pregnant. From the initial sample of 2,609 
eligible women, we excluded those with missing data for either depression (n=506) 
or serum vitamin D (n=92). Depression data for individuals younger than 18 years 
was not publicly available; therefore, our age range was restricted to women ages 
18-44 years. We also excluded women with acute inflammation denoted by CRP 
levels above 10 mg/L (n=201),40  those who were taking anti-inflammatory 
medications including NSAIDs (n=70) or reported current antidepressant use 
(n=135). The remaining sample contained 1,397 observations. 
9.3.2 Assessment of Depression Status 
The Patient Health Questionnaire-9 (PHQ-9)41  was administered during the 
MEC interview and assessed depressive symptom severity over the past two weeks. 
Based on the diagnostic criteria for major depressive disorder in the Diagnostic and 
Statistical Manual Fourth Edition (DSM-IV), the PHQ-9 employs a 4-point scale 
(0=not at all, 1= several days, 2= more than half the days, 3= nearly every day) to 
determine the frequency with which respondents experienced the following nine 
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symptoms of major depressive disorder: anhedonia, depressed mood, sleep 
disturbance, fatigue, appetite changes, low self-esteem, concentration problems, 
psychomotor retardation/agitation, and suicidal ideation. Total depression scores 
range from 0 to 27, and scores of 10 or higher are classified as clinical depression.42  
The PHQ-9 has been shown to be a reliable and valid questionnaire as indicated by 
its high internal consistency and good sensitivity (88%) and specificity (88%) for 
identifying cases of major depressive disorder in community samples.43–45   
In addition to the total depression score, we calculated somatic and 
cognitive-affective depression subscale scores. The somatic depression subscale was 
calculated by adding the scores for frequency of the four somatic depression 
symptom from the PHQ-9 (sleep disturbance, fatigue, appetite changes, and 
psychomotor retardation/agitation) and the cognitive-affective subscale score was 
calculated adding the scores for the five non-somatic symptoms (anhedonia, 
depressed mood, low self-esteem, concentration problems and suicidal ideation).46  
While previous factor analyses supported a one-factor model with all nine items,47,48  
recent confirmatory factor analyses have found that subscales of depression 
dimensions may provide a better fit to the data.49,50   Some also  argue that given the 
biological heterogeneity of symptoms for depression, individual symptoms should 
be analyzed separately.51  Thus, we included a separate analysis for individual 
depressive symptoms, coded as continuous variables (scores ranging from 0-3) and 
as binary variables. To dichotomize the variable, those items with responses “more 
than half the days” and “nearly every day” indicated the presence of the 
symptom.52,53   
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9.3.3 Serum Vitamin D 
Fasting whole blood samples were collected during the medical examination. 
Venipuncture was performed using standard phlebotomy techniques by NHANES 
trained personnel. Serum specimens were processed, stored and shipped to the 
Division of Environmental Health Laboratory Sciences, National Center for 
Environmental Health, Centers for Disease Control and Prevention in Atlanta, 
Georgia. Further detailed instructions on specimen collection and processing can be 
found at NHANES website.39  Briefly, measurements of serum 25(OH) vitamin D, the 
biomarker of vitamin D status,  were performed with the DiaSorin RIA kit 
(Stillwater, MN) for NHANES 2001-2006, and with liquid chromatography-tandem 
mass spectrometry (LC-MS/MS) method for NHANES 2007-2008.54  In order to use 
vitamin D data from these two different methods, NHANES converted the vitamin D 
data from 2001-2006 assayed with the RIA method to equivalent 25(OH)D 
measurements from a standardized LC-MS/MS method using regression analysis. 
This adjustment was completed to allow researchers to use vitamin D data that are 
equivalent to 25(OH)D measurements assayed with LC-MS/MS method.54  Serum 
vitamin D was categorized into variables indicating vitamin D deficiency 
(<50nmol/L), insufficiency (50 to 75 nmol/L) and sufficiency ( >75 nmol/L) 
following previously used cut-offs for vitamin D status.4,55   Given that 25(OH) 
vitamin D was not normally distributed, it was converted to its natural logarithm to 
improve normality. 
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9.3.4 Covariates and Confounders 
We considered as possible covariates a selected set of demographic, lifestyle, 
and socioeconomic factors available through data collected during the demographic 
or household section of the NHANES questionnaire. The National Center for Health 
Statistics (NCHS) standard definitions for ethnicities were used, and ethnicities 
were categorized as non-Hispanic whites, non-Hispanic blacks, Mexican-Hispanics, 
other Hispanics, and other race. Educational attainment was measured as the 
highest completed grade of school regardless of age, and categorized into four 
levels: less than high school, high school equivalent, some college, and college 
graduate or above. The smoking assessment for respondents aged 18-19 years 
(MEC) was not identical to that for respondents aged 20+ years (household 
interview). For respondents aged 20+ years, we classified as current smokers those 
who reported smoking at least 100 cigarettes during their lifetime and reported that 
they now smoke cigarettes every day or some days. For respondents ages 18-19 
years, we classified as current smokers those who reported smoking 15 or more per 
day in the last 30 days. To create the alcohol groups, we used data obtained during 
the alcohol use interview at the MEC and calculated the drinks per day as suggested 
by Case and Stewart.56   Alcohol consumption, which was only available for 
participants of legal drinking age (21 and older), was categorized into abstainer, one 
or fewer drinks/day and more than one drink per day.  Leisure-time physical 
activity (LTPA) was assessed by asking participants about their involvement in 48 
specific recreation activities of moderate or vigorous intensity. Frequency was first 
multiplied by the duration in hours and divided by 4.3 to obtain hours of LTPA per 
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week. To calculate MET hrs/week, each activity was multiplied by its MET level per 
NHANES physical activity codes.57   Participants were then categorized into quartiles 
of physical activity.  
Body mass index (BMI), OC use, sleep, and C-reactive protein (CRP) have 
been associated with both vitamin D levels and depression, and were examined as 
potential confounders/mediators of the relationship between vitamin D and 
depression.  BMI (kg/m2) was computed from height and weight measurements and 
categorized into four standard categories: underweight (BMI<18.5 kg/m2), normal 
weight (18.5 ≤ BMI<25), overweight (25≤ BMI<30) and obese (BMI≥30 kg/m2). OC 
use was determined by self-report of current use, and women were categorized into 
either “current”, “past” or “never” users. Sleep duration was assessed by asking 
participants how many hours of sleep they usually get on a weekday/workday, and 
those who reported sleeping 12 or more hours were labeled as sleeping 12 
hours/night. High sensitivity c-reactive protein was quantified using latex-enhanced 
nephelometry using a Behring Nephelometer (Dade Behring Diagnostics Inc, 
Somerville, NJ) and was classified into three categories: no inflammation (CRP 
<1mg/L), low inflammation (CRP 1-3mg/L) and moderate inflammation (CRP 3-
10mg/L) following previously used guidelines.40  CRP was also transformed to its 
natural logarithm due to its skewed distribution. 
9.3.5 Data Analysis 
The complex survey design used for NHANES data collection was 
incorporated into all data analyses using the “svy” command with appropriate 
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weighting in Stata 12.0 (StataCorp LP, College Station, TX). Detailed information on 
the procedures for taking into account survey sampling weights have been 
described elsewhere.58   
Descriptive statistics were calculated for the overall sample using frequency 
distributions for categorical variables and means and standard errors for 
continuous variables. Because both serum 25(OH) D and hs-CRP were 
logarithmically transformed when analyzed as continuous variables, geometric 
means (antilogarithms of the transformed means) and their 95% confidence 
intervals are presented. Bivariate analyses were carried out for each covariate and 
ln-transformed vitamin D and vitamin D categories as well as for covariates and 
total depression, somatic/non-somatic depression and binary depression variables, 
using weighted ANOVAs, Chi square tests and 2-sample t-tests as appropriate. T-
tests and chi-square tests were completed to assess group differences in mean ln-
transformed serum 25(OH) D as a continuous variable and proportions of vitamin D 
categories by individual depressive symptom. In linear regression modeling of 
depression, all covariates that changed the estimated coefficient for the primary 
predictor of interest by more than 10% were retained in the multivariable model. In 
addition, known risk factors for depression, such as smoking, and education, were 
retained in the model as well as those that were associated with both the predictor 
and the outcome, such as LTPA and OC use. Model adequacy was assessed using 
goodness of fit tests.  
To examine whether vitamin D status was more strongly related to certain 
dimensions of depression, we conducted a series of linear regression analyses in 
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which total depression score, somatic depression score, non-somatic depression 
score and each individual depression symptom served as outcome variables. A 
similar series of logistic regression analyses was also completed for dichotomous 
individual depressive symptoms. For all the individual depression symptoms, we 
adjusted for the remaining depression symptom to account for any potential overlap 
between different symptoms and to reduce the probability of type I error. Logistic 
regression analyses were also carried out for depression PHQ-9 score of 10 or 
greater.  
C-reactive protein, OC use, sleep, and BMI were assessed as potential 
mediators or effect modifiers by running mediation tests, stratifying regression 
analyses, and by including interaction terms in the model estimates. To quantify the 
effects of these variables on any observed relationships between continuous vitamin 
D (ln-transformed) and depression, we carried out Sobel mediation tests and 
Preacher and Hayes bootstrap tests of indirect effects.59,60  All linear and logistic 
regression estimates were weighted using NHANES sample weights, which account 
for the complex survey design, survey nonresponse, and post-stratification. 
9.4 Results 
Description of Study Cohort. The characteristics of the 1,397 women in our 
final sample are shown in table 16. The mean age of women in our sample was 31.7 
years. The majority of women were white (63.5%), married or living with a partner 
(60.5%,), did not use OCs (77%), slept an average of seven hours per night, and 
were nonsmokers (75.9%). Almost eight percent (7.3%) of our sample population 
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reported moderate to severe depression symptoms, indicative of clinically 
significant depression denoted by a score of 10 or higher on the PHQ-9.  
 In bivariate analyses (Table 16), all three depression scores (total, somatic 
and non-somatic depression) were positively associated with BMI (p for trend <0.02 
for all three depression scores) and CRP (p for trend<0.03 for all three depression 
scores) and negatively associated with education (p for trend<0.001) and LTPA (p 
for trend<0.001). Mean total depression score was lower for women currently 
taking OCs compares to non-and past-OC users (p=0.01) and higher for smokers 
compared to non-smokers (p<0.001 for all three depression scores).  Women with 
high depression scores slept less (6.1 vs 7.0 hours/night, p<0.001) compared to 
those with low depression scores. The prevalence of depression was significantly 
higher among women who were separated or divorced compared to married or 
single women, among smokers compared to non-smokers, and among those who 
reported the lowest levels of LTPA compared to those who reported higher levels of 
LTPA.  
Approximately two thirds of women (67.8%) were vitamin-D insufficient or 
deficient (Table 17). These proportions varied greatly by race/ethnicity. About half 
of non-Hispanic white females had optimal vitamin D levels, but only 2.5% and 6.3% 
of non-Hispanic Black and Mexican-Hispanic women, respectively, had optimal 
vitamin D levels (p<0.001). Serum vitamin D was negatively associated with BMI (p-
trend <0.001), and positively associated with LTPA (p-trend: 0.001) and education 
(p-trend<0.001). Serum vitamin D concentration was much higher in current OC 
users compared to non-users (79.9 vs 55 nmol/L, p<0.001), and the percentage of 
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women with sufficient vitamin D levels was much higher among current OC users 
compared to past or never users (62.8 vs 27.2 vs 18.5%, p<0.001 for current, past 
and never OC user, respectively). Women who provided blood samples between the 
months of November and April had twice the prevalence of vitamin D deficiency 
compared to those who donated blood between May and October (45.1 vs 21.3%, 
p<0.001). Vitamin D levels did not vary by age, sleep duration, CRP level or smoking 
status (Table 17). 
Association of Vitamin D with depression scores. In univariate linear analyses, 
vitamin D deficiency was associated with a higher total depression score (β: 0.66, 
p=0.02) and somatic depression score (β: 0.39, p=0.005), but not a higher non-
somatic depression score (β: 0.27, p=0.11). These associations were attenuated and 
were no longer significant after adjustment for demographics, lifestyle, behavioral 
factors and season of blood draw (Table 18).  
To assess whether inflammation affects the association between vitamin D 
status and depression, we first visualized the relationship using bar graphs (Figure 
7). Depression score tended to decrease with increasing vitamin D levels (p=0.03, p-
trend:0.02) in the total population (Figure 7a). When stratified by CRP levels, 
however, these trends were less clear. Among women with elevated CRP (3-
10mg/L), those with vitamin D sufficiency had lower depression scores (p=0.003, p-
trend:0.004, Figure 7a) and lower prevalence of high depression score (p=0.02, 
Figure 7b). A similar pattern was found in linear regression models stratified by CRP 
levels (data not shown). In unadjusted analyses, vitamin D deficiency and 
insufficiency were associated with higher total depression score (β: 1.63, p=0.002 
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and β:1.78, p=0.008), somatic depression score (β:0.85, p=0.003; β:0.98, p=0.008), 
and non-somatic depression score (β:0.78, p=0.009; β:0.80, p=0.02), evident only 
among those with moderate inflammation (CRP 3-10 mg/L). Adjustments for age, 
race/ethnicity, education, BMI, sleep duration, LTPA, smoking, OC use, and 
continuous CRP attenuated these results, all of which became non-significant. 
 Association of Vitamin D with Individual Depression Symptoms. To determine 
which depression symptoms were associated with vitamin D status, we first looked 
at the bivariate associations, followed by a series of linear and logistics models for 
continuous and dichotomized symptoms. In bivariate analysis, women experiencing 
the somatic symptoms of fatigue and abnormal appetite had significantly lower 
mean serum vitamin D levels (54.7 vs 60.8 nmol/L, p=0.004 and 55.4 vs 60.3 
nmol/L, p=0.03, respectively) compared to those without these symptoms (Table 
19). In linear regression with individual depression symptoms, vitamin D deficiency 
was significantly associated with a higher score for fatigue (β: 0.21, p=0.001), 
changes in appetite (β: 0.13, p=0.008), psychomotor abnormalities (β:0.06, p=0.03), 
anhedonia (β:0.12, p=0.004) and suicidal ideation (β:0.03, p=0.05). These 
associations were completely attenuated after adjustment for demographics, 
behavioral, lifestyle factors, and season of blood draw (data not shown).  
In stratified analysis, among women with moderate inflammation, vitamin D 
deficiency was associated with fatigue, abnormal appetite, psychomotor 
abnormalities, anhedonia, depressed mood, low self-esteem, and suicidal ideation in 
univariate analysis. In adjusted models, however, vitamin D deficiency was 
significantly associated only with a lower score for sleeping disturbances (β: -0.34, 
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p=0.01) (Table 20). Individual depression symptoms were not significantly 
associated with suboptimal vitamin D levels in multivariable logistic models (data 
not shown). Vitamin D insufficiency and deficiency were associated with higher 
odds of depression among those with moderate inflammation (CRP 3-10mg/L) in 
adjusted models (ORdeficiency: 6.55, p=0.02 and ORinsufficiency 9.54, p=0.001) (Table 21).  
Effects of potential modifiers or confounders. To examine BMI as a potential 
modifier of the vitamin D-depression association, we stratified our analysis by BMI 
category and found that after full adjustments a one standard-deviation increase in 
ln-transformed vitamin D was associated with a 1.7-point increase in total 
depression score (β: 1.71, p=0.01), almost a 1-point increase in somatic (β: 0.95, 
p=0.02), and 0.76-point increase in non-somatic depression score (β: 0.76, p=0.01) 
only among those who were underweight.  This association was not significant for 
any other BMI group (Table 22). Despite this apparent interaction, addition of an 
interaction term between continuous BMI and vitamin D in the final model was not 
statistically significant (not shown). 
To evaluate BMI as a potential mediator or confounder of the association 
between vitamin D and depression, we ran a series of Sobel mediation tests 
followed by bootstrap analysis for the Preacher and Hayes test of indirect effect.59,60  
For total depression score, 41.5% of the total effect was significantly mediated by 
BMI (p=0.01) (Figure 9). BMI also partially explained the association between 
vitamin D and both somatic (35.2%, p=0.01) and non-somatic depression (52%, 
p=0.03).  
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Influence of sleep duration on the association between vitamin D and 
depression. To determine whether sleep duration influences the association between 
vitamin D status and depression, we first assessed differences in sleep by vitamin D 
status. Mean sleep duration did not vary by vitamin D level (p=0.43), but mean 
vitamin D levels were slightly higher among women who reported sleeping more 
than 7 hours/night (60.9 vs 57.9, p=0.065). Adding an interaction term to the final 
model indicated that sleep is a strong effect modifier of the association between 
vitamin D and depression (p-interaction=0.01). When stratified by sleep 
(dichotomized at the median- less than 7 hours or 7 or more hours per night), 
vitamin D was inversely associated with odds of depression among women who 
slept 7 or more hours, but was positively associated with depression among women 
who slept less than 7 hours per night (Figure 9). We also ran logistic regressions 
using the “mfpigen” command to create a plot for the odds of depression at different 
hours of total sleep, and found a negative association between vitamin D and 
depression among women who slept 7-9 hours per night, but this association was 
positive among women who slept too little (5 hours/night) or too much (12 or more 
hours per night) (Figure 10). 
Influence of oral contraceptive use on the association between vitamin D and 
depression. Mean vitamin D was much higher among current OC users (79.9 
nmol/L), compared to past users (57.6 nmol/L) or never users (51.5 nmol/L; 
p<0.001).  In multivariable logistic regression, there were no statistically significant 
associations observed between vitamin D and depression when stratified by OC use, 
nor was a significant interaction evident. 
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9.5 Discussion 
In a large representative sample of reproductive age women, we found that 
depression score was inversely related to 25(OH)-vitamin D level, and among those 
with elevated CRP, suboptimal 25(OH)-vitamin D levels were associated with 
increased odds of depression. Furthermore, the association between vitamin D 
deficiency and depression was modified by sleep and by BMI. Although some studies 
have reported an association between lower vitamin D status and increased 
depressive symptoms among women,61–65   our study is the first to examine whether 
inflammation and lifestyle factors influence the association between 25(OH)-
vitamin D status and various dimensions of depression among reproductive-age 
women. 
Although studies on vitamin D status and depression have yielded 
inconsistent findings, those that assessed the different association between 25(OH)-
vitamin D and subtypes of depression have found that vitamin D deficiency is more 
strongly related to somatic symptoms of depression, rather than non-somatic 
symptoms.99  In our sample of women, we found a significant trend of increasing 
total depression score and somatic depression score with decreasing 25(OH)-
vitamin D level, which was not evident for non-somatic depression score or in 
adjusted models. Furthermore, women experiencing fatigue had significantly lower 
mean serum 25(OH)-vitamin D concentration, suggesting that 25(OH)-vitamin D 
may be involved in sleep regulation. Vitamin D receptors (VDR) have been found in 
brain areas that control the endocrine-autonomic system as well as the motor 
system.10  Fatigue may be common to both vitamin D deficiency and depression, 
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since muscle weakness and chronic fatigue are commonly experienced by persons 
with vitamin D deficiency.66,67   Mechanistic evidence, therefore, suggests that 
25(OH)-vitamin D levels may affect somatic symptoms related to motor function 
and sleep, and we found that suboptimal 25(OH)-vitamin D concentrations were 
associated with increased score for psychomotor retardation among women with 
elevated CRP levels, and these associations were borderline significant after full 
adjustments (βdeficiency: 0.15, p=0.06; βinsufficiency: 0.12, p=0.09). These findings suggest 
that in addition to vitamin D deficiency, a second trigger, such as inflammation, may 
exacerbate somatic depressive symptoms.  
Previous studies reported inverse associations between sleep and 
depression68  as well as sleep and vitamin D status.31,32   When we stratified our 
analysis by sleep duration, vitamin D-deficient women who slept seven or more 
hours per night had higher depression scores and much higher odds of depression 
than women who slept less (p for vitamin D x sleep = 0.01).  Adequate sleep is an 
indicator of health status69  and may be a proxy for health-related behaviors,70  so 
our findings suggest that among otherwise healthy women who regularly get 
enough sleep, vitamin D deficiency may be associated with increased odds of 
depression, but this is not the case among women who sleep less than 7 hours per 
night. The latter group may be experiencing insomnia, sleep apnea, stress, or other 
unmeasured comorbidity that could allow for residual confounding to affect the 
association between vitamin D and depression. When we adjusted for sleep, the 
effect size of serum 25(OH)-vitamin D on depression was somewhat attenuated, and 
mediation tests indicated significant indirect effects of 25(OH)-vitamin D on 
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depression through sleep. Sleep may be acting as a mediator between vitamin D 
deficiency and depression through the potential effects of vitamin D on neurons 
thought to be involved in sleep regulation.10,31  Some evidence suggests that 
insomnia leads to depression in 69% of cases of comorbid insomnia and depression, 
whereas prior depression does not lead to insomnia.71  However, given the cross-
sectional nature of this analysis, we cannot determine whether sleep is acting as a 
confounder or a mediator in the association between vitamin D and depression. 
Adjustment for BMI significantly attenuated the association between vitamin 
D and depression scores among women in our analysis, and this was especially true 
for non-somatic depression, where inclusion of BMI in regression models reduced 
the effect size of the association of vitamin D on depression by half. This finding 
suggests that adiposity accounted for much of the association observed between 
vitamin D and depression scores in crude analyses. From a physiologic perspective, 
non-specific sequestering of vitamin D in adipose tissue72  suggests a mechanism 
whereby increased adiposity leads to lower vitamin D levels.36  BMI has also 
predicted future depression,73  and therefore could potentially act as confounder or 
effect modifier of the association between vitamin D and depression. Although tests 
for an interaction between BMI and vitamin D status were nonsignificant, when 
stratified by BMI in multivariable analysis, serum 25(OH)-vitamin D was positively 
associated with depression scores, and this was only evident among underweight 
women. Among the rest of the women with higher BMI, the association was 
negative, but not significant, suggesting potential effect modification by adiposity on 
the association between vitamin D levels and depression.  
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In our sample, underweight women had the highest mean 25(OH)-vitamin D 
(mean 67.1 nmol/L, 95% CI 59.2-76, p<0.001) and the lowest prevalence of vitamin 
D deficiency compared to women in the rest of the BMI categories. Two recent 
cross-sectional studies74,75  found a positive association between 25(OH)-vitamin D 
and CRP at 25(OH)-vitamin D concentrations above 52-62 nmol/L, suggesting that 
below these levels, 25(OH)-vitamin D may have an anti-inflammatory effect, but 
above these levels it may have a pro-inflammatory effect. Inflammation has been 
positively associated with depression in numerous studies,28  and could potentially 
explain why 25(OH)-vitamin D was positively associated with depression in this 
group. If this is a true association, then the underlying mechanisms for a potential 
pro-inflammatory role of vitamin D at higher concentrations still needs to be 
discovered.  
Consistent with previous research, OC users had higher 25(OH)-vitamin D 
concentration compared to non-OC users.33,76,77  Since OC use has also been 
associated with both higher and lower depression risk,34,35  we considered OC use as 
a potential confounder. Including OC in the model significantly attenuated the 
association between 25(OH)-vitamin D and depression. Based on the Sobel 
mediation test, OC use can be considered a potential mediator of the association 
between vitamin D and non-somatic depression scores. However, from a biological 
perspective, mediation by oral contraceptive use seems unlikely, given that OC use 
affects both exposure and outcome, and not the other way around. Estrogen 
downregulates the main catabolic enzyme in the vitamin D pathway, 24-
hydroxylase,33,78,79  and may upregulate 1α-hydroxylase, the enzyme required to 
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activate vitamin D.  OC use may also affect the expression of the VDR and other 
vitamin D binding proteins.33,78,79  Together, these actions may lead to elevated 
circulating vitamin D levels, although the clinical significance of this effect remains 
unknown.76  Although current OC users appeared to have lower odds of depression 
compared to non-users in our unadjusted analysis, we did not find significant 
evidence of effect modification by OC use. 
Our study has important strengths, including use of a large, diverse sample of 
women representative of the U.S. population, the use of a validated, 
multidimensional depressive symptom measure, and the testing of multiple 
candidate mediators or confounders, such as CRP, sleep, BMI, and OC use. 
Furthermore, we excluded women who were currently taking antidepressants to 
prevent nondifferential misclassification of outcome, given that some of the 
common side effects of antidepressants reported by patients are the very symptoms 
that are used to measure depression, such as insomnia, hypersomnia, agitation, 
restlessness, fatigue, somnolence, weight gain or weight loss, and decreased or 
decreased appetite.80   This overlap of antidepressant side-effects and depression 
symptoms provides a compelling reason for analyzing symptoms separately from 
total depression scores.51   
Our study also has important limitations. First, due to the cross-sectional 
nature of the NHANES study design, we were unable to determine the directionality 
of the association between 25(OH)-vitamin D and depression symptoms. Although 
previous studies have found depression scores to improve upon supplementation 
with vitamin D in certain populations,81,82  conflicting evidence remains concerning 
  
176 
 
the directionality of the association between vitamin D status and depression and 
inconclusive findings in the vast majority of supplementation studies.83–85   
Depression may affect vitamin D-enhancing activities, such as healthy eating, 
exercising, or outdoor activities, and may lead to lower 25(OH)-vitamin D levels 
through weight gain and sequestering of vitamin D in adipose tissue. Prospective 
studies are warranted to establish directionality, and randomized clinical trials are 
needed to understand the complexity of this association and to determine whether 
there is, in fact, a direct link between 25(OH)-vitamin D and depression. Secondly, 
we did not account for region of residence and latitude for the participants, but we 
did account for the six-month period of blood draw, which was the only data 
publicly available from NHANES that could be used to address seasonal variations in 
serum 25(OH)-vitamin D levels. We do not consider this a major limitation since 
surrogate markers of vitamin D concentrations, such as regional latitude, although 
somewhat correlated to serum 25(OH)-vitamin D, have not been found to 
adequately reflect circulating 25(OH)-vitamin D measures. In a large nested-case 
control study of the Women’s Health initiative, mean annual solar irradiance only 
explained 1% of the variation in serum 25(OH)-vitamin D levels.86  And finally, this 
survey from a non-institutionalized population may represent only those with less 
severe depression, because women experiencing severe depression may either be 
institutionalized or may have disproportionately chosen not to participate in the 
survey. Therefore, our results might not be generalizable to women with severe 
depression or major depressive disorder. 
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9.6 Conclusion 
We found that suboptimal vitamin D status was associated with higher total 
depression score and somatic depression score and higher odds of depression in the 
presence of inflammation. We also found that among underweight women, 25(OH)-
vitamin D was positively associated with depression scores.  Previous research on 
vitamin D and depression has yielded inconsistent or null findings, which may be due 
in part to a failure to account for inflammation or lifestyle factors, such as sleep, that 
affect both vitamin D status and depression. Given the evidence linking inflammation 
to vitamin D status and depression, additional studies are needed to determine to 
what extent vitamin D influences depression through changes in adiposity, 
inflammation and sleeping patterns.  
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Table 16: Distribution of covariates by depression in women of reproductive age from NHANES 2005-2008 (N=1,397) 
  
Total              
Population 
Total PHQ-9 Score                  
(range 0-27) 
Somatic                           
Depression Score 
(range 0-12) 
Non-Somatic 
Depression Score 
(range 0-15) 
High Depression Score                                                         
(PHQ-9 score ≥10) 
No Yes   
    N % Mean SE p-value Mean SE p-value Mean SE p-value N  % N % p-value 
Total population sample 1397   2.9 0.1 -- 1.8 0.1 -- 1.1 0.1 -- 1276 92.7 121 7.3 -- 
Serum 25 (OH) D (nmol/L)* 59.8 
57.1, 
62.8 -- -- -- 60.1 
57.3, 
60.3 56.7 
50.6, 
63.5 0.27 
Age, years (mean, SE) 31.7 0.3 -- -- -- 31.6 0.3 32.3 0.9 0.47 
Sleep per night, hours (mean, SE) 6.9 0.1 -- -- -- 7.0 0.1 6.1 0.2 <0.001 
Body Mass Index (kg/m2)         0.06     0.13     0.10         0.42 
  less than 18.5 47 3.5 2.6 0.5   1.7 0.3   0.9 0.2   45 96.9 2 3.1   
  18.5 to 24.9 552 44.4 2.6 0.1   1.7 0.1   0.9 0.1   507 93.6 45 6.5   
  25-29.9 400 26.6 3.0 0.3   1.8 0.2   1.1 0.1   365 91.5 35 8.5   
  30 or greater 396 25.7 3.4 0.2   2.1 0.1   1.3 0.1   357 91.9 39 8.1   
  p-trend --       0.005     0.02     0.01           
Inflammation Categories         0.05     0.09     0.06         0.07 
  hs-CRP <1 mg/L 510 38.1 2.6 0.2   1.7 0.1   0.9 0.1   473 94.7 37 5.3   
  hs-CRP 1-2.99 mg/L 465 33.8 2.9 0.2   1.8 0.1   1.1 0.1   421 91.3 44 8.7   
  hs-CRP 3-10 mg/L 422 28.1 3.3 0.2   2.0 0.1   1.3 0.1   382 91.6 40 8.4   
  p-trend         0.01     0.03     0.02           
Marital Status         0.11     0.17     0.06         <0.001 
  Single/Never Married 526 29.4 2.9 0.2   1.9 0.1   1.0 0.1   487 94.5 39 5.5   
  Married/with partner 731 60.5 2.7 0.1   1.7 0.1   1.0 0.1   670 93.4 61 6.6   
  Divorced/Separated/Widowed 140 10.1 4.1 0.6   2.4 0.3   1.7 0.3   119 83.4 21 16.6   
Education         <0.001     <0.001     <0.001         <0.001 
  Less than Highschool 343 15.6 4.1 0.3   2.4 0.2   1.7 0.1   297 86.3 46 13.7   
  Highschool or GED 336 20.7 3.5 0.4   2.1 0.2   1.4 0.2   301 88.9 35 11.1   
  Some college 449 36.7 2.8 0.2   1.8 0.1   1.1 0.1   415 93.0 34 7.0   
  College graduate 268 28.00 1.9 0.2   1.4 0.1   0.5 0.1   262 98.7 6 1.3   
  p-trend         <0.001     <0.001     <0.001           
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Race/Ethnicity         0.28     0.41     0.29         0.25 
  Non-Hispanic White 521 63.5 2.7 0.2   1.7 0.1   1.0 0.1   477 93.2 44 6.8   
  Mexican Hispanic 130 6.6 3.1 0.3   1.8 0.2   1.2 0.1   317 93.1 25 6.9   
  Other Hispanic 342 10.1 3.6 0.4   2.1 0.2   1.5 0.2   112 89.2 18 10.8   
  Non-Hispanic Black 329 12.6 3.3 0.2   2.1 0.1   1.3 0.1   298 89.8 31 10.2   
  Other Race 75 7.2 2.7 0.3   1.7 0.2   1.1 0.2   72 96.0 3 4.0   
Smoke         <0.001     <0.001     <0.001         <0.001 
  Not current smoker 1082 80.3 2.4 0.1   1.6 0.1   0.9 0.1   997 95.5 63 4.5   
  Current smoker 246 19.7 4.4 0.4   2.7 0.2   1.7 0.2   242 83.6 56 16.4   
Leisure Time Physical 
Activity         <0.001     <0.001     <0.001         <0.001 
  Q1 (0-64 MET minutes/week) 343 23.9 4.2 0.3   2.5 0.2   1.7 0.2   286 84.7 57 15.3   
  Q2 (65-594 MET minutes/week) 291 26 2.5 0.2   1.6 0.1   0.9 0.1   273 95.2 18 4.8   
  
Q3 (595-1560 MET 
minutes/week) 256 24.6 2.4 0.2   1.5 0.1   0.8 0.1   244 96.1 12 3.9   
  Q4 (>1560 MET minutes/week) 297 25.5 2.10 0.2   1.3 0.2   0.7 0.1   284 96.4 13 3.6   
  p-trend         <0.001     <0.001     <0.001           
Oral Contraceptive use         0.01     0.09     0.001         0.19 
  Never user 425 23.0 3.1 0.2   1.9 0.1   1.2 0.1   393 92.3 31 7.7   
  Past user 728 58.2 3.0 0.1   1.8 0.1   1.1 0.1   657 92.1 71 7.9   
  Current user 199 18.8 2.1 0.3   1.5 0.2   0.8 0.2   188 96.1 11 3.9   
  p-trend     0.02   0.09     0.01             
Semester of blood draw         0.27     0.43     0.17         0.23 
  November 1 through April 30 669 41.6 2.7 0.2   1.7 0.1   1.0 0.1   627 93.9 42 6.1   
  May 1 through October 31 728 58.4 3.0 0.2   1.9 0.1   1.2 0.1   649 91.8 79 8.2   
Weighted regression and t-tests for continuous depression scores and design-based pearson chi square for categorical depression variables. *Ln-transformed vitamin D presented as geometric  
means and 95% CI. 
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Table 17: Distribution of covariates by vitamin D variables in women of reproductive age from NHANES 2005-2008 
(N=1,397) 
    
Serum 25(OH) Vitamin D* 
Serum Vitamin D Categories 
    
Deficiency                  
(<50 nmol/L) 
Insufficiency      
(50-75 nmol/L) 
Sufficiency              
(>75 nmol/L)   
    Mean 95% CI p-value N  % N % N % p-value 
Total population 59.8 57.1, 62.8 -- 643 31.2 459 36.7 295 32.2 -- 
Depression Score (PHQ-9)** -- 3.3 0.2 2.8 0.2 2.6 0.2 0.03 
Age (years)** -- 31.7 30.9, 32.5 32.1 31.3, 32.8 31.2 29.9, 32.4 0.43 
Sleep duration (hours)** -- 6.9 6.7, 7.0 6.9 6.8, 7.0 7.0 6.9, 7.2 0.19 
Body Mass Index (kg/m2)     <0.001             <0.001 
  less than 18.5 67.1 59.2, 76.0   15 21.3 18 32.8 14 46.0   
  18.5 -24.9 66.5 62.9, 70.4   193 22.7 196 36.6 163 40.7   
  25-29.9 59.0 54.9, 63.4   196 33.2 127 35.7 77 31.1   
  30 or greater 49.9 46.5, 53.4   239 45.2 116 38.1 41 16.8   
  p-trend     <0.001               
Inflammation Categories     0.07             0.099 
  hs-CRP <1 mg/L 60.5 57.1, 64.1   222 30.4 177 38.6 111 31.0   
  hs-CRP 1-2.99 mg/L 61.6 8.1, 65.4   200 26.9 160 37.8 105 35.3   
  hs-CRP 3-10 mg/L 57.0 53.1, 61.1   221 37.4 122 32.7 79 29.9   
  p-trend     0.11               
Marital Status     0.04             0.003 
  Single/Never Married 57.3 53.0, 61.9   298 38.7 131 28.5 97 32.9   
  Married/Living with partner 61.6 58.4, 64.9   278 26.3 280 40.9 173 32.8   
  Divorced/Separated/Widowed 57.4 52.8, 62.3   67 38.8 48 35.2 25 26.0   
Education     <0.001             <0.001 
  Less than Highschool 51.8 47.2, 56.8   198 48.6 105 33.0 40 18.5   
  Highschool or GED 58.3 53.8, 63.2   178 37.3 94 34.0 64 28.7   
  Some college 62.0 58.7, 65.6   
178.
0 25.4 158 37.8 113 36.8   
  College graduate 63.3 60.1, 66.6   88 24.2 102 39.3 78 36.5   
  p-trend     <0.001               
Race/Ethnicity     <0.001             <0.001 
  Non-Hispanic White 71.4 68.6, 74.3   78 14.4 207 39.8 236 45.8   
  Mexican Hispanic 46.6 43.3, 50.2   208 56.8 114 36.9 20 6.3   
  Other Hispanic 49.5 44.8, 54.8   69 56.7 38 26.2 23 17.1   
  Non-Hispanic Black 36.2 33.9, 38.6   252 75.1 70 22.4 7 2.5   
  
181 
 
  Other Race 51.6 46.5, 57.4   36 42.7 30 42.9 9 14.3   
Smoke     0.31             0.89 
  No 59.3 56.1, 62.7   496 31.0 349 37.2 215 31.8   
  Yes 62.1 57.7, 66.9   118 31.1 102 35.4 78 33.5   
Leisure Time Physical Activity     0.003             0.03 
  Q1 (0-64 MET minutes/week) 54.7 48.8, 61.4   176 38.3 104 32.6 63 29   
  
Q2 (65-594 MET 
minutes/week) 62.1 58.5, 66.0   127 29.7 96 35.8 68 34.4   
  
Q3 (595-1560 MET 
minutes/week) 61.2 57.5, 65.2   104 27.7 91 39.7 61 32.6   
  
Q4 (>1560 MET 
minutes/week) 67.2 63.4, 71.2   110 20.4 103 37.9 84 41.7   
  p-trend 0.001               
Oral Contraceptive use     <0.001             <0.001 
  Never user 51.5 47.9, 55.3   248 44.8 132 32.8 45 18.5   
  Past user 57.6 54.6, 60.7   329 32.8 258 39.9 141 27.2   
  Current user 79.9 74.8, 85.3   50 10.9 51 27.2 98 62.8   
  p-trend     <0.001               
Semester of blood draw     <0.001             <0.001 
  November 1 through April 30 51.7 47.7, 56.0   405 45.1 188 33.7 76 21.3   
  May 1 through October 31 66.4 63.6, 69.4   238 21.3 271 38.8 219 39.9   
  *ln-transformed hs-CRP, with geometric means and 95% confidence intervals. ** Mean(SE) for continuous variables. 
  Analysis of variance for continuous vitamin D and weighted, design-based pearson chi square for categories of vitamin D. 
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Table 18: Linear regression of the association of total depression score and 
depression subtypes with vitamin D in women (n=1,397) 
  
Depression defined as: 
Total PHQ-9 score 
(range: 0-27) 
Somatic                      
Depression score 
(range: 0-12) 
Non-somatic             
Depression score 
(range: 0-15) 
β                                
(95% CI) 
p-value 
β                                
(95% CI) 
p-value 
β                                
(95% CI) 
p-value 
Unadjusted Model             
  Vitamin D <50nmol/L 0.66 0.02 0.39 0.005 0.27 0.11 
    (0.11, 1.20)   (0.12, 0.65)   (-0.06, 0.60)   
  Vitamin D 50-75 nmol/L 0.15 0.67 0.06 0.78 0.09 0.58 
    (-0.53, 0.83)   (-0.36, 0.48)   (-0.23, 0.41)   
  Vitamin D >75 nmol/L ref   ref   ref   
Adjusted Model              
  Vitamin D <50nmol/L -0.03 0.94 -0.03 0.88 -0.001 0.99 
    (-0.77, 0.72)   (-0.36, 0.31)   (-0.47, 0.47)   
  Vitamin D 50-75 nmol/L -0.13 0.72 -0.07 0.74 -0.06 0.74 
    (0.86, 0.60)   (-0.49, 0.35)   (-0.44, 0.32)   
  Vitamin D >75 nmol/L ref   ref   ref   
Adjusted for age, race/ethnicity, education, smoking, oral contraceptive use, sleep duration, physical 
activity, body mass index, high-sensitivity CRP, and season of blood draw. 
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Figure 7: (a) Total depression score by CRP level and Vitamin D status. (b) 
Prevalence of high depression score varies by CRP level, evident mainly among 
women with CRP between 3-10mg/L. 
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Table 19: Distribution of serum 25(OH)D and vitamin D categories by individual depression symptoms among 
women (N=1,397) 
  
Serum Vitamin D* 
Serum Vitamin D Categories 
Deficiency                   
(Vit D <50 nmol/L) 
Insufficiency      
(50-75 nmol/L) 
Sufficiency            
(≥75 nmol/L)   
Mean 95% CI p-value N  % N % N % p-value 
  Trouble sleeping     0.87             0.46 
    No 59.9 57.2, 62.7   554 87.3 409 89.9 253 87.5   
    Yes 59.6 54.6, 64.9   89 12.7 50 10.1 42 12.5   
  Fatigue**     0.004             0.07 
    No 60.8 58.2, 63.6   526 80.3 389 85.9 256 88.0   
    Yes 54.7 49.9, 59.9   117 19.7 70 14.1 39 12.0   
  Abnormal appetite**     0.03             0.17 
    No 60.3 57.5, 63.2   576 89.2 419 91.8 275 93.6   
    Yes 55.4 50.9, 60.3   67 10.8 40 8.2 20 6.4   
  Moving or speaking too slow or too fast   0.46             0.62 
    No 59.9 57.1, 62.9   623 96.7 447 97.6 283 97.6   
    Yes 56.9 49.7, 65.3   20 3.3 12 2.4 12 2.4   
  Anhedonia     0.21             0.46 
    No 60.1 57.3, 63.0   602 94.5 437 96.0 280 96.3   
    Yes 55.6 48.8, 63.3   41 5.5 22 4.0 15 3.7   
  Depressed mood     0.79             0.49 
    No 59.9 57.1, 62.9   595 93.2 432 95.4 274 94.0   
    Yes 58.9 52.0, 66.7   48 6.8 27 4.6 21 6.0   
  Low self-esteem     0.82             0.76 
    No 59.8 57.0, 62.8   611 95.9 433 94.8 279 95.1   
    Yes 60.8 52.9, 69.7   32 4.1 26 5.2 16 4.9   
  Trouble concentrating     0.89             0.70 
    No 59.8 57.0, 62.8   617 96.2 436 95.1 281 96.1   
    Yes 60.4 53.1, 68.7   26 3.8 23 4.9 14 3.9   
  Suicidal ideation     0.13             0.41 
    No 59.9 57.1, 62.9   634 98.9 452 99.3 291 99.5   
    Yes 49.9 39.2, 63.5   9 1.1 7 0.7 4 0.5   
Weighted t-tests and design-based Pearson chi square for categories of plasma vitamin D. *ln-transformed vitamin D, reporting geometric mean and 95% CI. **Significant  
p-value for trend test of proportions.
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Figure 8: Linear regression analysis assessing mediators/confounders of the 
relationship between log-transformed vitamin D and (a) total depression 
score, (b) somatic depression score and (c) non-somatic depression score 
among women of reproductive age from NHANES 2005-2008.  
 
 
testing Potential Mediators of the Association between Vitamin D and 
Depression in Women of Reproductive Age from NHANES 2005
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Table 20: Association of individual somatic depressive symptoms with vitamin D - stratified by 
CRP levels 
  
Somatic Depression Symptoms 
Sleeping problems Fatigue 
Abnormal 
appetite 
Psychomotor 
abnormalities 
β                                
(95% CI) 
p-
value 
β                                
(95% CI) 
p-
value 
β                                
(95% CI) 
p-
value 
β                                
(95% CI) 
p-
value 
CRP <1 mg/L 
Unadjusted Model                 
  25(OH)D <50nmol/L -0.01 0.91 0.14 0.36 0.08 0.33 0.02 0.64 
    (-0.25, 0.22)   (-0.16, 0.43)   (-0.08, 0.23)   (-0.07, 0.12)   
  25(OH)D 50-75 nmol/L -0.11 0.39 0.06 0.66 0.08 0.46 -0.02 0.65 
    (-0.36, 0.14)   (-0.20, 0.31)   (-0.14, 0.30)   (-0.11, 0.07)   
  25(OH)D >75 nmol/L ref   ref   ref   ref   
Adjusted Model                 
  25(OH)D <50nmol/L 0.00 0.99 0.08 0.53 -0.01 0.88 0.03 0.50 
    (-0.22, 0.22)   (-0.17, 0.33)   (-0.15, 0.13)   (-0.06, 0.12)   
  25(OH)D 50-75 nmol/L -0.04 0.67 0.04 0.62 0.08 0.23 -0.01 0.78 
    (-0.21, 0.14)   (-0.12, 0.19)   (-0.15, 0.13)   (-0.10, 0.08)   
  25(OH)D >75 nmol/L ref   ref   ref   ref   
CRP 1-3 mg/L                 
Unadjusted Model                 
  25(OH)D <50nmol/L -0.07 0.54 0.19 0.10 0.09 0.41 0.01 0.86 
    (-0.32, 0.17)   (-0.04, 0.42)   (-0.13, 0.31)   (-0.12, 0.14)   
  25(OH)D 50-75 nmol/L -0.29 0.10 -0.06 0.61 -0.13 0.23 -0.05 0.49 
    (-0.64, 0.05)   (-0.28, 0.17)   (-0.36, 0.09)   (-0.18, 0.09)   
  25(OH)D >75 nmol/L ref   ref   ref   ref   
Adjusted Model                 
  25(OH)D <50nmol/L 0.08 0.49 0.08 0.53 0.06 0.55 -0.01 0.84 
    (-0.16, 0.33)   (-0.18, 0.34)   (-0.15, 0.28)   (-0.14, 0.12)   
  25(OH)D 50-75 nmol/L -0.10 0.25 -0.01 0.87 -0.01 0.91 0.01 0.82 
    (-0.27, 0.07)   (-0.18, 0.15)   (-0.19, 0.17)   (-0.11, 0.14)   
  25(OH)D >75 nmol/L ref   ref   ref   ref   
CRP 3-10 mg/L     
Unadjusted Model                 
  25(OH)D <50nmol/L 0.09 0.35 0.32 0.02 0.25 0.01 0.18 0.001 
    (-0.10, 0.28)   (0.07, 0.58)   (0.06, 0.45)   (0.09, 0.28)   
  25(OH)D 50-75 nmol/L 0.19 0.17 0.29 0.05 0.32 0.02 0.18 0.01 
    
(-0.08, 0.45)   
(-0.005, 
0.59)   (0.05, 0.59)   (0.05, 0.31)   
  25(OH)D >75 nmol/L ref   ref   ref   ref   
Adjusted Model                 
  25(OH)D <50nmol/L -0.34 0.01 -0.11 0.47 -0.14 0.38 0.15 0.06 
    
(-0.60, -
0.09)   (-0.42, 0.20)   (-0.46, 0.18)   
(-0.003, 
0.31)   
  25(OH)D 50-75 nmol/L -0.14 0.35 0.008 0.94 0.06 0.60 0.12 0.09 
    (-0.44, 0.16)   (-0.21, 0.23)   (-0.18, 0.31)   (-0.02, 0.26)   
  25(OH)D >75 nmol/L ref   ref   ref   ref   
Mutually adjusted model includes a variable sum of the remaining depressive symptoms. Adjusted model includes age, ethnicity, 
smoking, oral contraceptive use, sleep duration, physical activity, body mass index, hs-CRP and season of blood draw. 
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Table 21: Logistic regression analysis of the association of high depression 
score with vitamin D in women (n=1,397) 
  
High Depression Score (PHQ-9≥10) 
OR                                   
(95% CI) 
p-value 
CRP<1 mg/L         
Unadjusted Model   
0.86   Vitamin D <50nmol/L 1.13 
    (0.29, 4.47) 
0.87   Vitamin D 50-75 nmol/L 0.87 
    (0.17, 4.40)       
  Vitamin D >75 nmol/L ref       
Adjusted Model          
  Vitamin D <50nmol/L 1.47 0.69 
    (0.20, 10.6)       
  Vitamin D 50-75 nmol/L 1.44 0.65 
    (0.28, 7.29)       
  Vitamin D >75 nmol/L ref       
CRP 1-3 mg/L         
Unadjusted Model         
  Vitamin D <50nmol/L 0.89 0.80 
    (0.34, 2.30)       
  Vitamin D 50-75 nmol/L 0.58 0.35 
    (0.18, 1.87)       
  Vitamin D >75 nmol/L ref       
Adjusted Model          
  Vitamin D <50nmol/L 0.53 0.31 
    (0.15, 1.85)       
  Vitamin D 50-75 nmol/L 0.59 0.39 
    (0.17, 2.01)       
  Vitamin D >75 nmol/L ref       
CRP 3-10 mg/L         
Unadjusted Model         
  Vitamin D <50nmol/L 8.15 <0.001 
    (2.74, 24.3)       
  Vitamin D 50-75 nmol/L 6.55 0.002 
    (2.16, 19.8)       
  Vitamin D >75 nmol/L ref       
Adjusted Model          
  Vitamin D <50nmol/L 6.55 0.02 
    (1.30, 32.8)       
  Vitamin D 50-75 nmol/L 9.54 0.001 
    (2.70, 33.6)       
  Vitamin D >75 nmol/L ref       
Adjusted for age, race/ethnicity, education, smoking, oral contraceptive use, sleep duration, 
physical activity, body mass index, high-sensitivity CRP, and season of blood draw. 
 
. 
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Figure 9: Probability of depression changes with vitamin D levels based on 
sleep duration (<7 hours vs 7 or more hours per night). Interaction term 
significant at p=0.02 after adjustments for age, race/ethnicity, education, BMI, OC 
use, LTPA, CRP, smoking, and season of blood draw. 
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Figure 10: Probability of depression changes with vitamin D levels based on 
sleep duration. For women who sleep too little or too much (5 hours or 12+ 
hours per night), vitamin D is positively associated with odds of depression. 
Among women who sleep 7 or 9 hours per night, vitamin D is inversely related to 
odds of depression.  Interaction term significant at p=0.01 after adjustments for age, 
race/ethnicity, education, BMI, OC use, LTPA, CRP, smoking, and season of blood 
draw. 
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Table 22: Linear regression of the association of total depression score and 
depression subtypes with vitamin D in women of reproductive age from NHANES 
2005-2008 stratified by Body Mass Index categories 
Per 1 S.D. increase                   
in log-transformed 
25(OH) vitamin D: 
Depression defined as: 
Total PHQ-9 score              
(range: 0-27) 
Somatic                      
Depression score 
(range: 0-12) 
Non-somatic 
Depression score 
(range: 0-15) 
β                                
(95% CI) 
p-
value 
β                                
(95% CI) 
p-
value 
β                                
(95% CI) 
p-
value 
BMI <18.5 kg/m2             
  Unadjusted 0.13 0.73 0.18 0.44 -0.05 0.80 
    (-0.67, 0.94)   (-0.30, 0.66)   (-0.43, 0.33)   
  Adjusted 1.71 0.01 0.95 0.02 0.76 0.01 
    (0.41, 2.99)   (0.16, 1.73)   (0.18, 1.33)   
BMI 18.5-24.9 kg/m2             
  Unadjusted -0.27 0.11 -0.18 0.1 -0.09 0.35 
    (-0.60, 0.06)   (-0.39, 0.04)   (-0.28, 0.10)   
  Adjusted 0.07 0.78 -0.006 0.97 0.08 0.59 
    (-0.43, 0.57)   (-0.28, 0.26)   (-0.21, 0.36)   
BMI 25-29.9 kg/m2             
  Unadjusted -0.14 0.55 -0.11 0.37 -0.03 0.81 
    (-0.61, 0.33)   (-0.36, 0.14)   (-0.28, 0.22)   
  Adjusted 0.11 0.69 0.05 0.74 0.06 0.67 
    (-0.44, 0.67)   (-0.24, 0.33)   (-0.23, 0.35)   
BMI ≥30 kg/m2             
  Unadjusted -0.11 0.68 -0.09 0.59 -0.03 0.83 
    (-0.66, 0.44)   (-0.40, 0.23)   (-0.29, 0.23)   
  Adjusted -0.22 0.48 -0.10 0.55 -0.12 0.50 
    (-0.83, 0.40)   (-0.42, 0.23)   (-0.49, 0.24)   
Adjusted for age, race/ethnicity, education, smoking, sleep, physical activity, hs-CRP, continuous body mass 
index, OC use and season of blood draw. 
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CHAPTER 10 
CONCLUSION AND SIGNIFICANCE 
 
Our work highlights the complexity of the relationship among micronutrient 
status, inflammation, and depression in women of reproductive age. The etiology of 
depression remains to be fully understood, and given the higher prevalence of 
depression among women, it is important to understand how nutrition, 
inflammation, and lifestyle factors may contribute to different dimensions of 
depression in this population. Body mass index, a proxy for adiposity, accounts for a 
large portion of the association between c-reactive protein and serum 25-
hydroxyvitamin D with depression; vitamin B6 deficiency was associated with 
increased odds of suicidal ideation, and sleep duration modified the association 
between vitamin D concentration and depression.  These findings altogether 
indicate that the relationship between micronutrients and depression is 
multifaceted, and inflammation and lifestyle factors, such as sleep and body mass 
index, need to be considered when researching depression. Additionally, we provide 
increasing evidence in support of analyzing symptoms separately from total 
depression scores in order to shed light on the etiology of depression. This research 
expands our understanding of how deficiencies of vitamin B6 or D, inflammation, 
and other lifestyle factors affect depression symptoms among women and may help 
identify potential prevention strategies or adjuvant treatments for depression that 
incorporate changes in nutrition or lifestyle factors. 
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CHAPTER 11 
FUTURE DIRECTIONS 
 
Our research has contributed to the field of nutrition and depression 
research by identifying how vitamin B6 and vitamin D status may be related to 
various dimensions of depression among women, and how inflammation, sleep 
duration, and body mass index affect these associations. Our findings, which were 
mainly limited by the cross-sectional nature of the study design, provide scientific 
justification for future prospective studies where the directionality of the 
association between inflammation and micronutrient status can be examined over 
time to determine their contribution to each other and to the development of 
depression. In the context of low-grade inflammation, research is warranted to 
determine the optimal doses of vitamin B6 to achieve concentrations that are 
associated with good health. It should be noted that future studies may lead to the 
reassessment of the current Recommended Dietary Allowance for vitamin B6 among 
women of reproductive age. Furthermore, our findings emphasize the need for 
studies on vitamin D and depression to consider inflammatory status in order to 
determine whether those with inflammation would benefit from higher doses of 
vitamin D supplementation to alleviate depression symptoms. 
Future studies can also assess how dietary inflammatory indices are related 
to micronutrient status and depression in this population while considering lifestyle 
factors. Although we did not assess dietary intake, ultimately, it is our goal as 
nutrition researchers to find evidence as to how nutritional changes promote better 
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health and reduce inflammation and to test whether these changes lead to improved 
mental health and prevent or treat depression.   
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